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	Preface	
	
This	thesis	is	submitted	as	a	partial	fulfillment	of	the	requirements	to	obtain	a	PhD	degree.		
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Professor	Lone	Gram	has	been	the	main	supervisor	and	associate	professor	Henrik	Franzyk	has	
been	the	co-supervisor	of	this	project.		
The	Technical	University	of	Denmark	funded	this	project.	
The	results	obtained	during	the	three	years	are	presented	in	three	manuscripts,	all	included	in	the	
thesis.		
	
Linda	Citterio	
Kongens	Lyngby,	March	2017	
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Abstract	
	
Bacterial	resistance	to	conventional	antibiotics	has	become	a	global	challenge	and	there	is	urgent	
need	for	new	and	alternative	compounds.	Antimicrobial	peptides	(AMPs)	are	under	investigation	
as	novel	antibiotics.	These	are	part	of	the	immune	defense	of	all	living	organisms;	hence,	they	
represent	a	valid	candidate	both	for	their	antibacterial	activity	and	for	their	immunomodulation	
features.	However,	these	compounds	have	several	disadvantages	once	administered	in	vivo.	These	
shortcomings	have	led	to	extensive	attempts	of	improving	their	features	with	rational	synthetic	
design.	Peptidomimetics	are	one	class	of	such	synthetic	modified	peptides.	The	purpose	of	this	
PhD	project	was	to	determine	the	antibacterial	spectrum	and	potential	use	of	synthetic	
antimicrobial	peptides	and	peptidomimetics.	Another	key	investigation	has	been	the	experimental	
development	of	resistance	to	these	novel	antibacterial	agents.	
	
We	investigated	(Article	1)	the	antibacterial	effect	of	selected	peptidomimetics	in	a	simulated	in	
vivo	environment	using	human	blood	plasma	and	serum.	We	speculated	that	the	activity	of	
peptidomimetics	was	hampered	by	the	presence	of	blood	fluids.	However,	the	antibacterial	
activity	was	enhanced	in	presence	of	human	blood	plasma	but	not	in	in	presence	of	human	blood	
serum.	We	hypothesized	that	complement	system	or	clotting	factors	present	in	plasma	but	not	in	
serum	were	causing	the	enhanced	effect	of	peptidomimetics.	Interestingly,	in	presence	of	heat-
inactivated	blood	matrices,	the	activity	of	the	compounds	decreased	dramatically	or	no	
enhancement	was	observed,	indicating	that	inactivation	of	complement	has	occurred.	We	also	
determined	whether	the	antibacterial	activity	of	selected	conventional	antibiotics	was	affected	by	
the	presence	of	blood	fluids	and	indeed	the	activity	of	a	membrane	active	antibiotic	was	enhanced	
in	presence	of	human	plasma.	We	conclude	that	complement	system	and	other	factors	present	in	
human	blood	plasma	interact	synergistically	with	membrane	active	compounds	such	AMPs	are.	As	
a	result,	the	concentrations	of	peptidomimetics	and	peptide	antibiotics	needed	in	vivo	may	be	
lower	than	predicted	from	standard	antimicrobial	susceptibility	testing.	
	
Unfortunately	bacteria	can	easily	adapt	to	AMPs	in	laboratory	settings	and	we	found	(Manuscript	
2)	that	in	Escherichia	coli	through	an	adaptive	evolution	experiment.	We	hypothesized	that	
evolution	of	resistance	to	the	combination	would	be	slower	than	to	the	single	compounds.	
However,	the	lineages	exposed	to	P9-4	(alone	or	in	combination)	were	the	slowest	adapting	as	
compared	to	the	other	treatments.	We	suggest	that	the	AMP	P9-4	could	be	considered	a	
promising	candidate	for	future	application	in	clinical	settings,	because	of	its	slow	resistance	
development	rate.	Using	whole-genome	sequencing,	we	investigated	the	genetic	basis	of	
resistance	in	the	adapted	lineages	and	derived	clones.	Deletions	in	the	gene	encoding	for	the	
enzyme	CDP-glycerophosphotransferase	were	the	most	common	variants,	indicating	that	a	
common	sequence	of	mutation	events	has	led	to	development	of	resistance.	The	zeta	potential	of	
adapted	lineages	was	less	negative	than	that	of	the	wild	type	and	we	therefore	hypothesized	that	
a	potential	mechanism	of	resistance	relies	on	surface	charge	modifications.		
	
In	Manuscript	3	we	investigated	the	stability	of	the	evolved	resistance	by	re-cultivating	selected	
resistant	clones	in	absence	of	compound.	Several	clones	retained	resistance	after	re-cultivation	in	
absence	of	compound.	Genome	analyses	demonstrated	that	deletions	in	the	gene	encoding	for	
the	enzyme	CDP-glycerophosphotransferase	were	still	present	after	re-cultivation.	Thus,	this	
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enzyme	may	indeed	play	a	key	role	in	the	mechanism	of	resistance.	Cross-resistance	is	a	common	
feature	of	resistant	microorganisms	and	we	therefore	determined	whether	the	adapted,	resistant	
clones	had	altered	susceptibility	to	other	antibacterial	compounds.	The	resistant	clones	were	also	
resistant	to	compounds	with	intracellular	activity.	However,	the	same	clones	were	as	susceptible	
as	the	wild	type	when	exposed	to	membrane-active	compounds	with	specific	features	such	as	
lipidation,	incorporation	of	D-amino	acids	and	presence	of	IR	motifs.	Thus,	the	concern	that	AMPs-
resistant	clones	may	be	a	threat	to	our	immunity	may	be	overestimated.		
	
In	conclusion,	this	PhD	project	supports	the	belief	that	bacteria	hold	the	potential	to	develop	
resistance	to	each	novel	antibacterial	agent.	Nevertheless,	strategies	to	circumvent	resistance	
exist	and	must	be	pursued.		
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Resumé	(Dansk)	
	
Bakteriel	resistens	over	for	konventionelle	antibiotika	er	en	global	udfordring,	og	der	er	et	akut	
behov	for	nye	og	alternative	forbindelser.	Antimikrobielle	peptider	(AMP).	Der	er	en	del	af	alle	
levende	organismers	immunforsvar,	er	en	stofgruppe,	der	undersøges	som	nye	antibiotika.	AMP	
har	bred	antibakteriel	aktivitet	og	modulerer	immunsystemet.	AMPer	indeholder	positivt	ladede	
aminosyrer,	som	interagerer	med	den	negativt	ladede	bakterie-membran	og	ødelægger	bakteriers	
cellemembran,	så	cellen	lyseres	og	bakterien	dør.	På	trods	af	disse	lovende	egenskaber,	har	,	
AMPer	en	række	ulemper	in	vivo,	bl.a.	er	nogle	AMP	cytotoksiske	eller	har	lav	stabilitet.	Disse	
mangler	har	ført	til	forsøg	på	at	forbedre	deres	funktioner	med	rationel	syntetisk	design.	
Peptidomimetika	er	én	klasse	af	sådanne	syntetiske	modificerede	peptidforbindelser.	
	
I	dette	ph.d.-projektet	testede	vi	bakteriel	følsomhed	og	resistensrisiko	over	for	både	syntetiske	og	
naturlige	AMP.	Den	antibakterielle	aktiviteten	af	stofferne	forbindelserne	blev	øget,	når	
interaktionen	skete	med	tilsætning	af	humant	blodplasma,	men	ikke	med	tilsætning	af	varme-
inaktiverede	blodmatricer.	Det	er	vores	hypotese,	at	der	er	synergi	mellem	blodproteiner,	fx	
komplement,	og	peptidomimetika.	Derfor	kan	lavere	dosering	af	visse	klasser	af	peptider	
anvendes	i	behandlingen	af	infektionssygdomme.	Fra	et	klinisk	perspektiv	er	dette	et	lovende	fund	
og	fremtidige	undersøgelser	skal	fokusere	på	at	få	disse	resultater	implementeret	i	dyremodeller	
til	proof-of-concept.	
	
Bakterier	synes	ikke	at	udvikle	resistens	mode	AMP,	der	er	en	del	af	vores	naturlige	medfødte	
immunsystem.	Dog	kan	bakterierne	nemt	adaptere	til	AMP	i	laboratoriet	i	såkaldte	adaptive	
evolution	experiments.	Escherichia	coli	udviklende	nemt	resistens	over	for	både	enkelte	
peptidomiketika	og	kombination	af	disse.	Resistens	var	dog	vanskelig	at	inducere	over	for	en	ni	
aminosyre	lang	AMP	og	en	sådan	forbindelse	er	derfor	en	lovende	kandidat	til	fremtidige	
anvendelse	i	kliniske	omgivelser.	
	
Vi	undersøgte	det	genetiske	grundlag	for	bakteriernes	resistens	og	identificerede	et	gen,	i	hvilket	
mutationer	sandsynligvis	er	årsag	til	resistens.	Mutationen	resulterer	formodentlig	i	ændringer	af	
bakteriens	overfladeladning.	Mange	af	de	resistente	kloner	bevarede	modstand	også	når	
peptiderne	blev	fjernet,	hvilket	indikerer	en	stabil,	genetisk	kodet	resistens.	Nogle	af	de	AMP-
resistente	mutanter	var	også	resistente	overfor	andre	udvalgte	peptider,	men	bevarede	
følsomhed	overfor	de	fleste.	Dette	resultat	er	lovende,	og	indikerer	at	brug	af	AMPs	ikke	vil	gøre	
bakterier	resistente	overfor	vores	naturlige	medfødte	immunitet.	
	
Peptidmimetika	er	lovende	som	fremtidens	antibiotika,	men	det	er	nødvendigt	med	yderligere	
undersøgelser	af	resistensudvikling	ligesom	der	kræves	en	bedre	forståelse	af	krydsresistens	og	
modtagelighed	fænomen.	
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	Introduction	
	1.	The	challenge	of	antibiotic	resistance	development	
	
Bacterial	infectious	diseases	such	as	respiratory	and	gastro-intestinal	infections	are	generally	
treated	with	conventional	antibiotics.	Most	conventional	antibiotics	have	still	clinical	relevance;	
however	occurrence	of	resistance	to	them	has	become	a	global	challenge	(WHO	2012;	
Antimicrobial	resistant	threats,	USA,	2013).		The	phenomenon	of	antimicrobial	resistance	has	been	
known	even	before	the	introduction	of	penicillin	as	antibiotic	(Abraham	and	Chain,	1940)	and	over	
the	last	century,	it	has	been	observed	that	resistance	arises	independently	from	the	chemical	
group	of	drug	(Figure	1).	The	issue	has	recently	raised	global	awareness	due	to	the	increase	of	
resistant	organisms,	the	affected	geographic	locations	and	the	breadth	of	resistance	in	single	
organisms	(Levy	and	Marshall	2004).		
	
Also,	the	number	of	people	who	died	and	related	health	costs	contributed	to	the	increased	
urgency	of	the	problem.	It	is	estimated	that	about	25,000	people	die	in	Europe	yearly	due	to	
infections	related	to	antibiotic	resistant	bacteria,	which	represents	2/3	of	all	mortal	hospital-
acquired	infections	(Table	1).	During	a	hospital	stay	5%	of	the	patients	are	infected,	meaning	3.2	
million/year.	Moreover,	resistant	infections	cause	excess	hospital	days	and	related	health	care	
costs	e.g.	an	estimation	of	$	20	/	€ 16	billion	in	the	US	and	EU,	respectively,	as	reported	by	Fair	
and	Tor,	(2014).	Countries	with	the	lowest	income	may	be	even	more	affected	by	antibiotic	
resistance.	In	fact,	spread	of	resistant	bacteria	is	favored	by	poor	hygiene,	contaminated	food	and	
water	and	overcrowding.	Moreover,	susceptibility	to	infection	increases	with	malnutrition	
(Laxminarayan	et	al.,	2013).	
	
Table	1:	Estimated	annual	burden	due	to	selected	antibiotic-resistant	bacteria	in	European	Union,	
Iceland	and	Norway.	Numbers	in	parentheses	indicate	percentage	bloodstream	infections.	
	
	
*	Bloodstream	infections,	lower	respiratory	tract	infections,	skin	and	soft	tissue	infections,	and	urinary	tract	
infections.	Table	1.1,	WHO	2012,	adapted	from	ECDC	and	EMEA,	(2009).		
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Figure	1:	A	timeline	of	introduction	of	various	antibiotics	and	emergency	of	antibiotic	resistance	
against	them.	Figure	5	in	Penchovski	and	Traykovska,	(2015).	
	
Three	different	classes	of	drug-resistant	bacterial	pathogens	were	established	by	the	Centers	for	
Disease	Control	and	Prevention	(CDC	2013,	Threat	Report).	Such	classification	into	“urgent”,	
“serious”	and	“concerning”	pathogens	can	be	used	worldwide	in	order	to	recognize	and	prioritize	
the	bacterial	threats	(Penchovski	and	Traykovska,	2015).	In	the	category	of	“urgent”	pathogens	
one	finds	the	carbapenem-resistant	Enterobacteriaceae	(with	Klebsiella	spp.	as	the	most	recorded	
pathogen),	Clostridium	difficile	and	drug-resistant	Neisseria	gonorrhoeae.	Among	the	“serious”	
threats,	twelve	pathogens	have	been	included,	some	of	whom	are	considered	more	deadly	in	the	
developing	countries	rather	than	in	the	US	(Penchovski	and	Traykovska,	2015).	The	concern	
derives	from	accumulation	of	multiple	genes,	each	resistant	to	a	different	drug,	in	the	
chromosome	or	in	the	plasmid	of	these	bacteria,	thus	defined	multi	drug	resistant	(MDR)	
pathogens.	In	addition,	the	presence	of	multiple	efflux	pumps	can	extrude	a	great	variety	of	drugs	
(Nikaido,	2009).	Thus,	it	is	evident	that	MDR	pathogens	are	considered	a	growing	challenge	for	
healthcare	environment	and	community	too.	
	
An	example	of	“serious”	MDR	pathogen	is	the	Gram-positive	methicillin-resistant	Staphylococcus	
aureus	(MRSA).	In	the	USA	it	is	estimated	that	approximately	100,000	deaths	per	year	are	
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attributed	to	infections	caused	by	selected	MDR	pathogens,	18,000	of	these	caused	by	MRSA	
(Klevens	et	al.	2007).		
Examples	of	“serious”	Gram-negative	MDR	pathogens	are	Pseudomonas	aeruginosa	and	
Acinetobacter	baumannii	(Antimicrobial	resistant	threats,	USA,	2013;	Sabtu	et	al.,	2015).	In	
accordance	to	this	classification,	it	is	estimated	that	the	main	pathogens	causing	hospital-acquired	
infections	are	the	Gram-negative	Klebsiella	spp.	(K.	pneumoniae/K.	oxytoca),	Escherichia	coli,	P.	
aeruginosa	and	Enterobacter	spp.	(Magill	et	al.,	2014;	Amin	and	Deruelle,	2015).	
	
The	Gram-positive	Enterococcus	faecium	and	Staphylococcus	aureus,	along	with	the	Gram-
negative	Klebsiella	pneumoniae,	Acinetobacter	baumannii,	Pseudomonas	aeruginosa	and	
Enterobacter	spp.,	are	also	known	as	ESKAPE	pathogens.	According	to	the	National	Healthcare	
Safety	Network	(NHSN),	around	40%	of	the	hospital-acquired	infections	in	US	were	related	to	the	
Gram-negative	subset	of	the	ESKAPE	pathogens,	in	2009-2010	(Amin	and	Deruelle,	2015).	It	is	now	
believed	that	ESKAPE	pathogens	are	the	major	cause	of	nosocomial	infections	throughout	the	
world	(Santajit	and	Indrawattana,	2016).	
	
The	spread	of	resistant	clones	coupled	with	the	lack	of	effective	antibiotics	can	cause	serious	
consequences	in	health-care	settings	for	vulnerable	patients.	Patients	who	are	undergoing	
surgery,	transplantation	and	chemotherapy	have	the	highest	risk	of	acquiring	infections	
(Laxminarayan	et	al.,	2007).	In	order	to	understand	the	relevance	of	this	problem,	it	has	been	
estimated	that	30-40%	of	the	patients	having	hip	replacements	would	acquire	a	post-surgery	
infection,	with	fatality	rate	of	30%	(Smith	and	Coast,	2013).	
 
Despite	the	clinical	challenge	that	these	bacteria	represent,	the	approval	of	new	antibiotics	has	
declined	in	the	last	40	years	(Amin	and	Deruelle,	2015).	Oxazolidinones	(e.g.	linezolid	in	2000)	and	
lipopeptides	(e.g.	daptomycin	in	2006)	are	the	only	two	new	classes	of	antibiotics	that	during	the	
last	25	years	that	have	reached	clinical	application	against	Gram-positive	bacteria,	while	the	
others	are	older	modified	drugs	(Sabtu	et	al.,	2015).	Also,	antibiotic	classes	with	activity	against	
highly	resistant	Gram-negative	bacteria	are	very	scarce	(Antimicrobial	resistant	threats,	USA,	2013;	
Sabtu	et	al.,	2015).		
	
The	scarcity	of	novel	approved	antibacterial	compounds	derives	partially	from	the	observation	
that	pathogens	rapidly	will	evolve	resistance	to	novel	compounds.	This	concern	discourages	
investments	in	the	development	and	approval	of	novel	drugs	(Carlet	et	al.,	2012).	Moreover,	the	
cost	of	bringing	new	drugs	into	the	market	is	considerable,	with	an	estimation	of	US	$	1	billion	per	
drug	for	developing	and	marketing	a	new	antibiotic	(Amin	and	Deruelle,	2015).	In	addition	to	these	
costs,	and	partially	because	of	them,	there	is	less	interest	in	antibiotic	development	from	the	
pharmaceutical	companies.	It	is	estimated	that	only	1.6%	is	the	antibiotic	allotment	of	all	drugs	in	
development	by	the	major	pharmaceutical	companies	(Shlaes,	2010).	Moreover,	multinational	
pharmaceutical	companies	with	antibiotic	divisions	are	only	four	(Boucher	et	al.,	2013).	
	
Given	these	premises,	it	becomes	clear	that	the	burden	of	antibiotic	resistance	requires	prompt	
coordinated	global	interventions.	Indeed,	antibiotic	resistance	is	considered	one	of	the	top-
challenges	for	humanity,	in	accordance	to	the	WHO	(2014	Report).	
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2.	How	to	tackle	antibiotic	resistance	development	
	
There	is	no	universal	consensus	on	which	is	the	most	appropriate	way	of	addressing	the	problem	
of	resistance	to	antibiotics	(Sabtu	et	al,	2015)	and	there	are	several	approaches	to	tackle	
resistance	development	(Table	2,	Spellberg	et	al.	2003).	
	
Table	2:	New	interventions	to	address	the	antibiotic-resistance	crisis.	Adapted	from	Spellberg	et	
al.,	(2013).		
	
Intervention	 Status	
	
Preventing	infection	and	resistance	
	
Improvement	of	population	health	and	health	care	
systems	to	reduce	admission	to	hospitals		
Implementation	research	stage	
Self-cleaning	hospital	rooms;	automated	
disinfectant	application	e.g.	through	vapor	
Some	commercially	available	but	require	clinical	
validation;	more	needed	
Novel	drug-delivery	systems	to	replace	intravenous	
catheters;	regenerative-tissue	technology	to	replace	
prosthetics;	noninvasive	ventilation	strategies		
Basic	science	and	conceptual	stages	
Niche	vaccines	to	prevent	resistant	bacterial	
infections	
	
Basic	and	clinical	development	stages	
Refilling	antibiotic	pipeline	by	aligning	economic	
and	regulatory	approaches		
	
Government	or	nonprofit	grants	and	contracts	to	
defray	up-front	R&D	costs	and	establish	nonprofits	
to	develop	antibiotics	
Models	in	place,	expansion	needed,	new	nonprofit	
corporation	needed		
Institution	of	novel	approval	pathways	(e.g.	Limited	
Population	Drug	proposal)	
Proposed,	legislative	and	regulatory	action	needed	
	
Preserving	available	antibiotics,	slowing	resistance	
	
Public	reporting	of	antibiotic-use	data	for	
benchmarking	and	reimbursement	
Policy	action	needed	to	develop	and	implement	
Development	of	and	reimbursement	for	rapid	
diagnostic	and	biomarker	tests	to	enable	
appropriate	use	of	antibiotics	
Basic	and	applied	research	and	policy	action	needed	
Elimination	of	use	of	antibiotics	to	promote	
livestock	growth		
Legislation	proposed	
New	waste	treatments	for	degradation	of	
antibiotics	
One	strategy	approaching	clinical	trials	
	
Developing	microbe-attacking	treatments	with	
diminished	potential	to	drive	resistance	
	
Preclinical,	proof-of-principle	stage	
Immune-based	therapies,	such	as	infusion	of	
monoclonal	antibodies	and	white	cells	that	kill	
microbes	
Antibiotics	or	biologic	agents	that	do	not	kill	
bacteria	but	alter	their	ability	to	trigger	
inflammation	or	cause	disease	
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Developing	treatments	attacking	host	targets	
rather	than	microbial	targets	to	avoid	selective	
pressure	driving	resistance	
Preclinical,	proof-of-principle	stage	
Direct	moderation	of	host	inflammation	in	response	
to	infection	(e.g.	cytokine	agonists	or	antagonists)	
Sequestration	of	host	nutrients	to	prevent	microbial	
access	to	nutrients	
Probiotics	that	compete	with	microbial	growth	
	
The	main	strategies	would	be	to	prevent	infections	from	occurring,	encourage	investments	in	anti-
infective	treatments,	delay	resistance	development	and	alter	host-microbe	interactions	without	
directly	killing	the	microbes.	The	latter	approach	may	involve	the	usage	of	inhibitors	of	efflux	
pumps	and/or	quorum	sensing	inhibitors.	The	most	popular	suggested	approach	to	delay	
resistance	development	is	currently	the	reduction	of	usage	of	antibiotics.	Indeed,	a	cost	of	$	1.1	
billion	of	unnecessarily	prescribed	antibiotics	was	estimated	in	the	US.	In	addition	to	human	
usage,	24.6	million	pounds	of	antibiotics	per	year	were	administered	non-therapeutically	on	
animals	in	the	US,	in	the	early	2000’s.	(Fair	and	Tor,	2014).	In	parallel	to	reduction	of	usage,	
developing	of	new	compounds,	especially	against	MDR	bacterial	pathogens,	is	strongly	advocated	
(Penchovski	and	Traykovska,	2015).	
	
Over	the	past	twenty	years	several	studies	have	investigated	the	potential	of	cationic	antimicrobial	
peptides	(AMPs)	as	novel	anti-infective	agents	(Hancock	and	Lehrer,	1998;	Marr	et	al.,	2006).	
These	naturally	occurring	compounds	have	been	a	model	for	extensive	design	of	new	classes	of	
antibacterial	compounds	(McGrath	et	al.,	2013).	Hereafter	we	survey	the	features	common	to	the	
natural	compounds,	their	pros	and	cons	and	their	potential	applicability.		3.	Hypotheses	and	objectives	of	the	present	investigation	
	
The	efficacy	of	synthetic	natural	and	modified	variants	of	antimicrobial	peptides	may	be	hampered	
when	such	compounds	are	used	in	vivo.	We	therefore	hypothesized	that	the	activity	of	α-
peptide/β-peptoid	peptidomimetics	would	be	affected	by	the	presence	of	body	fluids	such	as	
human	blood	serum	and	plasma.	Based	on	this	hypothesis,	the	purpose	of	Article	1	was	to	
investigate	the	antibacterial	effect	of	α-peptide/β-peptoid	peptidomimetics	in	laboratory	media	
that	would	mimic	in	vivo	conditions.	
Bacterial	resistance	to	antimicrobial	peptides	and	peptidomimetics	can	develop	as	it	does	toward	
conventional	antibiotics.	AMPs	used	in	combination	may	decrease	the	risk	of	bacterial	resistance	
development	as	compared	to	single	AMP-treatments.	We	therefore	hypothesized	that	evolution	
of	resistance	to	a	combination	of	three	selected	antibacterial	compounds	would	be	slower	than	to	
the	single	compounds.		
The	objectives	addressed	in	Manuscript	2	and	3	have	been	the	following:	
o to	investigate	in	E.	coli	the	development	of	adaptive	resistance	to	two	AMPs	and	one	
peptidomimetic,	alone	and	in	a	combination	of	three;	
o to	identify	the	genetic	basis	of	the	evolved	resistance	in	E.	coli	by	whole-genome	
sequencing	analysis;	
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o to	investigate	the	stability	of	the	evolved	resistance;		
o to	search,	in	the	adapted	resistant	bacteria,	for	the	occurrence	of	cross-resistance	and	
susceptibility	to	other	antibacterial	compounds.	4.	Cationic	antimicrobial	peptides		
	
AMPs	are	a	group	of	compounds	produced	by	most	living	organisms	as	part	of	their	innate	defense	
(Hancock	and	Lehrer,	1998);	(Figure	2).	AMPs	can	have	different	mechanisms	of	antibacterial	
activity.	However,	perturbation	of	the	cell	envelope	is	a	key	mechanism	of	activity	of	many	AMPs.	
Use	of	AMPs	as	potential	novel	antibacterial	agents	is	considered	a	promising	approach	to	
overcome	bacterial	resistance	to	conventional	antibiotics.	They	constitute	an	innate	defense	
component	of	all	living	organisms,	have	small	size	and	have	demonstrated	activity	against	
bacterial,	viral	and	fungal	infections	(Tossi	et	al.,	2000;	Zasloff,	2002;	Brogden	et	al.,	2003).		
	
AMPs	exist	in	all	multicellular	organisms	and	have	evolved	in	living	organisms	over	2.6	billion	years	
(Kaufmann	et	al.,	2004).	It	is	known	from	the	beginning	of	20th	century	that	body	secretions	as	
well	as	blood	and	polymorphonuclear	leukocytes	contain	antimicrobial	compounds	(Skarnes	and	
Watson,	1957).	Example	of	secretions	where	human	AMPs	are	present	are	saliva,	tears,	sweat	and	
milk;	they	are	also	found	in	the	skin	and	the	tongue,	bone	marrow,	plasma,	kidneys,	liver,	heart,	
brain,	eyes,	intestine,	sperm,	urinary	tract,	amniotic	fluid,	and	respiratory	tract.	Many	different	cell	
types	such	as	epithelial/mucosal	cells,	macrophages,	neutrophils,	natural	killer	cells,	monocytes,	
eosinophilic	leukocytes,	Paneth	cells,	T-cells	and	B-cells	also	contain	AMPs	(Wang	and	Wang,	
2016).	
The	most	well-known	AMPs	comprise	lysozyme	(isolated	from	the	nasal	mucous;	Fleming,	1922),	
cecropins	(from	moths;	Steiner	et	al.,	1981),	magainins	(from	frogs;	Zasloff,	1987),	b-defensins	
(Lehrer,	2004)	and	cathelicidins	(Gennaro	and	Zanetti,	2000),	of	which	the	last	two	types	are	key	
components	of	the	antimicrobial	response	in	polymorphonuclear	leukocytes	in	humans.		
In	fact,	the	human	cathelicidin	LL-37	chemoattracts	neutrophils,	monocytes,	and	mast	cells	(Yang	
et	al.,	2000)	while	b-defensins	chemoattract	leukocytes	(Territo	et	al.,	1989)	as	well	as	dendritic	
cells,	which	ultimately	phagocytize	and	kill	the	pathogens	(Liu,	2001).	Hence,	cathelicidins	and	b-
defensins	are	key	effectors	both	in	the	adaptive	and	innate	immune	system.		
	
Mammalian	AMPs	can	be	expressed	constitutively	or	be	inducible	(Martin	et	al.,	1995),	and	they	
are	produced	by	ribosomal	translation	of	an	mRNA	template	followed	by	proteolytic	steps	
(Gudmundsson	et	al.,	1996).	Conversely,	peptide-based	antibiotics	of	bacterial	origin	(such	as	
polymyxins,	the	glycopeptide	vancomycin	and	the	lipopeptide	daptomycin)	or	fungal	origin	(b-
lactams)	are	produced	via	non-ribosomal	peptide	synthesis.		
	
AMPs	typically	possess	a	net	positive	charge	and	amphipathic	properties.	The	positive	charge	of	
AMPs	is	believed	to	be	key	to	their	effect,	interacting	with	and	perturbing	the	negatively	charged	
bacterial	cell	envelope.	The	net	charge	of	human	AMPs	varies	from	−3	to	+20,	but	most	natural	
AMPs	are	cationic.	In	fact,	it	is	often	stated	that	a	net	positive	charge	of	at	least	+2	is	necessary	for	
an	AMP	to	exhibit	a	reasonable	activity.	AMPs	normally	contain	two	or	more	residues	such	as	
arginine	or	lysine	that	are	positively	charged	at	neutral	pH	(Hancock	et	al.,	1995).	Some	AMPs	
contain	histidine	as	positively	charged	residues	in	weakly	acidic	environments.	
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The	length	of	human	AMPs	can	vary	from	10	to	150	amino	acids	(Wang,	2014).	Some	proteins	are	
too	big	to	be	classified	as	AMPs	or	are	produced	following	highly	regulated	immune	processes	
(Kondos	et	al.,	2010;	Voskoboinik	et	al.,	2010).	AMPs	longer	than	10	residues	may	fold	into	a	
three-dimensional	secondary	structure,	of	which	a-helices	are	most	common.	Notably,	a-helices	
are	barrel-shaped,	and	often	two	"sides"	can	be	distinguished:	a	hydrophobic	and	a	hydrophilic,	
consisting	of	non-polar	amino	acid	side	chains	and	positively	charged	residues,	respectively	
(Hancock,	1997).	The	content	of	hydrophobic	residues	is	approx.	40-60%	enabling	an	amphiphilic	
structure	(Tossi	et	al.,	2000).		
	
Up	to	2600	AMPs	are	listed	in	an	online	antimicrobial	peptide	database,	APD3,	accessible	at	
http://aps.unmc.edu/AP/main.html	(Wang	and	Wang,	2016).	A	few	examples	of	AMPs	are	shown	
in	Figure	3.	In	the	database,	112	are	different	human	host-defense	peptides,	of	which	100	were	
shown	to	have	broad-spectrum	antibacterial	activity	(Andersson	et	al.,	2016).		
In	the	APD3	database	AMPs	have	been	classified	based	on	their	3D	structure	into	four	major	
families	(Wang	et	al.,	2016):		
	
• a-family,	composed	of	AMPs	with	a-helical	structures,	such	as	the	human	cathelicidin	LL-
37	(Agerberth	et	al.,1995)	
• b-family,	composed	of	AMPs	with	b-strands,	such	as	the	human	a-defensins	(Selsted	et	al.,	
1985)	
• ab-family,	with	AMPs	with	structures	containing	both	a-helical	and	b-strands	(Andersson	
et	al.,	2016)	
• non-ab-family	contains	AMPs	with	neither	a-helical	nor	b-strands,	such	as	indolicidin	
(from	cattle;	Selsted	et	al.,	1992).	
	
Other	classification	modes	exist	such	as	linear	and	cyclic	peptides	(Kohli	et	al.,	2002).	Peptides	can	
also	be	grouped	according	to	the	most	abundant	amino	acids	e.g.	Pro-rich	(Gennaro	et	al.,	2002;	
Otvos,	2002)	and	Arg-rich	peptides	(Chan	et	al.,	2006).	
	
	
	
	
Figure	2:	AMPs	can	act	directly	against	the	
pathogens	or	indirectly	by	potentiating	
the	immune	host	defense;	certain	
peptides	have	one	or	the	other	activity	
preferentially	(Figure	1	in	Hancock	and	
Sahl,	2006).	
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might have dozens of different peptides, and these peptides presum-
ably have overlapping roles with respect to both their antimicrobial and 
innate immune–modulating activities. Thus, it is perhaps unsurpris-
ing that mouse gene knockouts deleting any single peptide have rather 
mild phenotypes, and there are rather few human deficiencies in such 
peptides (and those that exist such as specific granule deficiencies and 
Morbus-Kostmann syndrome are complicated in having other underly-
ing defects).
Host-defense peptides vary substantially even among mammalian 
species7. For example, the cathelicidin peptides mouse CRAMP and 
human LL-37 share only 67% homology, and both species lack the 
substantial variety of cathelicidins in cattle; mice lack neutrophil 
α-defensins that are the most prevalent protein in human neutrophils; 
and cattle completely lack α-defensins in the gut and neutrophils. 
Indeed, there are substantial variations in defensins even among primate 
species8, and these genes are considered to be subject to positive selec-
tion and to be among the most rapidly evolving group of mammalian 
proteins. It seems possible that the rapid coevolution of host-defense 
peptides, of innate immune systems of which they are a part, as well as 
of corresponding microbial counter strategies, including resistance and 
virulence (anti-immunity) strategies, has helped to drive diversity in all 
biological kingdoms4,9.
Some themes among the structures of host-defense peptides do exist, 
however. Mammalian gene structures for the so-called cathelicidins and 
defensins are relatively conserved, and sequences are conserved in their 
precursor (pre-pro) regions. Also within the disulfide bridge–contain-
ing peptides, a three-dimensional structural motif, the so-called gamma 
core, has been conserved throughout 2.5 billion years of evolution, and 
is also present in membrane-active toxins and chemokines, indicating 
possible evolutionary relationships and the potential role of such a motif 
in the effector functions that govern host-pathogen relationships10.
Unlike the β-sheet peptides, the α-helical and extended peptides 
(which include many cathelicidins) tend to be highly flexible in solution, 
and adopt amphipathic structures only upon contact with membranes 
and membrane-mimicking environments. This also holds true for many 
bacterial peptides (termed bacteriocins), even when they contain one or 
two disulfide bonds. Among the bacteriocins of Gram-positive bacte-
ria, there is a particular group, the lantibiotics (lanthionine-containing 
peptide antibiotics), which are characterized by thioether-based 
intramolecular rings resulting from post-translational modifications 
of serine (or threonine) and cysteine residues (for example, nisin and 
mersacidin; Fig. 2)11. Lanthionine rings, some of which represent con-
served binding motifs for recognition of specific targets, create segments 
of defined spatial structures in the peptides12. These ring structures also 
provide stability against proteases, possibly including the antigen-pro-
cessing machinery, because antibodies against highly cross-bridged 
antibiotics, such as mersacidin, are very difficult to obtain.
In addition to ribosomally synthesized antimicrobial peptides, 
microbes also produce peptide antibiotics of broad structural diversity 
using large multifunctional enzymes, the so-called nonribosomal-peptide 
synthetases13. These enzymes have modular structures with each module 
incorporating (and modifying) a specific amino acid, accommodating 
residues in D configurations as well as many other nonprotein amino 
acids, ring formation, glycosylation and acylation. Some prominent 
examples of nonribosomally synthesized peptides include the cationic 
peptides polymyxin B and gramicidin S that are used in the topical treat-
ment of infections, as well as the noncationic glycopeptide vancomycin 
and the lipopeptide daptomycin, which have become important reserve 
antibiotics against multiply resistant Gram-positive bacteria.
Because of the potent antibiotic activity, in the low-nanomolar con-
centration range, of many bacterially derived peptides, it is often taken 
for granted that these peptides are effective weapons in the fight for 
ecological niches. As with many other antibiotic compounds, however, 
experimental data have yet to be obtained showing that, for example, 
lantibiotics are produced in complex ecosystems such as the human 
gastrointestinal tract or skin, or that exogenous producer strains can 
effectively compete with preexisting normal flora because of their abi-
lity to produce an antibiotic compound. In contrast, the knockout of 
a staphylococcal lantibiotic gene cluster resulted in growth attenuation 
in a mouse abscess model14, indicating that there may be additional 
ecological roles for bacteriocins.
Mechanism of action of cationic antimicrobial peptides
Virtually every peptide sequence with a net positive charge and a few 
hydrophobic residues will have antimicrobial activity if assayed in buf-
fer or dilute medium as often used in the literature. It is worth noting, 
however, that the antimicrobial activity of cationic host-defense pep-
tides is antagonized to variable extents by divalent cations like Mg2+ and 
Ca2+ (at physiological concentrations of 1–2 mM), monovalent cations 
such as Na+ and K+ (100 mM), and polyanions such as glycosamino-
glycans (heparin and others) and mucins. Thus, the term antimicrobial 
peptides should be reserved for those peptides that are convincingly 
demonstrated to have an ability to directly kill microbes under such 
physiological conditions.
The cationic and amphiphilic nature of antimicrobial peptides is 
associated with their activity. The overall positive charge ensures accu-
mulation at polyanionic microbial cell surfaces that contain acidic 
polymers, such as lipopolysaccharide, and wall-associated teichoic 
acids in Gram-negative and Gram-positive bacteria, respectively. They 
transit the outer membrane of the former via self-promoted uptake1. 
Subsequently these peptides contact the anionic surface of the cytoplas-
mic membrane and insert in a manner such that they initially straddle 
the interface of the hydrophilic head groups and the fatty acyl chains 
of membrane phospholipids. After insertion into the membrane, anti-
microbial peptides act by either disrupting the physical integrity of the 
bilayer, via membrane thinning, transient poration and/or disruption 
of the barrier function, or translocate across the membrane and act on 
internal targets (Fig. 1).
Several complex and controversial models describe these subsequent 
events, including the reorientation of peptide molecules perpendicular 
Figure 1  Biological roles of host defense peptide. Both direct antimicrobial 
killing and innate immune modulation occur with such peptides although 
certain peptides have one or the other activity preferentially. For a more 
complete outline of direct killing and immune modulation see refs. 1–4.
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Figure	3:	Selected	structures	and	sequences	of	host-defense	peptides	(Figure	2	in	Hancock	and	
Sahl,	2006).	
	4.1	Advantages	of	AMPs	over	conventional	antibiotics	
	
Several	features	of	AMPs	(and	derivatives	thereof)	make	them	potential	promising	novel	
antibiotics:	AMPs	have	co-evolved	with	human	pathogens.	This	long	evolution	time	has	allowed	
for	emergence	of	high	modularity	and	diversity	in	length,	amino	acid	sequence	and	secondary	
structure	(Hancock,	1997;	Zasloff,	2002).	AMPs	exert	bactericidal	effect	rather	than	being	
bacteriostatic;	hence,	cell	membrane	disruption	and	inhibition	of	cell	functions	occur	during	a	
short	contact	time	and	cause	rapid	killing	of	bacteria	(Hirsch,	1956;	Hultmark	et	al.,	1980;	Tu	et	al.,	
2015).		They	act	in	synergy	with	the	immune	system	by	inducing	production	of	chemokines,	
accelerating	angiogenesis,	wound	healing	and	modulating	apoptosis	in	multicellular	organisms	
(Gudmundsson	and	Agerberth,	1999;	Lai	and	Gallo,	2009).	All	these	are	desirable	features	for	a	
drug	class	alternative	to	conventional	antibiotics.		
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to the membrane to form either barrel-stave 
or toroidal channels, the breakdown of mem-
brane integrity as a result of the swamping of 
membrane charge by a ‘carpet’ of peptides at 
the interface, the detergent-like dissolution of 
patches of membrane and the formation of 
peptide-lipid aggregates within the bilayer15. 
Each of these successfully predicts the ability of 
cationic antimicrobial peptides to break down 
the cytoplasmic membrane, but only the toroi-
dal channel and aggregate models explain the 
action of certain peptides on cytoplasmic tar-
gets. Indeed, the action of many peptides can-
not be explained by disruption of membrane 
permeability barriers, as discussed in several 
reviews9,15,16. Other highly charged peptides 
may interfere with the activity of the cell-wall 
lytic enzymes on the outside of the cell17. A 
similar complexity of mechanism also applies 
to the antiviral and anti-fungal action of such 
peptides15.
The development of clinically useable con-
ventional antibiotics has been often biased 
toward the concept of each antibiotic having 
a single primary target and a single mode of 
action, although this may not be entirely cor-
rect18. Nature appears to have chosen a dif-
ferent concept for the evolution of the innate 
host-defense peptides, favoring the design of 
‘dirty’ drugs that disturb many biological func-
tions with modest potency rather than blocking 
a specific high-affinity target9. Peptides have 
been effective for billions of years, so such an 
approach might represent a method of extend-
ing the half-life of these antimicrobials, beyond 
the 1–2 decades enjoyed by most conventional 
antibiotics. There is no question that such pep-
tides will eventually induce resistance9,19, and 
although resistance is clearly more difficult to 
attain than for conventional antibiotics, it has 
been suggested that it might have more severe 
connotations if it led to cross-resistance to innate human antimicrobial 
peptides19. However, several issues mitigate these concerns⎯including 
the fact that to date, (i) all knockout animals lacking host-defense pep-
tides are quite healthy with only modest alteration in susceptibility to 
infection, (ii) the cross-resistance of laboratory-selected mutants to 
other peptides seems to be limited20⎯and the importance of immu-
nomodulatory properties of these peptides, which would not be affected 
by antimicrobial resistance, has been increasingly recognized.
In the case of the lantibiotics, the concept of combining several 
antibiotic activities in one molecule has permitted the achievement 
of unprecedented potencies as demonstrated by, for exa ple, nisin, 
gallidermin and lacticin 3147 (ref. 21). In addition to moderate affin-
ity targets that these peptides use to antagonize a broad spectrum of 
Gram-positive bacteria, they also interact with high-affinity pyro-
phosphate binding sites on the membrane-bound cell wall precursor 
Lipid II (ref. 21), leading to more effective formation of pores and/or 
inhibition of cell wall peptidoglycan biosynthesis. When these activi-
ties operate together, which is usu lly the case with bacteria closely 
related to the producer strain, subnanomolar concentrations are suf-
ficient for killing.
Clinical experience to date
Nature has taught us that cationic peptides have tremendous structural 
diversity and an impressive array of clinically meaningful activities. This 
has provided a huge impetus to the development of new synthetic pep-
tides. Even so, despite nearly two decades of serious design efforts, there 
has been limited success in the clinic22.
To date, four cationic peptides or proteins have advanced into phase 
3 clinical-efficacy trials. These have been indicated for curing or pre-
venting impetigo and diabetic foot ulcers (the frog magainin deriva-
tive MSI-78; Pexiganan), oral mucosaitis (the pig protegrin derivative 
IB-367; Iseganan), sepsis (the human bactericidal permeability protei  
derivative rBPI23; Neuprex) and catheter-associated infections (the 
cattle indolicidin variant CP-226; Omiganan). Only two peptides dem-
onstrated efficacy.
Pexiganan, topically administered to sufferers of diabetic foot ulcer, 
was as effective as oral antibiotic treatment with ofloxacin, leading to a 
clinical cure or improvement in 90% of patients. Even so, the US Food 
and Drug Administrati n (FDA) did not appr ve this drug for medical 
use. In phase 3a clinical trials, Omiganan missed its primary clinical 
target, the prevention of catheter-associated infections, because of a low 
Figure 2  Selected structures and sequences of host-defense peptides.
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4.2	Mechanism	of	action	of	AMPs	
	
Net	charge	and	amphipathic	structure	are	the	two	interrelated	features	that	confer	antibacterial	
activity	to	AMPs.	Often	such	peptides	cause	lysis	of	the	bacterial	cell	and	it	is	believed	that	cell	
lysis	originates	from	the	interaction	between	the	bacterial,	anionic	membranes	and	the	positively	
charged	peptides.	First,	electrostatic	interaction	with	the	bacterial	surface	occurs	(Skarnes	and	
Watson,	1957;	Raguse	et	al.,	2002).		
	
In	Gram-negative	bacteria,	electrostatic	interactions	occur	between	the	positively	charged	AMPs	
and	the	negatively	charged	lipopolysaccharide	(LPS)	or	phospholipid	head	groups	of	the	
membrane	(Figure	4).	Teichoic	acids	(TAs)	are	the	negatively	charged	components	present	in	the	
bacterial	envelope	of	Gram-positive	bacteria.	In	Gram-positive	bacteria	AMPs	interact	with	and	
diffuse	into	the	cell	membrane	while	in	Gram-negative	bacteria	AMPs	interact	via	high	binding	
affinity	for	LPS	and	high	permeabilization	of	the	outer	membrane	leading	to	efficient	and	faster	
killing	(Balakrishnan	et	al,	2013).		
	
The	factors	influencing	interactions	of	AMPs	with	membranes	can	be	studied	by	modifying	their	
charge	and	hydrophobic	properties.	The	latter	are	assumed	to	be	more	important	for	activity	
against	Gram-positive	bacteria.	
	
After	the	electrostatic	interaction,	the	peptide	is	inserted	into	the	bacterial	cell	membrane	where	
the	amphipathic	nature	of	AMPs	allows	them	to	form	pores.	This	process	provokes	disruption	of	
the	membrane	integrity	leading	to	osmotic	lysis	of	the	bacterial	cell	accompanied	by	leakage	of	
cytoplasmic	components,	and	consequently	cell	death	(Van’t	Hof	et	al.,	2001;	Shai,	2002;	Brogden,	
2005;	Kawasaki	et	al.	2008).	Lysis	generally	increases	as	the	charge	increases	(Ringstad	et	al.,	2007;	
Malmsten,	2014).	The	nature	of	the	charged	group	and	charge	distribution	can	also	have	an	
impact	on	the	membrane	interactions	of	AMPs	(Pasupuleti	et	al.,	2012).	
	
Pore	formation	occurs	through	the	following	steps.	First	AMPs	accumulate	on	the	surface	of	the	
membrane	(Epand	and	Vogel,	1999),	and	then	after	reaching	a	threshold	concentration,	AMPs	
self-assemble	and	are	incorporated	into	the	membrane.	A	series	of	models	have	attempted	to	
predict	the	details	of	this	process:	(i)	in	the	barrel-stave	model,	peptides	associate	and	form	a	pore	
inserted	perpendicularly	in	the	bilayer;	(ii)	in	the	carpet	mechanism,	peptides	lie	parallel	to	the	
bilayer	and	ultimately	disintegrate	the	membranes	by	a	detergent-like	effect;	(iii)	in	the	toroidal	
pore	mechanism,	peptides	insert	perpendicularly	into	the	bilayer	and	cause	a	membrane	
curvature	where	the	pore	is	flanked	by	both	peptides	and	phospholipid	head	groups	(Melo	et	al.,	
2009).	These	different	models	can	all	be	valid	for	most	AMPs	under	different	conditions.	
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Figure	4:	Model	for	the	mechanism	of	action	of	AMPs.	In	Gram-negative	bacteria,	peptides	must	
be	able	to	penetrate	the	LPS-rich	layer	in	the	outer	membrane	in	order	to	enter	into	the	
periplasmic	space	(A).	Subsequently,	peptides	interact	with	the	anionic	cytoplasmic	membrane	
while	adopting	an	amphiphatic	secondary	structure	(B).	This	structure	is	able	to	integrate	into	the	
outer	leaflet,	causing	a	thinning	effect	that	is	followed	by	channel	formation,	thus	inducing	
depolarization	and/or	leakage	of	intracellular	contents	(C),	or	destruction	of	the	bilayer	structure	
by	formation	of	micelles	(D).	In	some	cases,	peptides	induce	contacts	between	outer	and	inner	
membranes,	allowing	mixing	of	lipids	and	therefore	changing	the	membrane	composition	(E),	
thus	resulting	in	osmotic	imbalance.	Finally,	peptides	may	translocate	across	the	cytoplasmic	
membrane	and	attack	intracellular	targets.	Figure	1	in	Rabanal	and	Cajal	(Villa	and	Vinas,	2016).	
	
	
Other	mechanisms	that	involve	much	more	specific	interactions	than	described	above	have	been	
suggested.	Phoenix	et	al.,	(2015)	and	Stromsted	et	al.,	(2016)	indicated	phosphatidylethanolamine	
(PE)	as	a	high-affinity	lipid	target	for	several	AMPs.	This	lipid	component	is	present	in	a	high	
concentration	on	the	surface	of	bacterial	membranes,	whereas	it	is	only	present	on	the	
cytoplasmic	leaflet	of	mammalian	membranes,	and	hence	promotes	specificity	of	AMPs	for	
bacterial	surfaces	(Andersson	et	al.,	2016).	Bacterial	membranes	do	not	contain	cholesterol	(Tytler	
et	al.,	1995).	Conversely,	the	plasma	membranes	of	mammalian	cells	contain	a	significant	amount	
(30-50	mol	%)	of	cholesterol	(Hao	et	al.,	2001),	along	with	neutral	zwitterionic	phospholipids,	
interspersed	with	low	amounts	of	anionic	lipids.	Also	these	features	ensure	selectivity	of	AMPs	
toward	bacteria	over	mammalian	cell	membranes	(Lai	and	Gallo,	2009).		
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The	mechanism	of	action	of	human	AMPs	is	clearly	targeted	toward	bacterial	cell	
walls/membranes	rather	than	mammalian	plasma	membranes.	However,	it	is	still	not	clear	how	
the	AMPs	traverse	the	bacterial	cell	outer	membrane.	Membrane	activity	is	the	most	frequently	
reported	antibacterial	mode	of	action	for	AMPs,	but	it	may	be	an	oversimplification	of	a	much	
more	complex	process	that	does	not	always	involve	interactions	with	the	bacterial	surface	(Huang	
et	al,	2000;	Guilhelmelli	et	al.,	2013).	Thus,	it	has	been	found	that	some	AMPs	may	traverse	
bacterial	envelope	without	damaging	the	membrane(s)	and	act	intracellularly	by	blocking	essential	
cellular	processes	(Patrzykat	et	al.,	2002;	Brogden,	2005;	Sharma	and	Nagaraj,	2015).	Suggested	
intracellular	targets	include	the	negatively	charged	DNA	to	which	AMPs	may	bind	through	
electrostatic	interactions	(Tu	et	al.,	2015).	Other	intracellular	mechanisms	comprise	inhibition	of	
nucleic	acid	and/or	protein	synthesis	as	described	by	Brogden	(2005)	and	Kawasaki	et	al.	(2008).	
Moreover,	other	examples	involve	inhibition	of	chaperone-assisted	protein	folding,	inhibition	of	
enzymatic	activity,	and	inhibition	of	cytoplasmic	membrane	septum	formation	and	cell	wall	
synthesis	(Nicolas,	2009).	Examples	of	AMPs	with	intracellular	activity	comprise	a-defensin	5	
(Chileveru	et	al.,	2015)	and	indolicidin,	a	bovine	cathelicidin	with	broad-spectrum	bactericidal	
activity.	The	latter	inhibits	DNA	synthesis	(Subbalakshmi	and	Sitaram,	1998;	Ghosh	et	al.,	2014).			
Nevertheless,	also	AMPs	that	target	specific	intracellular	functions	need	to	initially	interact	with	
the	membrane	(Otvos,	2002;	Nicolas,	2009).	Indeed	some	intracellularly-active	AMPs	may	be	
translocated	via	certain	membrane	transporter	proteins	e.g.	SbmA	(Mattiuzzo	et	al.,	2007;	
Corbalan	et	al.,	2013).		
Other	studies	have	shown	that	membrane	activity	and	intracellular	targets	are	not	clearly	
exclusive	of	each	other	(Podda	et	al.,	2006;	Gottschalk	et	al.,	2015).	It	follows	that	interaction	with	
microbial	membranes	and	the	resulting	increased	permeability	cannot	be	the	solely	lethal	steps	
for	certain	AMPs	(Nicolas,	2009).		
Therefore,	AMPs	are	not	merely	pore	formers	as	their	mechanism	of	action	is	much	more	complex	
and	diverse	than	previously	believed.	This	diversity	is	not	surprising	considering	the	fact	that	host	
defense	systems	have	evolved	several	strategies	to	fight	pathogens	(Nguyen	et	al.,	2011).	
The	mechanism	of	action	of	AMPs	also	depends	on	the	targeted	bacteria.	Furthermore,	
mechanism	of	action	of	AMPs	differs	not	only	between	Gram-positive	and	Gram-negative	bacteria,	
but	also	between	different	bacterial	strains	depending	on	the	lipid	composition	of	their	
membranes.		
	4.3	Methodologies	for	studying	the	mechanism	of	action	of	AMPs	
	
It	is	essential	to	understand	the	mechanism	of	action	of	the	antibacterial	effect	of	AMPs.	This	is	
part	of	assessing	potential	toxicity	and	risks	and	can	also	facilitate	the	modifications	of	AMPs	into	
potential	drugs	for	human	use.	
	
Linear	peptides	(<40	residues)	with	α-helical	domains	can	be	produced	by	solid-phase	synthesis	
and	characterized	by	CD	spectroscopy.	The	latter	is	used	to	infer	the	helical	content	of	a	given	
peptide,	hence	providing	preliminary	information	on	a	peptide	mechanism	of	action	(Tossi	et	al.,	
1997).	Structural	definition	of	a	given	peptide	can	also	be	obtained	by	applying	several	other	
spectroscopic	techniques	in	the	presence	of	model	systems	such	as	cell	wall	components	or	
liposomes.	Examples	of	these	techniques	are	NMR,	ATR-FTIR,	neutron	scattering	and	atomic	force	
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spectroscopy.	In	addition,	surface	plasmon	resonance,	fluorescent	dye	release	from	liposomes	and	
electrical	measurements	of	membrane	conductance	can	be	used	to	follow	insertion,	assembly	and	
permeabilization	events	of	AMPs	in	model	systems	(Zelezetski	and	Tossi,	2006).	A	typical	approach	
is	to	use	cytoplasmic	phospholipid	membranes	mimicking	bacterial	membranes	and	study	their	
morphological	changes	on	a	microscopic	level	before	and	after	the	insertion	of	the	compound	
(Matsuzaki	et	al.,	1994;	Andreev	et	al.,	2014).	
	
Confocal	and	electron	microscopy	and	flow	cytometry	are	techniques	used	to	study	the	
mechanism	of	action	of	AMPs	on	whole	cells	(Chapple	et	al,	1998).	The	first	ones	can	provide	
information	on	the	morphological	changes	occurring	on	the	bacterial	cell,	the	second	can	be	used	
to	monitor	changes	in	the	bacterial	cell	wall	potential.	
	
In	vitro	studies	with	real	bacteria	such	as	antimicrobial	susceptibility	testing	by	determination	of	
minimum	inhibitory	concentration	(MIC)	and	time-kill	assays	are	routinely	applied. 
	
Overall,	the	use	of	combined	specific	biophysical,	biochemical	and	microbiological	methods	would	
be	the	best	choice.	Indeed,	the	analysis	of	the	data	inferred	from	both	real	and	model	system	
would	provide	a	more	complete	understanding	of	the	mechanism	of	action	of	peptides	(Zelezetski	
and	Tossi,	2006).		4.4	AMPs	and	potential	application	in	treatments	
	
On	their	way	from	pre-clinical	phases	to	approval	by	FDA,	AMPs	are	facing	a	series	of	challenges,	
partially	due	to	the	concern	for	their	in	vivo	toxicity	and	resistance	development.			
	
The	polymyxins	B	and	E	(the	latter	also	known	as	colistin)	are	examples	of	AMPs	in	clinical	use	
since	the	1950s.	They	have	been	applied	for	both	topical	and	systemic	treatment	of	infections	
(Landman	et	al.,	2008).	Their	therapeutic	use	has	increased	to	combat	multidrug-resistant	
pathogens	(Falagas	and	Kasiakou,	2005).	However,	their	intravenous	use	has	been	limited	by	the	
high	nephrotoxicity	and	neurotoxicity	(Falagas	and	Kasiakou,	2006).	According	to	some	authors,	
the	concern	for	nephrotoxicity	and	neurotoxicity,	already	observed	with	the	polymyxins,	may	be	
one	of	the	reasons	for	preventing	further	development	of	AMPs	for	intravenous	treatment.	
Nevertheless,	these	risks	of	toxicity	seem	overrated,	considering	that	colistin	is	used	continuously	
for	years	for	treatment	of	patients	affected	by	cystic	fibrosis	(Valerius	et	al.,	1991;	Schuster	et	al.,	
2013).	The	discrepancies	between	in	vitro	and	in	vivo	trials	may	instead	have	discouraged	clinical	
development	of	other	AMPs	(Falagas	and	Kasiakou,	2005;	Zavascki	et	al.,	2007;	Landman	et	al.,	
2008).	
	
Andersson	et	al.,	(2016)	report	cationic	peptides	that	are	currently	in	clinical	development	(Table	
3).	Among	these,	the	human	derived	lactoferrin	1-11	and	OP-145	(based	on	LL-37)	are	intended	for	
intravenous	administration	and	chronic	ear	infections,	respectively.	Pexiganan	(analogue	of	
magainin,	frog-derived),	iseganan	(synthetic	protegrin;	from	pig	leucocytes)	and	omiganan	
(derivative	of	indolicidin;	from	bovine	neutrophils)	are	also	still	in	clinical	development	for	
treatment	of	diabetic	foot	ulcer,	pneumonia	and	skin	infections,	respectively.	Purely	synthetic	
AMPs	such	as	LTX-109	(Nilsson	et	al.,	2015)	and	C16G2	(Kaplan	et	al.,	2011)	are	in	clinical	trials	for	
treatment	of	Gram-positive	skin	infections	and	dental	diseases,	respectively.		
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AMPs	can	also	be	used	for	other	purposes	than	specifically	bactericidal,	e.g.	for	drug	delivery	into	
bacterial	cells.	Indeed	intracellular-active	AMPs	can	be	used	as	vehicles	for	delivery	of	novel	
antibiotics	such	as	the	PNA	(Antisense	Peptide	Nucleic	Acid)	oligomers	(Hansen	et	al.,	2016).		
	
AMPs	have	also	other	applications	than	clinical.	They	are	used	as	food	preservatives,	such	is	the	
case	of	the	bacteriocin	nisin	(Papagianni,	2003).	LL-37	and	lysozyme	are	applied	in	cosmetics	or	in	
antifouling	materials	(Brogden	and	Brogden,	2011).	
	
Table	3:	Antimicrobial	peptides	in	clinical	development	(Adapted	from	table	3	in	Andersson	et	al.,	
2016).	
	
Peptide	 AMP	source	
(host)	
Status	 Administration	 Indication	 Company	
OP-145	 LL-37	(human)	 Phase	I/II	 Ear	drops	 Chronic	bacterial	
ear	infection	
OctoPlus	Inc.	
hLF1-11	
(Lactoferrin)	
Lactoferrin	 Not	
specified	
Intravenous	 Neutropenic	stem	
cells	
transplantation	
patients	
AM-Pharma	B.V.	
Pexiganan	
(MSI-78)	
Magainin	(frog)	 Phase	III	
	
	
Phase	III	
	
Topical	cream	
	
Diabetic	foot	
infection	
	
Diabetic	foot	ulcers	
Dipexium	
Pharmaceuticals	
Inc.	
MacroChem	
Corporation	
Iseganan	(IB-
367)	
Protegrin-1	
(porcine	
leukocytes)	
Phase	III	
	
	
	
Phase	
II/III	
	
Mouth	wash	 Prevention	of	
chemotherapy-
induced	mucositis	
Prevention	of	
ventilator-
associated	
pneumonia	
National	Cancer	
Institute	
	
	
IntraBiotics	
Pharmaceuticals	
Omiganan	
(MBI-226,	
CLS001)	
Indolicidin	(bovine	
neutrophils)	
Phase	III	
	
	
	
	
Phase	III	
	
Phase	II	
	
	
	
Phase	II	
	
	
Phase	II	
Topical	cream	
	
Topical	skin	
antisepsis,	
prevention	of	
cetheter	infections	
Rosacea	
	
uVIN	(usual	type	
vulvaryl	
intraepithelial	
neoplasia)	
Moderate	to	severe	
acne	vulgaris	
Mild	to	moderate	
atopic	dermatitis	
Mallinckrodt	
	
	
	
	
Cutanea	Life	
Sciences	Inc.	
Cutanea	Life	
Sciences	Inc.	
	
	
Cutanea	Life	
Sciences	Inc.	
	
Cutanea	Life	
Sciences	Inc.	
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Lytixar	(LTX-
109)	
Synthetic	
antimicrobial	
peptidomimetic	
Phase	II	
	
	
Phase	
I/IIa	
Topical	cream	
	
	
Nasal	
Uncomplicated	
Gram-positive	skin	
infections	
Nasal	carriers	of	
Staphylococcus	
aureus	
Lytix	Biopharma	
AS	
C16G2	 Synthetic	
specifically	
targeted	
antimicrobial	
peptide	
Phase	II	 Mouth	wash		 Prevention	of	tooth	
decay	caused	by	
Streptococcus	
mutans	
C3	Jian	Inc.	
	
	4.5	Disadvantages	of	AMPs		
	
AMPs	unfortunately	come	with	several	shortcomings	(Table	4).	One	of	these	is	the	high	cost	of	
production	as	compared	to	conventional	antibiotics,	e.g.	the	penicillins.	Yet	this	depends	on	the	
length	of	the	compound.		
On	top	of	this,	despite	AMPs	have	been	studied	for	more	than	three	decades,	a	clear	molecular	
understanding	of	their	mechanism	of	action	still	represents	a	challenge	(Wimley,	2010).		
	
There	may	be	bioavailability	issues	in	vivo,	as	well	as	proteolytic	instability	(Chongsiriwatana	et	al.,	
2008).	In	fact,	AMPs	cannot	be	administered	orally	due	to	poor	absorption	after	ingestion,	
because	they	are	usually	large	and	strongly	cationic.	They	are	rapidly	degraded	by	proteases	both	
in	the	bloodstream	and	in	the	gastrointestinal	tract,	and	they	do	not	diffuse	easily	into	the	Central	
Nervous	System,	due	to	the	blood-brain	barrier;	they	are	rapidly	degraded	in	the	liver	and	
excreted	via	the	kidneys.		They	may	lead	to	undesired	effects	due	to	interactions	with	several	
receptors;	hence	they	may	be	too	toxic	to	allow	for	systemic	therapy	(Bush	et	al.,	2004).	
Moreover,	there	is	an	unknown	risk	of	compromising	the	immune	defense	(Bell	and	Gouyon,	
2003;	Andersson	et	al.,	2016).	
	
Table	4:	Advantages	and	disadvantages	of	AMPs	as	anti-infective	drugs.	Adapted	from	Gordon	et	
al.,	(2005).		
	
Advantages	 Disadvantages	
Broad-spectrum	activity	 Costs	of	synthesis,	screening	and	manufacturing	
Rapid	killing	 Patent	exclusivity	for	economic	viability	
Bactericidal	activity	 Reduced	activity	in	presence	of	salt,	serum	
Concomitant	broad	anti-inflammatory	activity	 Sensitivity	to	pH	
Potential	low	levels	of	induced	resistance	 Susceptibility	to	proteolysis	
High	diversity	 Local	and	systemic	toxicity	
Synergy	with	the	immune	system	e.g.	production	of	
chemokines,	accelerating	angiogenesis,	wound	
healing	
Confounding	biological	functions	(e.g.	angiogenesis)	
	 Pharmacokinetic	(PK)	and	pharmacodynamic	(PD)	
issues	
	 Sensitization	and	allergy	after	repeated	application	
	 Intrinsic	resistance	(e.g.	in	Serratia	marcescens)	
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All	these	potential	side	effects	make	development	of	AMPs	into	future	drugs	challenging	
(Malmsten,	2014).	Hence,	they	may	be	used	for	topical	applications	only,	rather	than	systemic	use	
(Cassone	and	Otvos,	2010).	Indeed	AMPs	have	proven	to	be	successful	when	incorporated	into	
topical	therapeutic	agents	(Andersson	et	al.,	2016).			
	
The	described	shortcomings	have	led	to	an	interest	in	designing	synthetic	AMPs	and	
peptidomimetic	analogues	(Jahnsen	et	al.,	2012;	Liu	et	al.,	2013;	Jahnsen	et	al.,	2015).	Short-
length	synthetic	AMPs	(5-11	residues)	have	also	received	attention	due	to	their	structural	
simplicity	(Lee	et	al.,	2011;	Lau	et	al.,	2015)	with	an	ensuing	benefit	in	cost	and	ease	of	
optimization	as	well	as	reduced	side	effects	(Won	et	al.,	2004;	Oyston	et	al.,	2009).		
	5.	Synthetic	variants	of	AMPs	/	peptidomimetics		
	
Peptidomimetics	exhibit	antibacterial	activity	similar	to	AMPs.	They	are	designed	to	improve	the	
features	of	AMPs	such	as	hydrophobicity,	net	charge	and	secondary	structure	(such	as	helicity)	
and	provide	reduced	hemolytic	activity	and	capability	to	assist	in	intracellular	drug	delivery	
(Marshall	et	al.,	2003).	Peptidomimetics	possess	non-peptidic	backbones	that	confer	proteolytic	
stability	(Figure	5).	
	
	
Figure	5:	Backbone	structures	of	natural	α	-peptides	and	peptidomimetic	residues	(Olsen	et	al.,	
2007).	
	
Improved	hydrophobicity	is	a	desired	feature	in	physiological	environment,	where	high	ionic	
strength	can	impair	the	membrane-disrupting	effect	of	highly	charged	hydrophilic	peptides	
(Ringstad	et	al.,	2008).	Yet,	too	hydrophobic	peptides	may	interact	both	with	bacteria	and	human	
cells	(Malmsten,	2014).	Hence,	hydrophobicity	shall	be	tuned	carefully	in	order	to	maintain	
activity,	but	at	the	same	time	avoid	toxicity.	Higher	hydrophobicity	can	be	reached	by	
incorporation	of	amino	acids	such	as	Leu,	Ile,	Phe	or	Trp	(Qi	et	al.,	2010)	or	by	attachment	of	fatty	
acids	to	the	peptide	chain	(Majerle	et	al.,	2003).	
	
Potency	can	be	increased	by	introducing	specific	a-amino	acids	such	as	Leu	or	Lys	(Beven	et	al.,	
2003).	Such	structure	modifications	stabilizes	a-helical	conformations	(Chou	and	Fasman,	1974;	
Giangaspero	et	al.,	2001),	however,	this	is	usually	accompanied	by	decreased	cell	selectivity.	
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Similarly,	tryptophan	constitutes	an	amino	acid	that	is	abundant	in	natural	AMPs	(e.g.	indolicidin	
and	tritrpticin)	(Epand	and	Vogel,	1999;	Sitaram,	2006).	Tryptophan	may	stabilize	the	a-helical	
structure	of	membrane-interacting	peptides	(Hu	et	al.,	1993;	Oh	et	al.,	2000),	and	its	indole	side	
chain	interacts	favorably,	via	intercalation,	with	the	outer	membrane	of	the	Gram-negative	
bacterial	envelope	(Jing	et	al.,	2003).	Hence,	incorporation	of	Trp	residues	may	confer	antibacterial	
potency	even	in	ultra-short	synthetic	AMPs	(Won	et	al.,	2002).	Discouragingly,	a	high	content	of	
Trp	also	promotes	hemolytic	activity	(Blondelle	and	Lohrer,	2000),	raising	the	concern	of	lowered	
cell	selectivity	toward	bacteria	over	mammalian	cells.	Nevertheless,	this	drawback	may	be	
circumvented	by	alternative	molecular	designs,	e.g.	Lee	et	al.,	(2011)	found	that	Leu®Trp	
substitutions	in	an	LK-based	amphipathic	a-helical	AMP	afforded	a	short	peptide	(LLKWLKKWLKK-
NH2)	with	high	antibacterial	activity	while	retaining	low	hemolytic	activity.	In	addition,	C-terminal	
end-tagging	with	Trp	or	Phe	residues	was	shown	to	improve	potency	and	cell	selectivity	of	the	
Pro/Arg-rich	peptide	RRPRPRPRP	(Schmidtchen	et	al.,	2011;	Malmsten	et	al.,	2011).		
	
Also,	a	high	content	of	Arg	often	confers	high	potency	as	it	increases	overall	positive	charge	as	well	
as	hydrogen-bonding	toward	negatively	charged	head	groups	of	negatively	charged	phospholipids	
abundant	in	the	bacterial	membrane	(Chan	et	al.,	2006).	The	nine-residue	Pac-525	(Ac-
KWRRWVRWI-NH2)	and	its	derivatives	were	reported	to	be	essentially	devoid	of	cytotoxicity	(Qi	et	
al.,	2010;	Li	et	al.,	2015).	Their	high	potency	is	believed	to	arise	from	the	presence	of	Arg-Trp	(RW)	
repeats,	also	present	in	other	well-known	natural	AMPs,	such	as	lactoferricin	B,	indolicidin	and	
tritrpticin	(Vogel	et	al.,	2002;	Liu	et	al.,	2007).	A	screening	of	30	ultra-short	peptides	(up	to	9	
residues)	revealed	that	Pac-525	and	an	octapeptide	(IRIRIRIR-NH2),	containing	(RW)	and	
isoleucine-arginine	(IR)	repeats,	respectively,	both	displayed	broad-spectrum	activity	(MIC	6.25	
µM	toward	MRSA,	P.	aeruginosa	and	Candida	albicans)	as	well	as	low	cytotoxicity	(Lau	et	al.,	
2015).	The	RW	motif	appears	preferentially	to	induce	membrane	disruption	rather	than	pore	
formation.	
	
The	presence	of	chiral	hydrophobic	b-peptoids,	guanidinylated	amino	acid	side	chains	and	the	
relatively	short	length	are	some	of	the	strategies	adopted	in	order	to	keep	a	favorable	balance	
between	AMP	potency	and	cytotoxicity	(Liu	et	al.,	2013).		
	
Evaluation	of	peptide	toxicity	simply	by	hemolysis	test	is	not	enough	to	infer	the	toxicity	of	the	
compounds	in	vivo.	Hence,	considerable	effort	has	been	devoted	to	improved	design	towards	
enhanced	selectivity	against	selected	mammalian	cell	lines	(Jahnsen	et	al.,	2014).		
	
An	alternating	cationic-hydrophobic	design	was	shown	to	enhance	selectivity	against	Gram-
negative	pathogens	over	mammalian	benign	cells	(Jahnsen	et	al.,	2014).	Improved	selectivity	
toward	Gram-positive	such	as	Enterococcus	faecium	and	Staphylococcus	aureus	can	be	achieved	
by	introduction	of	specific	hydrophobic	moieties	at	the	N-terminus,	unlike	introduction	of	cationic	
moieties	(Jahnsen	et	al.,	2015).		
Control	of	selectivity	against	mammalian	cells	can	also	be	achieved	by	introduction	of	D-amino	
acids	and	fluorinated	amino	acids.	These	are	believed	to	break	the	secondary	structure	and	reduce	
the	hydrophobic	bonds	involved	in	the	interaction	with	mammalian	cells.	
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5.1	Mechanism	of	action	of	peptidomimetics		
	
Mechanism	of	action	is	inferred	by	studying	the	interaction	of	peptidomimetics	with	lipid	bilayer	
membranes	by	microcalorimetric	and	spectroscopic	analysis;	by	these	means	effect	of	length,	
charge	and	N-terminal	end	group	can	be	studied.	Membrane	depolarization,	dye	leakage	and	
Scanning	Electron	Microscopy	(SEM)	assays	can	be	applied	to	study	membrane	interactions	(Qi	et	
al.,	2010).	The	mechanism	of	action	of	peptidomimetics	largely	resembles	that	of	AMPs.	Hence,	
activity	and	membrane	specificity	are	fine-tuned	by	keeping	a	balance	between	hydrophobicity	
and	presence	of	cationic	residues	(Porter	et	al.,	2002;	Al	Badri	et	al.,	2008).	
	5.2	Disadvantages	of	peptidomimetics	
	
Toxicity	in	the	human	body,	due	to	high	hemolytic	activity,	is	one	of	the	main	current	challenges	
for	the	application	of	peptidomimetics	(Qi	et	al.,	2010;	Cruz-Monteagudo	et	al.,	2011).	High	
hemolytic	activity	can	correlate	with	high	hydrophobicity,	high	amphipathicity	and	high	helicity.	
Hence,	accurate	rational	design	shall	be	pursued	in	light	of	developing	peptides	with	lower	or	no	
toxicity	over	erythrocytes.	Cruz-Monteagudo	et	al.,	(2011)	proposed	a	chemoinformatic	model	
where	hemolytic	activity	of	a	given	compound	is	predicted.	This	tool	may	aid	in	selection	of	
compounds	with	great	antimicrobial	potency	and	at	the	same	time	low	toxicity.	
Potential	undesirable	side	effects	due	to	interaction	of	peptidomimetics	with	components	of	our	
immune	system	are	also	a	concern	and	may	prevent	their	further	application.	
	5.3	Treatment	applications	of	peptidomimetics		
	
According	to	Gordon	et	al.	(2005),	no	modified	AMP	has	received	FDA	approval;	in	a	more	recent	
review,	two	compounds	(synthetic	mimics	of	defensin	and	protegrin,	respectively)	are	in	proccess	
of	approval	(Table	5);	(Amin	&	Deruelle,	2015).	
	
Table	5:	Preclinical	compounds	currently	in	development	against	Gram-negative	pathogens.	
Adapted	from	Amin	and	Deruelle,	(2015).	
	
Agent	name	 Company	 Antibiotic	class	 Target	Gram-
negative	
pathogens	
Development	
status	
POL7080	 Polyphor	Ltd	
(Allschwil,	
Switzerland)	
Protegrin	mimetic	 Pseudomonas	
aeruginosa	
Phase	I	trial	
completed,	
recruiting	
participants	for	
phase	II	trial	
CTIX1278	 Cellceutix	(MA,	
USA)	
Defensin	mimetic	 Klebsiella	
pneumoniae	
In	vivo	animal	
model		
RPX2014/RPX7009	 The	Medicines	
Company	(NJ,	
USA)	
Carbapenem/new	
β-lactamase	
inhibitor	
combination	
K.	pneumoniae	 Phase	I	
completed	
BAL30072	 Basilea	 Monosulfactam	 Acinetobacter	 In	phase	I		
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Pharmaceutica	
(Basel,	
Switzerland)	
baumannii,	
Enterobacter	
spp.,	Klebsiella	
oxytoca,	and	P.	
aeruginosa	
DS-8587	 Daiichi-Sankyo	
(Tokyo,	Japan)	
Quinolone	 Acinetobacter	
baumannii	
In	phase	I	
	
	6.	The	efficacy	of	AMPs	and	peptidomimetics	in	vivo		
	
The	efficacy	of	novel	compounds	is	first	evaluated	in	vitro,	in	standard	laboratory	medium	(e.g.	
Mueller-Hinton	broth).	However,	it	is	known	that	the	Minimum	Inhibitory	Concentration	(MIC)	
required	for	in	vitro	activity	is	generally	higher	than	the	concentration	required	in	vivo,	due	to	
accumulation	of	the	compound	at	the	site	of	infection	and	synergy	with	other	AMPs	(Lai	and	Gallo,	
2009).	Also,	interaction	of	AMPs	with	components	of	the	human	body	may	affect	the	actual	
efficacy	in	vivo	(Deslouches	et	al.,	2005).	For	instance,	in	presence	of	high	salt	concentrations	(e.g.	
of	NaCl	and/or	MgCl2)	the	activity	of	AMPs	may	be	lower	than	expected	from	MIC	values	
determined	in	vitro.	In	fact,	divalent	cations	such	as	Mg2+	and	Ca2+	compete	with	the	cationic	
AMPs	for	binding	sites	on	the	LPS	(Tomita	et	al.,	2000).	Also,	reduced	activity	of	natural	and	
synthetic	peptides	in	presence	of	serum	has	been	reported	for	several	known	AMPs	(Knappe	et	al.,	
2010;	Gottschalk	et	al.,	2016).	It	follows	that	the	efficacy	of	compounds	in	vivo	may	differ	from	
that	in	vitro.	Hence,	it	is	necessary	to	find	ways	to	predict	the	functionality	of	compounds	in	vivo.		
	
An	improved	approach	is	to	test	the	compounds	in	laboratory	systems	that	mimic	in	vivo	
conditions	i.e.	in	the	presence	of	biologically	relevant	concentrations	of	blood	matrices.	
Previous	studies	have	shown	that	such	conditions	can	be	provided	by	human	blood	serum	and	
plasma	added	to	the	standard	laboratory	medium	(Yeaman	et	al.,	2002;	Hein-Kristensen	et	al.,	
2013(b).		We	applied	a	similar	approach	and	found	that	the	presence	of	human	blood	plasma	
increased	the	activity	of	two	α-peptide/β-peptoid	peptidomimetics	against	a	broad	range	of	Gram-
negative	and	Gram-	positive	human	pathogens	(Table	1	in	Citterio	et	al.,	2016).	This	finding	further	
supports	the	potential	of	two	α-peptide/β-peptoid	peptidomimetics	in	vivo.	In	fact,	concentrations	
of	peptidomimetics	and	peptide	antibiotics	may	be	lowered	than	usually	predicted	from	standard	
antimicrobial	susceptibility	testing.	Moreover,	these	compounds	were	selected	for	their	low	
general	cellular	toxicity	(Liu	et	al.,	2013;	Jahnsen	et	al.,	2014).	This	means	that	cytotoxic	side	
effects	will	decrease	significantly	when	the	concentration	needed	for	bacterial	killing	is	lowered	2-	
to	16-fold.	
	
Hence,	modification	of	AMPs	in	order	to	enhance	their	effect	in	presence	of	blood	or	at	
physiological	ionic	strength	constitutes	a	viable	strategy	for	assessing	their	utility	in	vivo.	
In	these	regards,	Deslouches	et	al.,	(2005)	designed	an	arginine-rich	AMP	that	can	retain	its	
activity	in	presence	of	serum	and	plasma	against	Pseudomonas	aeruginosa.	Conversely,	in	the	
same	study	it	was	found	that	the	human	cathelicidin	LL-37	loses	its	activity	when	in	contact	with	
serum	and	plasma.	We	also	found	a	decreased	activity	of	LL-37	in	the	presence	of	plasma	(Table	5	
in	Citterio	et	al.,	2016).	Indeed,	Wang	et	al.	(1998)	proposed	that	LL-37	binds	to	a	30-kDa	plasma	
protein.	It	may	be	that	LL-37	binds	to	blood	components	in	order	to	balance	its	otherwise	
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cytotoxic	effects	in	vivo	(Panyutich	and	Ganz,	1991).	In	contrast,	synthetic	highly	cationic	non-
helical	compounds	may	not	bind	to	blood	components.	Based	on	these	observations,	synthetic	
analogues	gain	a	further	advantage	over	natural	AMPs	(Brogden	and	Brogden,	2011;	Godballe	et	
al.,	2011).		
	6.1	Causes	of	potentiation	of	antibacterial	compounds	by	plasma	
	
Endogenous	blood	components	such	as	complement	proteins	as	well	as	factors	of	the	coagulation	
cascade	may	be	involved	in	the	potentiation	effect.	It	is	known	that	complement	proteins	can	act	
in	synergy	with	antibacterial	compounds	such	as	antibiotics	(Dutcher	et	al.,	1978)	and	AMPs	
(Yeaman	et	al.,	2002).	A	previous	study	showed	that	terminal	complement	components	could	
enhance	the	antibacterial	effect	of	the	membrane	active	polypeptide	polymyxin	B.	Conversely	the	
same	effect	was	not	seen	for	β-lactams	or	aminoglycoside	antibiotics	(Fierer	and	Finley,	1979).	
Similarly,	in	Article	1	we	showed	that	plasma	enhanced	the	activity	of	polymyxin	B,	as	opposed	to	
gentamicin	or	ampicillin	(Table	5	in	Citterio	et	al.,	2016).	Hence	we	hypothesized	that	potentiation	
of	antibacterial	compounds	by	plasma	may	preferentially	occur	for	membrane-targeted	
compounds	such	as	AMPs	and	peptidomimetics.		
A	connection	between	activation	of	complement	proteins	and	the	coagulation	cascade	has	been	
discovered.	Complement	is	known	to	enhance	the	coagulation	process	by	inhibiting	
anticoagulation	factors	(Markiewski	et	al.,	2007).	Also,	specific	coagulation	factors	in	plasma	
trigger	the	release	of	antimicrobial	compounds	in	vivo	(Frick	et	al.,	2006).		The	human	plasma	that	
we	have	used	in	our	study	is	devoid	of	platelets.	Hence,	we	discarded	the	hypothesis	that	platelet-
derived	antimicrobial	peptides	may	be	involved	in	the	potentiation	of	the	peptidomimetics.		
In	these	regards,	AMPs	derived	from	or	based	on	human	platelets	are	known	for	retaining	activity	
in	the	presence	of	plasma	(Darveau	et	al.,	1992;	Yeaman	et	al.,	2002).	In	addition,	peptides	
released	by	platelets	such	as	platelet	microbicidal	proteins,	defensins	and	kinocidins	have	gained	
increased	attention	for	their	involvement	in	clearance	of	pathogens	(Yeaman	et	al.,	2014).	Thus,	it	
is	clear	that	platelets	retain	a	hemostatic	role	as	well	as	a	key	function	in	antimicrobial	host	
defense.	These	observations	lead	us	to	speculate	that	all	these	processes	may	aid	the	activity	of	
peptidomimetics	in	vivo.	Nevertheless	we	acknowledge	that	these	interconnected	processes	can	
only	be	confirmed	in	whole-blood	models.	7.	Causes	of	antibiotic	resistance	development	
	
Antibiotic	resistance	is	defined	as	an	inherited	feature	of	microorganisms	that	are	able	to	grow	at	
high	concentrations	of	an	antibiotic	(Scholar	and	Pratt,	2000;	Brauner	et	al.,	2016).		
Genetically	encoded	resistance	can	be	located	on	chromosomal	genes	as	well	as	on	plasmids.	
Resistance	already	exists	as	an	evolutionary	trait;	indeed	resistance	can	be	selected	for	within	a	
window	of	drug	concentrations	high	enough	to	inhibit	wild	type	growth	but	low	enough	for	some	
resistant	mutants	to	grow	(Drlica,	2003;	Michel	et	al.,	2008).	
Since	some	antibiotics	are	themselves	a	bacterial	product,	bacterial	adaptation	to	antibiotics	
produced	by	other	bacteria	occurred	over	the	history	of	life	(Spellberg	et	al,	2013).	Indeed,	several	
examples	of	resistant	bacteria	exist	in	nature.	Moreover,	resistance	can	develop	in	susceptible	
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bacteria	following	selection	pressure	from	antibiotic	use.	Indeed,	suboptimal	concentrations	of	
antibiotics	are	known	to	trigger	a	stepwise	selection	of	mutations	that	confer	competitive	
advantage	(Laxminarayan	et	al.,	2013).	In	fact,	a	major	cause	of	resistance	spread	is	represented	
by	sub-optimal	doses	of	antibiotics,	according	to	US	CDC	(2013)	and	ECDC	(2013).	
	
Emergence	of	resistance	is	driven	by	the	interplay	between	several	factors	such	as	mutation	rate,	
strength	of	the	selective	pressure,	fitness	of	the	resistant	mutant,	compensatory	evolution,	
epistasis	(Hughes	and	Andersson,	2015).	These	concepts	are	briefly	discussed	below.		
	
Mutation	rate	of	antibiotics	is	the	product	of	population	size	and	rate	of	mutation,	which	is	
typically	in	the	range	of	10-5	to	10-10	per	generation	per	cell.	In	an	infected	human,	the	bacterial	
population	size	may	be	unknown.	However,	some	estimates	exist	and	it	is	known	that	the	bacterial	
population	size	can	increase	so	that	the	presence	of	resistant	mutants	becomes	more	likely	(i.e.	
population	size	x	mutation	rate	>1).	Hence,	emergence	of	resistance	becomes	more	likely	in	
circumstances	such	as	an	infection.		
	
Selection	strength	depends	on	the	concentration	of	antibiotics	to	which	bacterial	pathogens	are	
exposed.	Both	concentrations	above	and	below	the	MIC	of	a	given	compound	can	induce	selection	
of	resistant	mutants	to	such	compound	(Sabtu	et	al,	2015).	In	particular,	sub-MIC	(or	sublethal)	
concentrations	of	antibiotics	not	only	can	induce	selection	of	resistance,	but	also	increase	genetic	
and	phenotypic	variability	in	bacteria,	as	well	as	acting	as	signaling	molecules.	Hence,	exposure	to	
sublethal	concentrations	of	antibiotics	represents	a	growing	concern	for	the	control	of	resistance	
development	and	its	environmental	propagation	(Andersson	and	Hughes,	2014).		
	
Fitness	is	the	evolutionary	success	of	a	drug-resistant	pathogen	in	presence	of	a	drug,	as	
compared	to	that	in	absence	of	that	drug.	In	other	words	fitness	can	be	defined	as	the	probability	
that	a	mutant	emerges,	fixes,	transmits	and	remains	within	a	host	population.	
	
Compensatory	evolution	refers	to	the	emergence,	in	a	drug-resistant	mutant,	of	mutations	that	
can	reduce	fitness	cost	of	the	mutations	conferring	resistance.	Such	compensatory	mutations	can	
increase	the	probability	that	resistance	is	maintained	in	absence	of	compound	(Habets	and	
Brockhurst,	2012;	Hughes	and	Andersson,	2015).	
	
Epistasis	refers	to	a	phenomenon	where	one	component	in	a	system	is	modulated	by	another	
component	in	the	system.	The	relation	of	a	phenotype,	given	by	a	certain	mutation,	to	other	
mutations	in	the	genome,	is	an	example	of	epistatic	interaction	(Chou	et	al.,	2011).			
Examples	of	epistasis	in	antibiotic	resistance	may	be	synergy	and	antagonism	between	drugs	(Yeh	
et	al.,	2009).	Epistasis	also	involves	phenomena	such	as	cross-resistance	and	collateral	sensitivity,	
meaning	that	resistance	to	a	given	drug	can	alter	the	susceptibility	to	other	drugs	(Macvanin	and	
Hughes,	2005).	Epistasis	may	drive	the	acquisition	of	resistance	as	well	as	contribute	to	the	level	of	
overall	resistance	within	a	population	(Chou	et	al.,	2011).	
	
In	addition	to	the	factors	described	above,	epidemiological	factors	such	as	structure,	density	and	
immunity	of	the	host	population	can	contribute	to	the	spread	of	resistant	bacteria.	Moreover,	
interspecies	gene	transmission,	poor	hygiene	both	in	communities	and	hospitals,	as	well	as	the	
increasing	global	travel	and	trade,	all	favor	the	dissemination	of	resistance	(Laxminarayan	et	al.,	
2013).	
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 8.	Bacterial	resistance	to	AMPs	and	peptidomimetics	
	
It	has	been	pointed	out	that	bacteria	would	have	encountered	a	great	challenge	in	developing	
resistance	towards	AMPs	(Hancock,	1997;	Wimley	and	Hristova,	2011),	or	at	least	that	the	
probability	of	resistance	emergence	would	have	been	low,	due	rapid	bactericidal	activity	of	the	
compounds	(Fox,	2013).		
Despite	these	assumptions,	development	of	resistance	toward	antimicrobial	compounds	is	a	
naturally	occurring	phenomenon	in	bacteria	and	several	mechanisms	are	known	(Figure	6	and	7;	
Table	6).	Indeed	bacteria	and	AMPs	have	co-evolved	and	a	parallel	evolutionary	race	has	taken	
place	(Peschel	and	Sahl,	2006;	Hale,	2012).		
However,	it	is	true	that	in	vivo,	injury	and	infections	increase	the	expression	of	AMPs	that	are	
released	by	leukocytes,	neutrophils	and	skin	keratinocytes.	In	these	conditions	bacteria	face	the	
challenges	to	survive	immune	clearance	and	at	the	same	time	the	metabolic	cost	of	undergoing	
resistance-conferring	mutations.	It	follows	that	the	metabolic	cost	of	the	resistance	mutations	
constrains	adaptation	to	AMPs.		
It	is	also	generally	believed	that	mutation	frequencies	are	higher	for	antibiotics	than	for	AMPs	
(Marr	et	al.,	2006).	This	is	because	the	latter	lack	a	specific	receptor	as	molecular	target.	Indeed	
AMPs	act	mainly	by	binding	to	different	macromolecules	in	the	bacterial	cell	membrane.	As	a	
result,	when	the	bacterial	cell	is	targeted	in	such	multi-mode	way,	simultaneous	alteration	of	
several	targets	would	appear	less	probable	than	it	would	be	for	single-target	molecules	(Sallum	
and	Chen,	2008).		
	
However,	bacterial	susceptibility	to	AMPs	varies	a	lot	in	nature	and	the	existing	resistance	
mechanisms	can	be	considered	virulence	phenotypes	of	pathogenic	bacteria	(Nizet,	2006).	
These	AMP	resistance	mechanisms	have	been	shown	to	contribute	to	pathogenesis;	proof	was	
given	by	comparison	between	wild	type	bacteria	and	AMP-sensitive	mutants	in	in	vivo	infection	
models	(Nizet,	2006).	It	thus	appears	that	the	ability	to	resist	AMP	killing	is	a	typical	feature	of	
human	pathogens	(Joo	et	al.,	2016).		
	
A	distinction	between	intrinsic	resistance	and	inducible	(or	adaptive)	resistance	is	usually	made.	
Inducible	(or	adaptive)	resistance	is	driven	by	environmental	stimuli	and	can	be	reversible	due	to	
the	fitness	cost	it	imposes	on	bacteria	(Andersson	et	al.,	2016).	Bacteria	can	indeed	experience	
transient	molecular	modifications	in	the	composition	of	bacterial	membrane.	The	molecular	
mechanisms	behind	these	modifications	are	known	for	both	Gram-positive	and	Gram-negative	
bacteria	(Yeaman	and	Yount,	2003;	Kraus	and	Peschel,	2006;	Nizet,	2006;	Matamouros	and	Miller,	
2015).	Known	strategies	of	resistance	are	membrane	efflux	pumps,	that	export	AMPs,	and	
bacterial-produced	proteolytic	enzymes,	which	cleave	the	peptides	before	they	can	act.	Also,	
external	trapping	alterations	can	bind	AMPs	before	they	reach	the	cell	membrane,	with	
consequent	neutralization.	The	most	common	strategies	are	cell	surface	charge	alterations	that	
induce	overall	decreased	negative	charges	(Fernandez	et	al.,	2010).	This	can	occur	by	
incorporation	of	positively	charged	molecules	in	the	cell	surface	in	order	to	reduce	the	interaction	
with	AMPs	(Andersson	et	al.,	2016).	Also,	thickening	of	the	peptidoglycan	layer	can	contribute	to	
resistance	(Kramer	et	al.,	2008)	as	well	as	modifications	of	membrane	permeability,	such	as	
increased	membrane	rigidity	or	the	opposite	(Nizet,	2006).	
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Other	strategies	can	be	the	downregulation	of	host	AMP	production	(Nizet,	2006)	and	the	
activation	of	two	components	system	in	presence	of	compounds	(Weatherspoon-Griffin	et	al.,	
2011).	
	
Development	of	resistance	to	AMPs	in	vivo	has	been	highlighted	as	a	potential	concern,	if	we	
consider	that	AMPs	mimic	natural	compounds	(Bell	and	Gouyon,	2003;	Perron	et	al.,	2006).	Hence,	
the	issue	has	been	addressed	experimentally	and	there	is	evidence	that	laboratory	stress	can	
cause	intense	selection	and	lead	to	bacterial	adaptation	to	AMPs	(Jochumsen	et	al,	2016).	There	is	
also	evidence	that	resistance	to	peptide	mimics	of	antimicrobial	peptides	can	develop	(Hein-
Kristensen	et	al.,	2013(a);	Citterio	et	al.,	2016;	Submitted).	Based	on	the	current	knowledge,	we	
believe	that	every	novel	AMP	or	peptidomimetic	may	induce	development	of	resistance	in	the	
bacterial	target.	
	
	
	
Figure	6:	Potential	mechanisms	of	resistance	to	antimicrobial	peptides	in	pathogenic	
microorganism.	Figure	2	in	Gallo	and	Nizet,	(2003).	
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Figure	7:	Summary	of	intrinsic	antimicrobial	peptide	resistance	mechanism	in	Gram-negative	and	
Gram-positive	bacteria.	The	main	pathways	resulting	in	transient	high-level	AMP	resistance	in	
bacteria	are	membrane	modifications,	increased	efflux	and	proteolytic	degradation.	Figure	1	in	
Andersson	et	al.,	(2016).		8.1	Methodology	of	resistance	development	in	laboratory	settings	
	
AMP	and	peptidomimetic	resistance	can	be	achieved	experimentally	by	slowly	adapting	the	
bacteria	through	serial	passages	in	liquid	medium	(Samuelsen	et	al.,	2005;	Perron	et	al.,	2006)	or	
direct	plating	(Roland	et	al.,	1993;	Sun	et	al.,	2009).	Mutants	can	be	selected	for	with	two	
methods:	one	is	based	on	serial	passaging	in	medium	containing	increasing	concentrations	of	
antibiotic	or	AMP;	the	other	is	based	on	selection	on	agar	containing	the	compound	in	
concentration	higher	than	MIC	(Figure	8).	The	serial	passaging	method	is	based	on	serial	transfer	
of	bacterial	cultures	in	liquid	medium	supplemented	with	the	compound,	starting	from	sub-
inhibitory	concentrations	(Perron	et	al.,	2006;	Jochumsen	et	al.	2016).	Such	exposed	bacteria	are	
defined	“selection	lines”	(Perron	et	al.,	2006)	or	“lineages”,	(Hein-Kristensen	et	al.,	2013(a).	
Lineages	are	replicates	of	populations	that	grow	in	parallel	and	provide	a	tool	to	study	the	
sequential	accumulation	of	adaptive	mutations.		
	
Perron	et	al.,	(2006)	proposed	a	number	of	ten	transfers	at	constant	concentration	of	compound	
specifying	that	the	number	of	transfers	was	reduced	when	the	selection	lines	were	growing	
vigorously.	In	Manuscript	2	(Citterio	et	al.,	2016;	Submitted)	we	kept	the	concentration	constant	
for	a	number	of	five	transfers,	as	previously	done	in	Hein-Kristensen	et	al.,	2013(a).	Nevertheless,	
we	transferred	selected	lineages	for	a	number	of	times	higher	than	five,	once	concentrations	of	
compound	were	above	MIC	(Citterio	et	al.,	2016;	Submitted).	Hence,	it	is	clear	that	the	choice	of	
number	of	transfers	is	arbitrarily	based	on	the	experimental	design.		
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This	gradual	selection	in	liquid	medium	can	select	for	high	fitness	mutants,	which	is	considered	a	
disadvantage	of	this	method.	Also,	genetic	reconstitution	is	recommended,	in	order	to	confirm	the	
individual	mutations	responsible	for	the	acquired	resistance.		
	
Selection	in	solid	medium	has	the	disadvantage	that	it	requires	higher	amount	of	compound	and	
that	some	of	them	are	less	active	in	agar	plate	(Dhawan	et	al.,	1997).	Also,	if	evolution	of	
resistance	requires	formation	of	several	mutations,	this	would	be	detectable	only	with	the	serial	
passage	method.	As	opposed	to	the	first	method,	selection	on	agar	has	the	advantages	that	low	
fitness	mutants	can	be	isolated	and	mutation	rate	can	be	determined	(Andersson	et	al.,	2016).	
	
	
Figure	8:	Methods	used	for	isolation	of	AMP-resistant	mutants.	(A)	Serial	passage	involves	the	
growth	of	bacteria	in	liquid	media	containing	progressively	increasing	concentrations	of	AMPs.	(B)	
Selection	on	plates	involves	direct	plating	of	bacteria	on	agar	plates	containing	AMP	
concentrations	above	the	MIC.	Adapted	from	Figure	2	in	Andersson	et	al.,	(2016).	
	8.2	Development	of	resistance	to	AMPs	in	laboratory	settings	
	
Several	studies	have	used	adaptive	evolution	to	AMPs	to	address	the	issue	of	potential	resistance	
development	and	overall	show	that	AMP-resistant	mutants	can	be	easily	obtained.		
	
Evolution	of	resistance	to	increasing	concentrations	of	the	AMP	pexiganan	was	studied	in	E.	coli	
and	P.	fluorescens	(Perron	et	al.,	2006),	where	levels	of	resistance	reached	2-	to	64-	fold	and	32-	to	
512-	fold	the	wild	type	MIC,	respectively.		
Samuelsen	et	al.,	(2005)	exposed	S.	aureus	to	the	AMP	lactoferricin	B	and	obtained	a	30-fold	
increase	in	the	wild	type	MIC	after	only	four	passages.	MIC	remained	10-fold	higher	than	the	wild	
type	MIC	in	the	same	strains,	re-cultivated	for	30	passages	in	absence	of	compound,	indicating	
stable	resistance.	Exposure	of	S.	Typhimurium	to	LL-37,	CNY100HL	(a	derivative	of	complement	C3)	
and	wheat	germ	histones	also	led	to	stable	resistant	mutants	(Lofton	et	al.,	2013).		
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Hong	et	al.,	(2016)	studied	bacterial	evolution	to	the	antimicrobial	peptide	tachyplesin	I	in	three	
Gram-negative	bacteria	(Pseudomonas,	Escherichia	and	Aeromonas)	and	also	found	stable	
resistance.	This	finding	may	pose	a	considerable	risk	in	the	clinical	use	of	tachyplesin,	despite	its	
known	promising	antibacterial	activity	against	bacteria,	viruses	and	cancer	cells	(Nakamura	et	al.,	
1998).		
	
Dobson	et	al.,	(2013)	studied	in	vitro	the	adaptive	evolution	of	S.	aureus	to	AMPs	already	
developed	as	drugs	(selected	from	phylogenetically	diverse	taxa	such	as	mammals,	amphibians	
and	insects)	alone	and	in	combination	of	two	e.g.	iseganan,	pexiganan,	melittin	and	a	1:1	
combination	of	melittin	and	pexiganan,	in	parallel	with	vancomycin	and	streptomycin.	The	
treatment	of	melittin	and	pexiganan	in	combination	caused	the	earliest	extinction	among	all	the	
other	treatments,	indicating	that	bacteria	encountered	the	highest	challenge	when	exposed	to	
two	agents	with	different	mechanism	of	action.	Dobson	et	al.,	(2013)	hypothesized	that	this	is	a	
general	phenomenon	that	relies	on	the	interaction	between	the	compounds,	as	previously	noted	
by	Chait	et	al.	(2007);	Yeh	et	al.,	(2009);	Fischbach	(2011).	These	interactions	may	constrain	
evolution	of	resistance	in	natural	settings,	where	multiple	AMPs	are	present.	This	interpretation	is	
partially	in	contrast	with	our	results.	Indeed	in	Citterio	et	al.	(2016;	Submitted),	we	showed	that	
exposure	to	a	single	compound	such	as	the	AMP	P9-4	caused	the	earliest	extinction	among	all	the	
other	treatments,	including	a	combination	of	three	compounds.	This	finding	indicated	that	
bacteria	were	more	challenged	by	exposure	to	P9-4	alone	rather	than	exposure	to	the	same	
compound	in	a	combination	of	three.	Hence,	we	suggested	that	bacterial	resistance	development	
is	compound-dependent	rather	than	combination-dependent.	
	
Based	on	all	these	findings,	we	advocate	early-stage	investigation	of	resistance	development	for	
each	novel	promising	compound.	
	8.2.1	Colistin	example	
	
Colistin	represents	a	special	case,	despite	being	an	AMP;	it	has	the	tendency	of	inducing	resistance	
when	administered	in	sublethal	doses,	which	is	common	practice	when	the	compound	is	used	in	
synergistic	combinations.	However,	this	phenomenon	seems	to	arise	quite	frequently	with	colistin	
rather	than	for	other	conventional	antibiotics	(Cassone	and	Otvos,	2010).		
Roland	et	al.	(1993)	and	Moffatt	et	al.,	(2010)	studied	the	development	of	resistance	to	colistin	in	
agar	plates	in	S.	Typhimurium	and	A.	baumannii,	respectively.	In	the	S.	Typhimurium	colistin-
resistant	mutant	there	was	constitutive	activation	of	PmrAB,	that	caused	increased	Ara4N	(4-
aminoarabinose)	with	consequent	phosphoethanolamine	covalent	modification	of	LPS.	This	
modification	also	caused	1000-fold	increased	resistance	to	polymyxin	B.	The	A.	baumannii	colistin-
resistant	mutants	lost	LPS	consequent	to	the	activation	of	one	of	the	lpx	genes,	that	are	involved	
in	lipid	A	biosynthesis.		
Jochumsen	et	al.,	(2016)	exposed	Pseudomonas	aeruginosa	to	colistin	through	a	long-term	
adaptive	evolution	experiment	based	on	serial	transfers	in	liquid	medium.	They	showed	that	
evolution	of	resistance	is	a	multistep	process	where	mutations	arise	with	a	specific	pattern,	as	
previously	formulated	by	Toprak	et	al.,	(2012),	Palmer	and	Kishony,	(2013)	and	De	Visser	and	Krug,	
(2014).	The	resulting	resistant	phenotype	is	dependent	on	mutations	in	independent	loci	that	act	
synergistically	i.e.	there	is	intergenic	epistasis.	Epistatic	interactions	can	affect	the	number	of	
	 38	
potential	evolutionary	pathways	to	resistance	reducing	them	to	a	few	trajectories,	in	which	fitness	
increases	monotonically	with	each	single	mutation	(Weinreich	et	al.,	2006).		
 
Jochumsen	et	al.,	(2016)	found	mutations	in	the	DNA	mismatch	repair	gene	mutS,	in	the	regulators	
of	LPS	modification	operon	(pho,	pmr)	and	in	genes	affecting	biosynthesis	of	lipid	A	(lpxC	and	
lpxD).	Thus,	evolution	of	resistance	depends	on	mutations	in	transcriptional	regulators	that	can	
fine-tune	the	effect	of	other	mutations	i.e.	a	series	of	modifications	in	the	lipopolysaccharide.	At	
least	this	is	the	case	for	resistance	mechanisms	towards	AMPs	in	Gram-negative	bacteria	(Olaitan	
et	al.,	2014).		DOI:	10.1038/ncomms1300	
Table	6:	Known	mechanisms	of	resistance	to	AMPs,	acquired	with	several	methods.	Adapted	from	
Table	1	in	Andersson	et	al.	(2016).	Ara4N	=	4-aminoarabinose;	PEtN	=	phosphoethanolamine.	
	
Organism	 Method	for	
isolation	
AMP	resistance	 Genes	
involved	in	
AMP	
resistance	
Proposed	mechanism	 Reference	
study	
S.	aureus	 Clinical	
isolates	
LL-37,	human	b-
defensin	2	and	
3,	lactoferricin	B	
hemB	
	
Inactivation	results	in	
small	colony	variants	
with	reduced	AMP	
binding/uptake	
Glaser	et	al.,	
2014	
E.	coli,	K.	
pneumoniae	
Clinical	
isolates	
Colistin,	
polymyxin	B	
	
	
Colistin,	
polymyxin	B	
	
Colistin,	
polymyxin	B	
mcr-1	 Encodes	a	PEtN	
transferase	
modifies	lipid	A	to	
reduce	anionic	charge	
Hu	et	al.,	
2016	
A.	baumannii	 Direct	plating	
with	colistin	
lpxA,	lpxD	or	
lpxC	
Inactivation	results	in	
loss	of	LPS	production,	
reduced	AMP	binding	
Moffatt	et	
al.,	2010	
S.	
Typhimurium	
Direct	plating	
with	colistin	
pmrA,	pmrB	 Constitutive	activation	
of	pmrAB-regulated	
Ara4N	and	PEtN	LPS	
modification	reduce	
anionic	charge	
Roland	et	al.,	
1993;	Sun	et	
al.,	2009	
Direct	plating	
with	
protamine	
Protamine,	
colistin,	
lactoferricin,	
human	a-	
defensin	1	
hemA,	
hemB,	hemC	
hemL	
Inactivation	results	in	
small	colony	variants	
with	reduced	AMP	
binding/uptake	
Pränting	and	
Andersson,	
2010	
Serial	
passages	
with	LL-37	or	
CNY100HL	
LL-37,	
CNY100HL,	
wheat	germ	
histones	
pmrB,	phoP	 Constitutive	activation	
of	various	LPS	
modifications	reducing	
anionic	charge	
Lofton	et	al.,	
2013	
	8.2.2	Cross	resistance	
	
Mutants	that	are	resistant	to	a	specific	drug	can	also	be	resistant	to	structurally	similar	drugs.	This	
phenomenon	is	known	as	cross-resistance.	Resistance	to	drugs	belonging	to	different	classes	can	
be	observed	too,	as	pointed	out	by	Sanders	et	al.,	(1984).	The	same	study	suggests	that	this	
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phenomenon	was	due	to	changes	in	the	outer	membrane	proteins	of	the	investigated	
microorganisms.	Likewise,	AMP-resistant	bacterial	mutants	can	display	broad	cross-resistance	to	a	
variety	of	AMPs	with	different	structures	and	modes	of	action.		
	
For	AMP-resistant	mutants,	the	derived	concern	is	that	resistance	could	develop	toward	other	
AMPs	that	are	part	of	our	immunity.	Thus,	cross-resistance	clearly	represents	a	potential	risk	for	
each	novel	antibacterial	compound	and	requires	more	detailed	investigations	and	understanding	
(Andersson	et	al.,	2016).		
For	instance	Hong	et	al.,	(2016)	found	that	tachyplesin	I-resistant	mutants	were	also	resistant	to	
other	AMPs	such	as	pexiganan,	tachyplesin	III	and	polyphemusin	I,	as	well	as	resistant	to	
antibiotics	such	as	cefoperazone	and	amikacin.		
Hein-Kristensen	et	al.,	2013(a)	investigated,	in	peptidomimetic-resistant	mutants,	in	vitro	cross-
resistance	to	other	AMPs.	We	also	addressed	the	development	of	cross-resistance	in	AMP-	and	
peptidomimetic-resistant	mutants	in	Manuscript	2	(Citterio	et	al.,	2016;	Submitted)	and	3	(Citterio	
et	al.,	2016;	In	preparation).	From	these	studies	we	infer	that	resistance	and	susceptibility	patterns	
in	resistant	mutants	are	difficult	to	explain.		
	9.	Investigation	of	resistance	mechanisms	by	sequencing	technologies		
	
The	development	of	high-throughput	sequencing	(HTS)	technologies	and	their	reduced	cost	now	
allow	for	deep	and	accessible	knowledge	on	bacterial	evolution	(Metzker,	2010;	Loman	et	al.,	
2012;	McAdam	et	al.,	2014).	Indeed,	Illumina	currently	provides	the	highest	throughput	per	run	
coupled	with	the	lowest	per-base	cost	(Liu	et	al.,	2012;	Van	Dijk	et	al.,	2014).		
	
The	main	challenge	of	WGS	projects	is	the	management	of	the	amount	and	complexity	of	
generated	data.	The	chosen	analysis	workflow	shall	aim	at	obtaining	meaningful	biological	results	
(Schadt	et	al.,	2010). Such	challenge	of	WGS	data	analysis	has	prompted	the	development	of	
numerous	tools,	up	to	205,	as	reported	by	Pabinger	et	al.,	(2013).	Nevertheless,	common	to	all	
these	tools	are	the	five	main	steps	of	the	analysis	pipeline:	quality	assessment,	alignment,	variant	
identification,	variant	annotation	and	visualization	(Figure	9).	In	the	alignment	step	reads	can	be	
mapped	to	a	known	sequence;	alternatively,	reads	can	be	de	novo	assembled.	This	choice	of	
analysis	is	made	based	on	read	length,	availability	of	a	known	reference	sequence	and	the	
biological	application	(Loman	et	al.,	2012).	Variant	identification	allows	for	detecting	point	
mutations	(also	known	as	single	nucleotide	polymorphisms	i.e.	SNPs	or	single	nucleotide	variants	
i.e.	SNVs).	These	positional	data	provide	information	down	to	the	level	of	individual	genomic	
variation.	Such	in-depth	analysis	may	become	the	standard	for	genetic	studies	of	natural	
populations	(Ekblom	and	Wolf,	2014).	Thus,	the	single-nucleotide	resolution	of	HTS	has	enabled	
the	identification	of	molecular	mechanisms	underlying	bacterial	resistance	and	pathogenesis	
(Köser	et	al.,	2014;	McAdam	et	al.,	2014).		
	
In	Manuscript	2,	we	sequenced	and	analyzed	the	whole	genomes	of	lineages	and	clones	derived	
from	the	adaptive	evolution	experiment	(Citterio	et	al.,	2016;	Submitted).	We	found	single-
nucleotide	deletions	in	the	gene	encoding	for	the	enzyme	CDP-glycerophosphotransferase	(CDP-
glycerol:	N-acetyl-β-D-mannosaminyl-1,4-N-acetyl-D-glucosaminyldiphosphoundecaprenyl	
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glycerophosphotransferase)	as	the	most	common	variants	in	the	adapted	lineages	and	derived	
clones.	We	know	that	parallel	populations	can	acquire	similar	mutations	in	a	specific	order,	
resulting	in	similar	phenotypic	trajectories	(Toprak	et	al.,	2012).		
We	then	hypothesized	that	a	common	evolutionary	trajectory	has	led	to	development	of	
resistance,	both	to	the	individual	compounds	and	to	the	combination	of	all	three	compounds.		
We	speculated	that	the	emergence	of	the	same	variant	across	lineages	exposed	to	distinct	
compounds	may	also	relate	to	the	similar	nature	of	such	compounds	(Band	and	Weiss,	2015).		
	
The	gene	CDP-glycerophosphotransferase	encoded	for	an	enzyme	consisting	of	1266	amino	acids.	
We	described	three	deletion	types	in	such	gene	(Citterio	et	al.,	2016;	Submitted).	Two	of	these	
deletion	types	were	located	in	the	enzyme	region	responsible	for	the	phosphotransferase	activity.		
We	measured	the	zeta	potential	of	adapted	lineages	and	found	that	it	was	less	negative	than	that	
of	the	wild	type.	Thus,	we	speculated	that	the	resistance	mechanism	was	based	on	reducing	the	
negative	charge	of	the	membrane,	and	limiting	the	interaction	with	positively	charged	AMPs.	Such	
mechanism	seems	to	constitute	a	novel	variation	as	compared	to	the	known	strategies	of	limiting	
the	attraction	of	cationic	compounds	(Band	and	Weiss,	2015).	
	
However,	it	remains	unproven	whether	this	deletion	is	the	actual	resistance-conferring	mutation.	
This	can	only	be	confirmed	by	introducing	such	variants	back	in	wild	type	strains	(Hachmann	et	al.,	
2011;	Jochumsen	et	al.,	2016).	
	
In	conclusion,	the	deep	understanding	of	bacterial	resistance	mechanisms,	supported	by	HTS,	can	
markedly	aid	the	discovery	of	potential	targets	in	drug-resistant	bacteria	(Punina	et	al.,	2015;	Cole	
and	Nizet,	2016).	
Beyond	the	HTS	analysis,	increasing	effort	is	now	targeted	toward	metabolic	network	
reconstructions,	meaning	that	annotated	genomes	can	serve	as	a	basis	for	predicting	a	model	of	
microbial	physiology.	This	process	aims	at	building	a	mechanistic	genotype-phenotype	relationship	
with	the	ultimate	goal	of	designing	antibiotics	interfering	with	strain-specific	capabilities	(Feist	et	
al.,	2009).		
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Figure	9:	Basic	workflow	for	whole-genome	sequencing	projects.	After	library	preparation,	
samples	are	sequenced	on	a	certain	platform.	The	next	steps	are	quality	assessment	and	read	
alignment	against	a	reference	genome,	followed	by	variant	identification.	Detected	mutations	are	
then	annotated	to	infer	the	biological	relevance.	The	found	mutations	can	further	be	prioritized	
and	filtered,	followed	by	validation	of	the	generated	results	in	the	lab.	Figure	1	in	Pabinger	et	al,	
(2014).	
		10.	Strategies	of	circumventing	resistance	development		
	10.1	Drug	combination	strategy		
	
Drug	combinations	can	be	applied	in	clinical	settings	due	to	a	number	of	reasons.	These	can	be	the	
necessity	for	a	long-term	treatment,	synergistic	therapeutic	effects	between	the	drugs	in	the	
combination	or	a	larger	spectrum	of	activity	(Tamma	et	al.,	2012).	Another	relevant	reason	is	the	
belief	that	combinations	of	drugs	with	different	targets	could	disfavour	the	evolution	of	resistance	
(Dobson	et	al.,	2013).	This	is	because	the	pathogen	is	unlikely	to	acquire	mutations	and	resistance	
against	several	targets	at	one	time.	Also	the	risk	of	resistance	is	reduced	if	the	treatment	clears	
the	infection	faster.	A	further	advantage	of	combination	treatment	over	monotherapy	may	be	the	
diminished	side	effects	of	the	drugs,	due	to	reduction	of	dosage	of	the	single	drugs	in	the	
combination	(Tu	et	al.,	2015;	Lin	et	al.,	2015).	
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Drug	combination	therapy	has	been	successful	in	the	treatment	of	Mycobacterium	tuberculosis	
since	the	late	1940s.	Indeed,	streptomycin	combined	with	para-aminosalicylic	acid	was	shown	to	
markedly	reduce	evolution	of	resistance	as	compared	to	streptomycin	alone	(Dunner	et	al.,	1949).	
Treatment	of	HIV	infections	has	been	another	success	in	reducing	drug	resistance	and	increasing	
life	expectancy	of	HIV	patients	(Palella	et	al.,	1998).	Examples	of	combination	therapies	in	
advanced	development	against	Gram-negative	bacterial	infections	are	two	β-lactam/β-lactamase	
inhibitor	combinations	and	or	one	non	β-lactam/β-lactamase	inhibitor	combination	(Amin	&	
Deruelle,	2015).	Combination	therapy	is	also	advocated	for	cancer	treatment	(Glickman	and	
Sawyers,	2012).	Indeed	Zhao	et	al.,	(2014)	have	explored	the	applicability	of	combination	therapy	
based	on	α-helical	peptides	and	chemical	drugs	(doxorubicin	and	epirubicin)	against	cancer	cells.	
Their	promising	results	in	mouse	model	prompt	for	further	clinical	applicability.	Promising	results	
are	also	available	for	treatment	of	HIV	with	peptidomimetic	inhibitors	of	HIV	protease	used	in	
combination	with	antiretroviral	agents	(Randolph	and	DeGoey,	2004).	
	
Some	AMPs	can	increase	the	activity	of	conventional	antibiotics	with	synergistic	interactions	in	
vitro	(Cassone	et	al.,	2008;	Anantharaman	et	al.,	2010;	Feng	et	al.,	2015;	Lin	et	al.,	2015).	However	
their	applicability	in	clinical	is	still	unknown	(Giacometti	et	al.,	2000)	or	not	thoroughly	
investigated	(Ngu-Schwemlein	et	al.,	2015).	Niu	et	al.,	(2013)	showed	that	the	4kD	scorpion	
defensin	potentiates	the	activity	of	conventional	antibiotics	in	vitro.	Hu	et	al.,	(2015)	also	showed	
synergy	between	the	defensin	plectasin	and	conventional	antibiotics	such	as	β-lactams	and	
aminoglycosides,	both	in	vitro	and	in	vivo.	Synergy	between	plectasin	and	cell	wall-targeting	
antibiotics	was	also	investigated	in	Breidenstein	et	al.,	(2015)	who	found	synergism	of	plectasin	
with	some	of	the	tested	agents.	McGrath	et	al.,	(2013)	showed	synergy	between	a	D-enantiomer	
peptidomimetic	and	piperacillin,	an	antibiotic	commonly	combined	with	tazobactam	and	applied	
in	therapeutic	applications.	AMPs	in	combination	with	four	selected	conventional	antibiotics	have	
also	proven	their	potential	against	bacterial	biofilms	(Reffuveille	et	al.,	2014).			
In	contrast	to	all	these	studies	in	favor	of	combinations,	He	et	al.,	(2014)	did	not	find	results	that	
support	combination	of	membrane-permeabilizing	AMPs	with	antibiotics.		
	
AMPs	act	naturally	in	combination	of	more	than	two	compounds	and	Yu	et	al.	(2016)	found	that	
three-AMPs	combinations	were	more	synergistic	than	two-AMPs	combinations.		
Moreover,	AMPs	have	proven	to	act	in	synergy	also	with	their	modified	counterparts	in	vitro	
(Chongsiriwatana	et	al.,	2011;	Zdybicka-Barabas	et	al.,	2012).	However,	it	is	still	unclear	whether	
combinations	solely	made	of	AMPs	and/or	peptide	mimics	are	more	advantageous	than	(antibiotic	
+	antibiotic)	or	(AMP	+	antibiotic)	combinations.		
	
It	is	believed	that	exposure	to	a	combination	of	several	AMPs	can	reduce	the	selective	pressure	
needed	for	resistance	development	(Malmsten,	2014).	Despite	the	extensive	literature	on	the	
potential	of	drug	combinations,	much	fewer	studies	have	explored	the	actual	risk	of	bacterial	
resistance	development	to	such	drugs	combinations.	
		10.2	Disadvantages	of	combination	strategy	
	
Drug	combination	therapy	based	on	synergistic	couples	of	drugs	can	have	adverse	effect	on	
resistance	development.	Indeed	Vestergaard	et	al.,	(2016)	showed	that	antibiotic	combination	
therapy	could	select	for	high-fitness	drug-resistant	mutants	of	Pseudomonas	aeruginosa.	
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In	fact,	synergistic	drugs	increase	the	selective	advantage	of	single	drug-resistant	mutants	(Torella	
et	al.,	2010).	On	the	contrary,	antagonistic	drug	combinations	can	limit	evolution	of	resistance	
(Munck	et	al.	2014).	This	is	supported	by	lower	fitness	in	the	bacteria	that	are	induced	to	develop	
resistance	to	antagonistic	as	opposed	to	synergistic	combinations	(Chait	et	al.,	2007;	Hegreness	et	
al.,	2008;	Michel	et	al.,	2008).	
	
Overall,	drug	interactions	such	as	synergy,	additive	effect	or	antagonism	as	well	as	cross-resistance	
have	an	impact	on	selection	(Michel	et	al.,	2008);	however	it	remains	unclear	which	of	these	
factors	has	higher	impact	on	long-term	evolution	of	drug	resistance	(Andersson	et	al.,	2016).	
	10.3	Inversion	of	resistance	
	
The	main	advocated	strategies	for	tackling	resistance	development	are	the	restriction	of	use	along	
with	the	concept	of	combining	antibiotics	with	compounds	that	inhibit	their	specific	resistance	
mechanism.	These	strategies	are	certainly	valid	in	neutralizing	the	advantage	of	resistant	bacteria.	
However,	they	do	not	prevent	the	eventual	selection	of	resistance	over	time.		
	
Conversely,	inversion	of	the	selective	advantage	of	resistance	is	believed	to	turn	a	resistant	
population	susceptible	again.	Inversion	of	the	selective	advantage	can	be	triggered	by	suppressive	
drug	interactions	e.g.	in	the	situation	where	there	is	collateral	sensitivity	between	two	drugs.	
Indeed,	resistance	to	a	first	applied	drug	can	increase	the	sensitivity	to	a	second	applied	drug	
(Imamovic	and	Sommer,	2013).	The	latter	creates	a	concentration	regime	that	inhibits	the	
resistant	bacteria,	hence	selecting	for	the	sensitive	ones	(Baym	et	al.,	2016).	
	
So	far	a	few	studies	have	focused	on	the	extent	of	collateral	sensitivity	for	AMP-resistant	mutants	
in	presence	of	different	AMPs	and/or	antibiotics	(Berti	et	al.,	2015;	Garcia-Quintanilla	et	al.,	2015).	
Hence,	more	efforts	shall	be	devoted	into	understanding	whether	this	strategy	could	be	applicable	
in	clinical	settings.		
	11.	Perspectives	in	the	potential	of	AMPs	and	peptidomimetics	as	novel	drugs	
Several	challenges	still	prevent	novel	compounds	such	as	AMPs	or	peptidomimetics	from	
proceeding	more	rapidly	to	approval.	Among	these	challenges,	a	few	are	disclosed.		
	
The	mechanism	of	action	and	the	role	of	immune	response	modulation	remain	unclear	for	many	
AMPs.	Lower	toxicity	as	a	desirable	feature	remains	challenging	to	achieve	and	test	(Andersson	et	
al.,	2016).	This	testing	can	be	impaired	by	lack	of	standardization	and	critical	evaluation	of	testing	
methods	(Cassone	and	Otvos,	2010).	A	matter	of	discussion	could	also	be	whether	more	effort	
shall	be	devoted	to	better	characterize	existing	compound	and	the	strategies	to	apply	them	most	
efficiently	rather	than	investing	in	discovering	novel	compounds.	In	this	regard,	combining	
membrane	permeabilizers	may	help	potentiating	the	activity	of	existing	approved	compounds.		
In	addition,	in	light	of	translation	of	basic	research	into	clinical	application,	a	better	
characterization	of	the	intercellular	communication	would	be	preferable	to	the	investigation	of	
microbiological-based	pathways	(Cassone	and	Otvos,	2010).	
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Nevertheless,	AMPs	and	peptidomimetics	do	represent	effective	candidates	as	novel	antibiotics	
for	topical	uses	as	well	as	helper	drugs	for	conventional	antibiotics	or	novel	antibacterial	
compounds.	Overcoming	common	misconceptions	on	peptide	drugs,	such	as	high-price,	
unfavorable	pharmacodynamics	and	lack	of	delivery	options,	also	represents	a	key	goal	for	the	
advancement	of	peptide	drugs	(Otvos,	2014).	Otvos	and	Wade	(2014)	highlight	that	strategies	
exist	to	overcome	their	alleged	poor	oral	bioavailability	and	pharmacodynamics	parameters.	The	
acknowledgments	of	these	strategies	may	also	help	expanding	clinical	application	of	AMPs	beyond	
topical	use.	Discussion	and	conclusion	
	
The	development	of	resistance	to	antibiotics	has	urged	the	search	and	discovery	of	new	potential	
drug	candidates.	Many	efforts	are	currently	directed	towards	bioprospecting	for	novel	compounds	
and	assessing	their	spectrum	of	use.	The	compounds	researched	in	the	present	thesis,	the	
antimicrobial	peptides	(AMPs)	and	their	synthetic	analogues	(peptidomimetics),	constitute	one	
avenue.		
	
A	key	feature	of	a	novel	drug	is	the	effect	under	in	vivo	conditions.	It	is	well	known	that	there	is	
often	a	gap	between	the	activity	tested	in	vitro	and	actual	in	vivo	applicability	of	novel	
compounds.	For	instance,	AMPs	are	known	to	suffer	from	protease	sensitivity	and	poor	
bioavailability	in	vivo	while	their	synthetic	derivatives	are	feared	for	the	risk	of	toxicity.	Thus,	the	
choice	of	new	compounds	as	antibiotics	poses	the	challenge	to	test	their	actual	applicability	in	
vivo.	On	top	of	this	challenge,	the	potential	of	bacterial	resistance	development	may	prevent	
novel	compounds	from	entering	the	process	of	approval	as	future	therapeutics.	Based	on	these	
premises,	the	purpose	of	this	thesis	was	to	address	the	challenges	of	applicability	of	novel	
compounds,	such	as	AMPs	and	peptidomimetics,	and	the	development	of	bacterial	resistance	
towards	them.	
	
Previous	studies	have	found	that	the	effectiveness	of	antimicrobial	compounds	was	reduced	in	
presence	of	body	fluids.	Nevertheless,	a	study	in	our	group	had	found	that	the	activity	of	selected	
peptidomimetics	was	instead	potentiated	in	presence	of	body	fluids	(Hein-Kristensen	et	al.,	2013).	
However,	this	was	found	in	only	one	out	of	two	tested	bacterial	species.	Therefore,	a	broader	
spectrum	of	bacterial	species	was	needed	in	order	to	infer	whether	the	potentiation	is	a	more	
general	effect.	Hence,	the	hypothesis	behind	Article	1	was	that	AMPs	and	their	analogues	could	be	
affected	by	the	presence	of	body	fluids.	From	our	results	we	inferred	that	the	tested	compounds	
were	actually	potentiated	by	human	blood	plasma	in	all	tested	(thirteen)	bacterial	species.	
Therefore,	we	believe	that	these	compounds	may	be	used	in	vivo	in	lower	concentrations	than	
those	predicted	by	traditional	in	vitro	testing.		This	is	a	significant	advantage.	Since	high	dosage	of	
antibiotics	is	considered	one	of	the	causes	of	the	spread	of	resistance	in	bacteria,	the	most	
advocated	strategy	is	to	reduce	dosage.	Hence,	the	possibility	of	decreased	dosing	of	novel	
compounds	while	potentiating	their	effect	is	promising.	Also,	decreased	concentrations	in	vivo	
may	overcome	a	general	concern	about	AMPs	such	is	cytotoxicity.	
	
The	AMPs	tested	were	potentiated	to	a	different	degree	and	this	correlated	with	different	
mechanism	of	action,	and	from	this	we	inferred	that	only	compounds	acting	on	the	cell	membrane	
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or	envelope	were	potentiated	by	human	blood	plasma.	We	speculated	that	such	effect	is	due	to	
synergistic	interaction	between	the	compounds	and	factors	present	in	blood,	especially	
complement	proteins	that	are	in	fact,	as	many	AMPs,	known	to	act	primarily	toward	the	bacterial	
membrane.	Further	studies	in	this	direction	shall	confirm	that	there	is	a	correlation	between	body	
fluid	potentiation	of	the	antimicrobial	activity	of	the	compounds	and	their	mechanism	of	action.	
Nevertheless	such	investigation	may	be	challenging	for	compounds	whose	mechanism	of	action	is	
still	unclear.	Therefore,	clarity	on	the	mechanism	of	action	remains	a	key	issue	for	advancement	of	
novel	compounds.	A	consequent	reflection	is	that	a	limit	exists	to	the	range	of	compounds	for	
which	decreased	dosage	could	be	applied.		
	
The	problem	of	identifying	the	real	cause	(mechanism)	of	potentiation	remains	unsolved.	The	
selected	compounds	were	indeed	potentiated	when	exposed	to	human	blood	plasma,	in	a	
concentration	that	alone	was	not	bactericidal.	Based	on	previous	knowledge	on	decreased	activity	
of	the	compounds	in	presence	of	heat-treated	blood,	we	inferred	that	proteins	essential	for	the	
potentiation	activity	were	denatured	and	we	originally	believed	that	complement	proteins	were	
the	major	cause	of	potentiation.	However,	complement	proteins	are	present	in	both	blood	serum	
and	plasma,	and	we	observed	a	higher	potentiation	of	the	tested	compounds	in	plasma	as	
compared	to	serum.	We	therefore	concluded	that	there	must	be	another	cause	other	than	
complement,	which	contributes	to	the	effect	of	potentiation.	Based	on	other	studies	on	the	
functions	of	clotting	factors	and	platelets,	we	speculated	that	clotting	factors	might	be	involved	
and	synergistically	interact	with	complement	proteins.	However,	the	plasma	we	have	used	is	
devoid	of	platelets	and	thus	it	becomes	difficult	to	relate	the	observed	potentiation	to	clotting	
factors,	since	other	components	of	the	coagulation	cascade	are	missing.	One	consequent	
experiment	would	be	to	test	whether	platelet-rich	plasma	also	potentiates	the	activity	of	the	
compounds.	
Interactions	between	complement	and	the	coagulation	cascade	may	occur	in	vivo	as	a	part	of	the	
immune	response	to	pathogens.	Hence,	future	work	shall	address	the	interaction	between	
complement	and	clotting	factors	in	order	to	clarify	their	impact	on	the	activity	of	novel	drugs	in	
vivo.		
	
The	challenge	of	testing	novel	compounds	in	whole-blood	models	constitutes	another	unresolved	
issue.	This	testing	is	challenging	due	to	the	viscosity	of	whole	blood.	Also,	the	presence	in	blood	of	
cell-derived	immune	factors	may	largely	affect	the	interpretation	of	the	results.	On	top	of	these	
challenges,	the	cost	of	such	human	sample	and	its	limited	shelf	life	may	further	limit	the	studies.	
Nevertheless,	AMPs	and	peptidomimetics	are	acclaimed	for	their	immune-modulating	properties	
and	they	are	supposed	to	act	in	the	context	of	human	immunity,	where	several	factors	would	
concur	to	potentiate	their	activity.	Thus,	another	challenge	is	to	evaluate	whether	traditional	MIC	
is	the	appropriate	test	for	such	compounds.	Serum	stability	has	been	considered	for	long	a	reliable	
screening	tool	in	drug	development.	However,	our	results	indicate	that	human	blood	plasma	may	
represent	a	better	predictor	of	the	drug	pharmacokinetics,	as	compared	to	serum.	Based	on	these	
reflections,	we	suggest	that	future	MIC	testing	uses	traditional	laboratory	growth	media	
supplemented	with	human	blood	plasma.	In	parallel,	we	believe	that	future	studies	shall	also	
consider	whether	pre-clinical	investigations	using	whole	blood	are	actually	feasible.	Along	these	
lines,	it	has	already	been	suggested	that	future	in	vitro	model	systems	shall	at	least	contain	
phagocytic	cells	or	even	the	patient’s	own	blood	(Nizet,	2015).	
	
To	summarize,	Article	1	demonstrates	that	previous	thinking,	namely	that	synthetic	compounds	
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may	face	a	decreased	activity	in	the	presence	of	body	fluids,	is	not	always	true.		The	goal	of	future	
research	shall	be	to	obtain	pre-clinical	results	that	are	the	most	representative	of	in	vivo	
conditions.	We	believe	that	compounds	with	promising	increased	activity	in	the	presence	of	body	
fluids	shall	be	preferred	for	proceeding	studies	for	approval	as	future	therapeutics.	
	
For	years	it	has	been	repeatedly	stated	that	bacteria	could	not	become	resistant	to	AMPs,	because	
AMPs	are	part	of	the	natural	innate	human	defense	and	it	seems	that	they	have	retained	
effectiveness.	However,	studies	have	emerged	and	demonstrated	that	using	an	adaptive	evolution	
approach,	resistance	can	indeed	evolve	rapidly.	Therefore,	if	AMPs	and	synthetic	analogues	are	to	
be	used,	one	must	address	and	possibly	overcome	the	resistance	issue.	In	Manuscript	2	we	
investigated	whether	the	use	of	a	combination	of	three	AMPs	might	prevent	development	of	
bacterial	resistance	as	compared	to	single	compounds.		
This	has	been	predicted	based	on	the	feature,	typical	of	AMPs,	of	having	multiple	targets.	Such	
feature	is	supposed	to	hinder	resistance	development	in	bacteria,	which	would	be	exposed	to	the	
great	challenge	of	modifying	several	targets	at	once.	This	effect	may	be	amplified	once	a	
combination	of	compounds	with	multiple	targets	is	used.	Indeed,	we	observed	delayed	resistance	
development	in	the	lineages	exposed	to	a	combination	of	three	compounds.	However,	we	also	
found	delayed	resistance	development	toward	a	short	AMP	such	as	P9-4.	This	may	occur	due	to	
the	presence	of	RW	groups,	which	are	supposed	to	have	an	increased	number	of	targets	in	the	
membrane,	concomitantly	with	a	strong	membrane	disruptive	mode.	It	becomes	evident	that	
resistance	development	is	compound-dependent	and	this	suggests	that	other	compounds	with	
similar	features	to	P9-4	are	investigated	for	resistance	development.		
	
Our	findings	that	resistance	did	develop	against	all	individual	AMPs	tested	lead	to	the	
recommendation	that	all	novel	compounds	shall	be	tested	by	different	experimental	approaches	
(such	as	adaptive	evolution)	for	resistance	development	before	introduction	and	use.	It	follows	
that	the	choice	of	novel	drugs	shall	be	directed	towards	drug	with	confirmed	delayed	resistance	
development.	The	studies	that	provide	a	resistance	assessment	of	new	antibacterial	agents	tend	
to	use	only	short	time	exposure	to	the	compounds.	By	these	means,	there	exists	a	risk	of	
underestimating	the	actual	potentiality	of	resistance	development.	Indeed,	every	bacterium	could	
develop	resistance	after	continuous	exposure,	provided	that	it	is	given	enough	time.	Thus,	it	is	
evident	that	assessing	the	potential	of	resistance	development	over	time	is	critical,	as	the	
temporal	set-up	allows	several	mutations	to	take	place.	A	standardized	procedure	with	a	
reasonably	ample	but	still	limited	time	frame	for	such	testing	is	necessary.	We	propose	a	
systematic	protocol	that	other	scientists	can	follow	in	order	to	investigate	the	pattern	of	
resistance	development	to	novel	promising	compounds.	Automated	ALE	procedures	are	also	
available	but	are	often	intended	for	industrial	or	basic	research	purposes.	Therefore	we	encourage	
further	optimization	of	ALE	in	order	to	be	specifically	targeted	to	assess	the	emergence	of	
resistance	to	novel	drugs.	
Overall,	our	results	suggest	that	some	compounds	are	more	effective	than	others	in	circumventing	
resistance	development	in	a	limited	time	frame	such	could	be	the	time	of	infection	control.	Hence,	
we	consider	our	method	highly	informative	both	from	a	clinical	but	also	from	an	evolutionary	
perspective.	
	
In	manuscript	2	we	also	investigated	the	adapted-evolved	resistant	lineages	with	a	parallel	
genomic	analysis.	The	purpose	of	such	analysis	was	to	identify	variants	that	differentiate	the	
adapted	lineages	from	the	wild	type	that	was	cultured	in	absence	of	compound.	We	found	
	 47	
deletions	in	the	gene	encoding	for	the	CDP-glycerophosphotransferase	and	speculated	that	these	
independent	mutations	were	involved	in	the	adaptive	resistance.	Our	results	suggest	that	the	
mechanism	of	resistance	may	involve	modification	of	the	bacterial	surface	charge,	resulting	in	a	
less	negative	membrane	that	could	repel	the	positive	compounds.	We	envision	that	further	
studies	might	confirm	this	prediction	and	clarify	whether	a	single	mutation	or	rather	the	interplay	
between	different	cooperative	mutations	is	the	cause	of	resistance.	We	first	suggest	the	
construction	of	wild	type	mutants	with	deletions	in	the	CDP-glycerophosphotransferase,	in	order	
to	confirm	whether	this	indeed	is	the	primary	cause	of	the	observed	resistant	phenotype.			
The	same	deletions	were	found	in	bacteria	exposed	to	structurally	different	compounds.	
Therefore	we	speculated	that	a	common	evolutionary	trajectory	has	been	followed.	This	may	
indicate	that	other	compounds,	not	yet	tested,	could	favor	the	emergence	of	the	same	mutation	
pathway.	Therefore	we	encourage	that	a	database	system	compiles	upcoming	knowledge	on	novel	
antimicrobial	compounds,	tested	bacteria	and	relative	predicted	resistance	genes.	Such	system	
may	also	largely	benefit	from	distinguishing	between	resistance	genes	detected	in	experimentally	
evolved	model	bacteria	and	resistance	genes	already	present	in	intrinsically	resistant	
microorganisms.	The	derived	shared	accessible	knowledge	may	improve	the	current	
understanding	and	overcome	the	existing	misconceptions	on	the	potential	of	resistance	
development	to	novel	compounds.		
	
Manuscript	3	highlights	that	some	AMP-resistant	mutants	become	susceptible	as	the	wild	type,	
simply	after	exposure	to	compounds	with	certain	features.	In	particular,	we	found	that	all	the	six	
tested	resistant	mutants	were	susceptible	as	the	wild	type	when	exposed	to	an	Arg-rich,	IR-
containing	peptide.	The	relevance	of	this	discovery	has	two	main	implications.	One	is	that	there	
may	be	a	strong	correlation	between	bacterial	susceptibility	and	specific	features	of	the	
compound.	We	therefore	envision	that	future	studies	test	a	larger	number	of	AMPs	against	
resistant	bacteria.	The	concern	of	resistance	development	is	primarily	toward	AMPs	that	are	part	
of	our	immunity.	Thus,	further	testing	of	natural	human	AMPs	(such	as	LL-37)	towards	AMP-
resistant	mutants	shall	be	prioritized.	
The	second	main	implication	is	that	the	impact	of	the	resistance	trait	on	cross-resistance	to	other	
compounds	may	be	overestimated.	This	overestimation	may	suggest	that,	in	a	clinical	context,	
adaptive	resistance	to	a	widely	used	drug	could	be	easily	circumvented	simply	by	exposure	to	a	
different	drug.	This	strategy	has	been	supported	for	conventional	antibiotics	(Baym	et	al.,	2016,	
Stone	et	al.,	2016).	Hence,	proven	efficacy	of	such	approach	may	reassure	from	considering	that	
there	is	no	way	out	from	the	issue	of	resistance	development.	On	the	other	hand,	if	this	strategy	
proves	to	be	effective	in	clinical	settings	with	conventional	antibiotics,	there	will	be	higher	
discouragement	in	proceeding	with	the	approval	of	AMPs	as	substitutes	of	conventional	
antibiotics.	Nevertheless,	AMPs	and	their	analogues	remain	versatile	molecules	that	can	aid	in	
innovative	treatments,	not	simply	aimed	at	killing	the	pathogens,	but	rather	focused	on	restoring	
impaired	immune	functions	or	preventing	damage	to	the	local	microbiota.	
	
Overall,	our	study	attempted	to	answer	the	question:	“Can	AMPs	become	the	drugs	of	the	
future?”	AMPs	and	their	synthetic	analogues	retain	a	great	potential	for	different	applications.	
However,	the	substantial	consideration	they	receive	in	basic	research	does	not	seem	to	attract	
adequate	support	in	translational	studies.	In	order	to	gain	more	chances	to	proceed	in	the	process	
for	approval,	AMPs	need	to	gain	equal	consideration	in	the	clinical	research.		
We	reaffirm	that	despite	resistance	to	each	novel	compound	is	a	reality,	further	investigation	shall	
clarify	under	which	conditions	resistance	and	cross-resistance	become	actual	threats.	
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Abstract
Stable peptidomimetics mimicking natural antimicrobial peptides (AMPs) have emerged as a promising class of potential novel anti-
biotics. In the present study, we aimed at determining whether the antibacterial activity of two a-peptide/b-peptoid peptidomimetics against
a range of bacterial pathogens was affected by conditions mimicking in vivo settings. Their activity was enhanced to an unexpected degree in
the presence of human blood plasma for thirteen pathogenic Gram-positive and Gram-negative bacteria. MIC values typically decreased 2- to
16-fold in the presence of a human plasma concentration that alone did not damage the cell membrane. Hence, MIC and MBC data
collected in these settings appear to represent a more appropriate basis for in vivo experiments preceding clinical trials. In fact, concen-
trations of peptidomimetics and peptide antibiotics (e.g. polymyxin B) required for in vivo treatments might be lower than traditionally
deduced from MICs determined in laboratory media. Thus, antibiotics previously considered too toxic could be developed into usable
last-resort drugs, due to ensuing lowered risk of side effects. In contrast, the activity of the compounds was significantly decreased in
heat-inactivated plasma. We hypothesize that synergistic interactions with complement proteins and/or clotting factors most likely are
involved.
© 2015 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
Keywords: Antimicrobial peptide; Peptidomimetics; Antibiotics; Plasma; Synergy
1. Introduction
Bacteria and other microorganisms are becoming resistant
to conventional antibiotics at an alarming rate, and hence,
novel antimicrobial compounds for treatment of infectious
diseases are urgently needed [1]. Several strategies are
being pursued in the search for novel anti-infectives, such
as development of compounds with anti-virulence activity
[2].
Almost all living organisms have an innate frontline de-
fense against microbial infections. Antimicrobial peptides
(AMPs) comprise a diverse group of natural defense com-
pounds that have been isolated from most organisms ranging
from bacteria to humans [3]. Most AMPs are highly cationic
hydrophobic compounds that interact with the bacterial cell
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membrane and cause cell lysis and cell death. AMPs have
been suggested as new antibacterials [4]; however, many
natural AMPs exhibit side effects, e.g. hemolysis or general
cytotoxicity. Also, due to their peptide nature, many AMPs
will rapidly be degraded in vivo by proteases, thereby
diminishing their efficacy [5]. Stable synthetic variants of
AMPs incorporating unnatural residues have been developed
to overcome these shortcomings, and such peptidomimetics
have also been suggested as potential future antibiotics [6,7].
In fact, structural modification may allow optimization of
their bactericidal activity versus cytotoxicty toward human
cells, and hence an improved therapeutic index [8].
Despite the vast plethora of antibacterial compounds being
discovered and chemically synthesized, the transition from
pre-clinical to clinical trial phases still represents a challenge
[9]. In the first evaluation of potential efficacy of novel an-
tibiotics, they are typically tested in laboratory media (e.g.
Mueller-Hinton broth) for minimum inhibitory and minimum
bactericial concentrations (i.e. MICs and MBCs). However,
the actual efficacy in vivo may be different due to in-
teractions with components of the human body [10]. There-
fore, development of laboratory systems that mimic in vivo
conditions will constitute important progress toward a more
efficient selection of candidates for clinical trials. One
obvious approach involves testing the compounds in the
presence of biologically relevant concentrations of blood
matrices and/or at physiological ionic strength. Reduced ac-
tivity of natural and synthetic peptides in serum has often
been raised as a concern [11]. It may, however, be possible to
modify AMPs to overcome this issue or even enhance their
effects in the presence of blood. Indeed, antibacterial pep-
tides derived from or based on human platelets retain their
activity in the presence of human plasma [12]. Also,
Deslouches et al. [10] found that a de novo engineered AMP
rich in arginine (WLBU2) maintained its activity against
Pseudomonas aeruginosa in the presence of both serum and
plasma. In contrast to these synthetic peptides, human cath-
elicidin LL-37 lost its activity in the presence of human
serum as well as in plasma [10]. These findings highlight the
advantages of synthetic analogs over natural AMPs (e.g.
enhanced proteolytic stability in vivo and increased cell
selectivity) [13e15], but also emphasize the need to include
laboratory test methodologies mimicking physiological
conditions.
We recently found that the presence of human blood
plasma unexpectedly increased the activity of a-peptide/b-
peptoid peptidomimetics against Escherichia coli [16];
however, we did not investigate whether this effect is limited
to E. coli or may be extended to other pathogens. The purpose
of the present study was to determine how the antibacterial
effect of these peptidomimetics is influenced by plasma or
serum for a broad range of pathogenic bacteria. Human
plasma proved to potentiate peptidomimetics against all
tested bacteria, and we hypothesized that synergy with
components of the complement system might account for this
observed potentiation. Thus, a major objective became the
testing of this hypothesis.
2. Materials and methods
2.1. Bacterial strains
The effect of human plasma and serum on the antibacterial
activity of peptidomimetics was tested against a panel of
Gram-negative and Gram-positive pathogenic bacteria: E. coli
ATCC 25922, Salmonella typhimurium L354, Serratia mar-
cescens, P. aeruginosa PAO1, Vibrio vulnificus cmcP6, V.
vulnificus DSM 10143, Vibrio parahaemolyticus RimD
D2210633, V. parahaemolyticus ATCC 17802, Staphylococcus
aureus 8325-4, Staphylococcus epidermidis RP62A, S. epi-
dermidis 1457, Listeria monocytogenes EGDe BUG 1600 and
Bacillus cereus ATCC 11778. References to these strains are
reported in Supplemental Table S3.
2.2. Growth conditions and chemicals
The strains were stored at !80 "C and grown overnight at
37 "C (250 rpm) in cation-adjusted Mueller-Hinton II broth
adjusted to pH 7.4 ± 0.2 (MHB, Becton Dickinson, 212322).
The MICs of peptidomimetics were determined in MHB or
MHB supplemented with 1.25% defibrinated horse blood
(REF236999, Statens Serum Institute) to improve growth of B.
cereus and L. monocytogenes [17]. The MBC was determined
by plating from wells with no visible growth on brain heart
infusion agar (BHI, Oxoid, CM1135) containing 1.5% agar
(AppliChem, A7354). Human lyophilized plasma was recon-
stituted in MilliQ water to its original volume of 5 ml to a
concentration of 100%. It was then stored at !20 "C. Human
serum (Sigma Aldrich, H4522) was kept at !20 "C. Both
plasma and serum were purchased as commercially available
products. Plasma from human (Sigma Aldrich, P9523) was
obtained from a pool of 1000e1500 donors, while human
serum derived from human male AB plasma was obtained
from a pool of approximately 200 donors. Ampicillin (Sigma
Aldrich, A9518), gentamicin (Sigma Aldrich, G3632) and
polymyxin B (Sigma Aldrich, P4932) were dissolved in Mil-
liQ water to give stock solutions (10 mg/ml). Citrate solutions
were prepared in MilliQ water with trisodium citrate dihydrate
(Merck Millipore, 106448).
2.3. Peptidomimetics and antimicrobial peptide LL-37
The a-peptide/b-peptoid peptidomimetics 1 and 2 (Fig. 1)
consist of alternating repeats of natural cationic a-amino acids
and synthetic lipophilic b-peptoid residues, and they were
prepared by solid-phase synthesis as previously reported
[8,18]. These compounds were tested for cytotoxicity against
HeLa cells in previous studies [19,20]. Their cytotoxicity (IC50
values) was 32 mM and 96 mM, respectively, while the cyto-
toxicity of closely related compounds towards HeLa cells was
lower (i.e. IC50 values of 316 ± 20 and 228 ± 4 mM,
respectively) [19]. The peptidomimetics exhibited very low
toxicity toward Caco-2 and HUVEC cells (IC50 > 1000 mM)
[19]. The sequence of the human cathelicidin LL-37 is
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-
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CONH2. The compounds were dissolved in MilliQ water to
reach a stock concentration of 10 mg/ml. These stock solutions
were stored at !20 "C.
2.4. Determination of MIC and MBC
MIC was determined by the microdilution broth method
[21] in 96-well non-binding polypropylene microtiter plates
(Thermo Scientific Nunc, 267245) with sterile polystyrene lids
(Sigma Aldrich, CLS3930-100EA). Plates were autoclaved
before use. To determine whether the materials used might
influence the measured activity of the compounds, MIC and
MBC were also tested in plates or vials of different materials.
These included polystyrene plates (Thermo Scientific Nunc,
163320), UV-sterilized polypropylene plates (Thermo Scien-
tific Nunc, 267334; as recommended by Hancock Laboratory
Methods [22]), the above-mentioned non-binding poly-
propylene plates and glass vials (VWR Bie and Berntsen,
2775/378). Stock solutions of peptidomimetics 1 and 2,
ranging from 4096 mg/ml to 32 mg/ml, were prepared in
MilliQ water. Fifty ml of compound solution and 50 ml of the
medium (MHB or MHB supplemented with plasma or serum)
were dispensed into the first well of each row and then twofold
diluted. The influence of native and heat-inactivated plasma
and serum on the antibacterial activity of peptidomimetics and
antibiotics was tested by adding plasma or serum to MHB in
concentrations of 50% and 25%. After addition of peptide
solution and bacterial culture, the resulting exposure concen-
trations were 25% and 12.5%. These tested concentrations of
plasma and serum were based on previous work on E. coli
[16]. However, several strains were unable to grow at these
concentrations of serum and plasma, and therefore, MICs of
serum and plasma for these strains were determined and then
appropriate concentrations of serum and plasma were chosen
based on these MIC values.
Overnight cultures of the strains were diluted in sterile
0.9% NaCl to OD546 ¼ 0.2 (accepted range: 0.195e0.210)
corresponding to approximately 1 $ 108 CFU/ml. This sus-
pension was further diluted 1:100 in MHB and 50 ml of this
culture were inoculated into microtiter plates to reach a final
concentration of 5 $ 105 CFU/ml in a final volume of 100 ml.
Plates were incubated for 20 h at 37 "C. Growth was deter-
mined visually either as turbidity or as formation of a pellet.
MIC was determined to be the lowest concentration of pepti-
domimetics or antibiotics where no growth was observed.
MBC was determined to be the lowest concentration where a
3-log reduction of the original CFU/ml was observed based on
plating from the wells on BHI agar.
2.5. Potentiation of the antibacterial activity of
peptidomimetics by human plasma and serum
The peptidomimetics had more pronounced antibacterial
activity in the presence of plasma and serum (Tables 1e4;
Supplemental Tables S1 and S2), and several experiments
were conducted to determine the mechanism behind this
potentiation. Plasma and serum were heated for 15 min at
56 "C as a non-specific procedure for inactivating the com-
plement [23]. In addition, sodium polyanethole sulfonate
Fig. 1. Chemical structure of a-peptide/b-peptoid peptidomimetics 1 and 2.
Table 1
MIC of plasma (expressed as % of plasma) for all strains used in the present study. MIC of peptidomimetic 1 in MHB, and in MHB supplemented with native
plasma as well as with heat-treated plasma. Nd ¼ not determined; ng ¼ no growth; h.t. ¼ heat-treated. The values are based on two individual experiments
conducted in duplicate.
Target strain MIC of plasma (%) MIC of peptidomimetic 1 (mg $ ml!1)
Added plasma (%)
0 3 6 12.5 25 12.5 h.t.
E. coli %75 2e8 nd nd 0.5e1 0.25e0.5 >64
S. typhimurium 25e50 4e8 nd 1 1e4 ng >512
S. marcescens 12.5 16e128 16 ng ng-2 ng 64
P. aeruginosa 75 128e512 nd nd 16e128 8 >512
V. vulnificus cmcP6 25e75 4e16 nd nd 1e4 0.125e0.25 8e>64
V. vulnificus DSM 10143 25 4e8 nd nd 0.5e2 ng 4e8
V. parahaemolyticus R. 25 4e8 2e4 2e4 ng ng >128
V. parahaemolyticus A. 6 4e8 ng-2 ng-2 ng ng >64
S. aureus 8325-4 75 8e128 nd nd 8e128 2e4 16e>512
S. epidermidis RP62A %75 4e16 nd 0.5e8 nd <0.25 8e64
S. epidermidis 1457 25 4e8 2 1 nd ng >128
L. monocytogenes 6e12.5 8e16 4e8 nd ng ng 8e16
B. cereus %75 2e8 nd nd 0.5e1 0.5e1 4e8
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Table 2
MBC of peptidomimetic 1 in MHB, MHB supplemented with native plasma and with heat-treated plasma, respectively. Nd ¼ not determined; ng ¼ no growth;
h.t. ¼ heat-treated.
Target strain MBC for peptidomimetic 1 (mg $ ml!1)
Added plasma (%)
0 3 6 12.5 25 12.5% h.t.
E. coli 4e16 nd nd 1e8 1e2 >64
S. typhimurium 8e32 nd 1 0.5e4 ng >64
S. marcescens 32e128 16e32 0.125 ng ng 64
P. aeruginosa 512e>512 nd nd 512 >16e>32 >512
V. vulnificus cmcP6 4e16 nd nd 1e2 0.125e0.5 16e>64
V. vulnificus DSM 10143 4e8 nd nd 0.5 ng 4e16
V. parahaemolyticus R. 4e8 2e4 2e4 nd ng >128
V. parahaemolyticus A. 4e8 2 nd ng ng >64
S. aureus 8325-4 32e128 nd nd 8 4e16 16e>64
S. epidermidis RP62A 4e16 nd 1e8 1 >0.25 8e16
S. epidermidis 1457 4e16 4 2 nd ng >128
L. monocytogenes 8e32 8e16 nd &0.125 ng 32
B. cereus 2e16 nd nd 0.5e1 0.5e1 4e8
Table 3
MIC of serum (expressed as % of serum) for all the strains used in the present study. MIC of peptidomimetic 1 in MHB, and in MHB supplemented with native
serum as well as with heat-treated serum. Nd ¼ not determined; ng ¼ no growth; r ¼ resistant to 100% serum; h.t. ¼ heat-treated. The values are based on two
individual experiments conducted in duplicate.
Target strain MIC of serum (%) MIC of peptidomimetic 1 (mg $ ml!1)
Added serum (%)
0 3 6 12.5 25 12.5 h.t.
E. coli r 2e8 nd nd 2e4 4 8e16
S. typhimurium 75 4e8 nd nd 2 2 16e32
S. marcescens 25 16e128 2e32 2e8 ng-0.125 ng >64
P. aeruginosa 75 128e512 nd nd 128e256 64 >512
V. vulnificus cmcP6 50e75 4e16 nd nd 4 2e4 8
V. vulnificus DSM 10143 75 4e8 nd nd 2 2e4 8
V. parahaemolyticus R. 25 4e8 4e>64 4 8e16 <0.125 16e32
V. parahaemolyticus A. 12.5 4e8 2e4 ng-2 8e16 ng 8e16
S. aureus 8325-4 75 8e128 nd nd 32e64 8 256
S. epidermidis RP62A %75 4e16 nd nd 8 2 4e16
S. epidermidis 1457 r 4e8 nd nd 8 2 8
L. monocytogenes r 8e16 nd nd 8e16 8 8e16
B. cereus r 2e8 nd nd 2e4 1e2 4
Table 4
MBC of peptidomimetic 1 in MHB, and in MHB supplemented with native serum and with heat-treated serum, respectively. Nd ¼ not determined; ng¼ no growth;
h.t. ¼ heat-treated.
Target strain MBC for peptidomimetic 1 (mg $ ml!1)
Added serum (%)
0 3 6 12.5 25 12.5% h.t.
E. coli 4e16 nd nd 2e8 4e8 16
S. typhimurium 8e32 nd nd 4e8 2e4 32
S. marcescens 32e128 32 2e8 ng-0.125 ng >64
P. aeruginosa 512e>512 nd nd >256 256 >512
V. vulnificus cmcP6 4e16 nd nd 8 2e8 8e16
V. vulnificus DSM 10143 4e8 nd nd 2e4 2e4 8e16
V. parahaemolyticus R. 4e8 >64 4 8e16 ng-4 16
V. parahaemolyticus A. 4e8 2e4 <0.25e2 8 ng 16
S. aureus 8325-4 32e128 nd nd 64 16e64 512
S. epidermidis RP62A 4e16 nd nd 8 4 8
S. epidermidis 1457 4e16 nd nd 16 2e4 16
L. monocytogenes 8e32 nd nd 16e32 16e32 32
B. cereus 2e16 nd nd 2e8 2 4e8
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(SPS; Sigma Aldrich P2008-5G), an inhibitor of activation of
complement function [24], was dissolved in Tris-buffered sa-
line (1 mg/ml) and added at 50% to plasma and serum for
5 min before MIC assays. Complement protein C3-depleted
and complement-deficient sera were provided by the Depart-
ment for Cancer and Inflammation, University of Southern
Denmark. Complement protein C3-depleted and complement-
deficient sera were stored at !80 "C.
2.6. Time-kill assay of E. coli by peptidomimetic 1 in
presence of human plasma
One colony of E. coli grown overnight on BHI agar at
37 "C was inoculated into MHB and grown overnight at 37 "C
with orbital shaking at 250 rpm. The culture was diluted 106-
fold and grown for 18 h at 37 "C at 200 rpm. Optical density
was adjusted to OD546 ¼ 0.2 in MHB to give an initial inoc-
ulum of 108 CFU/ml. Peptidomimetic 1 was added at con-
centrations of 8, 16, and 32 mg/ml to a final volume of 1 ml.
Killing kinetics was also tested in the presence of 25% plasma.
For this experiment, 13 ml-centrifuge tubes made of poly-
propylene (Almeco 91016) were used. The peptidomimetic-
exposed cultures were incubated at 37 "C at 200 rpm, and
bacterial density was determined by plating of a dilution series
on BHI agar plates after 1, 2, 5, 7 and 24 h of exposure. The
experiment was performed as biological duplicates on two
separate days (each with two technical replicates). Bactericidal
activity of the peptidomimetic alone was compared to the
peptidomimetic in the presence of 25% plasma by Student's t-
test on log-transformed colony counts.
2.7. Visualization of the activity of peptidomimetics by
scanning electron microscopy (SEM)
Many AMPs cause damage to the bacterial cell envelope,
and SEM of peptidomimetic- and plasma-treated E. coli was
used to visualize potential cell envelope damage. E. coli was
grown and diluted (OD546 ¼ 0.2) as described above. Pepti-
domimetic 1 was added at concentrations of 8, 16 or 32 mg/ml.
The influence of 25% plasma (without addition of peptido-
mimetic) on cell morphology was also determined. MilliQ
water was added to control samples. The peptidomimetic-
exposed cultures were incubated at 37 "C at 200 rpm for
2 h; cell density was determined at the start of the exposure
and after 2 h. The total volume after the 2 h treatment was
transferred to Eppendorf tubes and centrifuged at 20,000 $ g
for 15 min in a MiniSpin-Plus Eppendorf 48276. The super-
natant was removed and the cells were fixed for 16 h at 5 "C
by treatment with 3% glutaraldehyde (Sigma Aldrich, G5882)
in 0.5 ml MHB, pH adjusted to 7.3. Next, samples were
washed three times in distilled water followed by staining
with 1% osmium tetroxide (Sigma Aldrich, 75632) overnight
at 5 "C. Dehydration was done by sequential treatment with
ethanol solutions (30%, 50%, 70%, 80%, 90%, 100%) and
acetone solutions (30%, 50%, 100%). Samples were stored
overnight at 5 "C. All washing, staining and dehydration steps
were carried out by applying 0.5 ml of substrate, incubating at
room temperature for 10 min followed by centrifugation at
20,000 $ g for 5 min. After dehydration, the samples were
placed on a silicon disc and further dried in a Leica CPD300
critical point drier. The silicon disc was next attached to an
aluminum stub by means of a double-sided C tape and coated
with 2 nm Pt in a Cressington 208HR High Resolution Sputter
Coater. The experiments were performed in two independent
trials. Cell length was measured from a minimum number of
20 SEM micrographs using NIST Image J on cells lying flat
on the surface. The length was defined as the median line
along the cell length. Cell clustering was avoided by initial
adjustment of the cell number. Also, a hydrophilic substrate
such as a silicon wafer was used in order to ensure that the
bacterial solution was well spread. This preparation favored
the measurement of length of cells lying flat on the analyzed
surface.
3. Results
3.1. MIC and MBC of peptidomimetics in the presence of
plasma and serum
Plasma and serum were initially used at concentrations of
25% and 12.5% based on previous studies with E. coli [16].
Some of the strains in the present study did not grow at these
concentrations, and therefore MICs and MBCs of plasma and
serum were determined. In subsequent experiments, we used
plasma and serum concentrations equivalent to ¼ or ½ of the
MIC of plasma or serum for each strain (Tables 1e4).
Addition of plasma lowered the MIC of peptidomimetic 1
against all strains (Table 1). The presence of 25% plasma
caused a higher potentiation (it lowered the MIC even more)
than addition of 12.5% plasma. The MIC value of peptido-
mimetic 1 was reduced at least 4-fold in the presence of 12.5%
plasma as compared to that in MHB alone for E. coli, S.
typhimurium, P. aeruginosa, V. vulnificus and B. cereus,
whereas no change was observed for S. aureus. For S. mar-
cescens, V. parahaemolyticus, S. epidermidis and L. mono-
cytogenes, plasma could only be tested at concentrations lower
than 12.5%, as mentioned above, but in these cases, a reduc-
tion in the MIC value was observed as well.
A reduction in the MIC value for peptidomimetic 1 in the
presence of 25% plasma, as compared to that found in MHB,
was observed for all strains that grew well at this concentration
(E. coli, P. aeruginosa, V. vulnificus cmcP6, S. aureus and B.
cereus). For strains that did not grow at this concentration, a
reduction in MIC values was observed when determined at
lower plasma concentrations.
In the presence of serum at a concentration of 12.5%, a 2-
fold reduction in the MIC values was typically observed for
Gram-negative strains, except for P. aeruginosa and V. para-
haemolyticus. For these strains as well as for Gram-positive
bacteria, the MIC of peptidomimetic 1 was similar to that
found in MHB alone. When the concentration of serum was
doubled, a reduction in the MIC was observed for P. aerugi-
nosa, V. parahaemolyticus and all Gram-positive bacteria
tested. For V. vulnificus, E. coli and S. typhimurium there was
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no further reduction in the MIC compared to that found in
12.5% serum.
MBC values of peptidomimetic 1 toward most bacteria in
MHB alone were slightly higher than corresponding MIC
values, and relative changes in MBC values observed in the
presence of serum or plasma (Tables 2 and 4) followed trends
analogous to those of MIC values (Tables 1 and 3), inferring
that the apparent synergism between peptidomimetic 1 and
serum/plasma indeed leads to significantly more efficient
killing of a wide range of pathogenic bacteria.
Similar patterns for MIC and MBC were found for pepti-
domimetic 2 (Supplemental Tables S1 and S2).
The effect of plasma on the activity of conventional anti-
biotics and LL-37 was determined for four strains. Human LL-
37 was moderately active against E. coli and P. aeruginosa,
with a MIC of 32e64 mg/ml and 64 mg/ml, respectively; MIC
values against S. aureus were less consistent, ranging from 32
to higher than 512 mg/ml. LL-37 was not potentiated by
plasma, but rather, displayed a 4-fold increase in its MICs
against both E. coli and P. aeruginosa. For S. aureus, MIC
values remained higher than 512 mg/ml (Table 5).
No potentiation of ampicillin in the presence of plasma was
observed (Table 5). The MICs of gentamicin against E. coli
and P. aeruginosa were lowered from 1 to 0.25 mg/ml and
from 1 to 2 to 0.5e1 mg/ml in 25% plasma, respectively, while
no significant effects on the MICs were observed in S. aureus
and L. monocytogenes.
In contrast, the presence of 25% plasma caused a ~10-fold
reduction in the MIC of polymyxin B against E. coli and P.
aeruginosa, while a 4-fold reduction was observed in S. aureus
(Table 5). In L. monocytogenes, the MIC of polymyxin B was
virtually unchanged in the presence of plasma.
3.2. Potentiation of activity of peptidomimetics by
human plasma and serum
MICs and MBCs of peptidomimetic 1 and polymyxin B in
the presence and absence of 25% plasma were assessed using
plates of different materials (Supplemental Table S4). MICs of
both peptidomimetic 1 and polymyxin B were reduced both in
the absence and presence of 25% plasma in the two types of
polypropylene plates. However, in polystyrene plates and glass
vials, the MICs were much higher, probably as a consequence
of substantial binding of these cationic compounds to the
negatively charged surfaces of these materials. Plasma had no
or only a limited effect on the MIC of peptidomimetic 1 in
these systems (polystyrene, glass) most likely as a conse-
quence of partial depletion of active compound in the medium
due to surface adsorption, which inherently becomes relatively
much more pronounced at the very low concentrations tested
in the potentiation experiments.
The human blood used in the experiments was supple-
mented with 4% citrate as an anticoagulant in order to ach-
ieve citrate plasma. As citrate can chelate divalent cations
that stabilize the bacterial cell envelope, it was speculated
that it might be involved in plasma potentiation. Addition of
citrate to serum and to MHB at concentrations of 2e8% and
0.5e4%, respectively, had no effect on the subsequent MIC
values of peptidomimetic 1 (data not shown). Hence, the
potentiation of peptidomimetics was not caused by the citrate
added to plasma. An increase in pH from 7.2 to 8 was
measured when plasma was added to the culture. This change
in pH might affect the charge towards less overall proton-
ation of the peptidomimetic, which would be expected to
lower its affinity toward the cell membrane that would be
equally or slightly more anionic when pH was raised to 8.
However, the MIC of the peptidomimetics in MHB adjusted
to pH 8 did not differ from the MIC in MHB at pH 7.2.
Hence, the pH change caused by the addition of plasma did
not contribute to the increased activity of the peptidomi-
metics, as the bacteria were able to grow equally well under
these conditions.
Plasma and serum were heat-treated to abolish the inherent
activity of the complement system (Tables 1e4). As opposed
to untreated plasma, an increase in the MIC value was seen for
all strains when grown in the presence of 12.5% heat-treated
plasma, indicating lowered sensitivity to peptidomimetics,
possibly due to inactivation of these by interaction with de-
natured plasma components.
Addition of 12.5% heat-treated serum, as compared to
untreated serum, caused no major changes in the MIC values
of peptidomimetic 1 for V. parahaemolyticus ATCC 17802 and
Table 5
MIC and MBC of conventional antibiotics and LL-37 for bacterial pathogens in MHB, and in MHB þ 25% plasma. Nd ¼ not determined; AMP ¼ ampicillin,
GEN ¼ gentamicin, PMB ¼ polymyxin B.
Medium Activity Target strain MIC and MBC (mg $ ml!1)
MHB alone/MHB þ 25% plasma
AMP GEN PMB LL-37
MIC E. coli 4e8/4e8 1/0.25 0.25e0.5/<0.03 32e64/128e256
P. aeruginosa >128/>128 1e2/0.5e1 1/0.06 64/>256
S. aureus 0.125/0.06 0.125e0.25/0.125e0.25 8e16/2e4 32e>512/>512
L. monocytogenes 0.06e0.125/0.25 0.06/0.06e0.125 8e64/32 nd
MBC E. coli 4e8/4e8 1/0.25 0.25e0.5/<0.06 32e64/128e256
P. aeruginosa >128/>128 2e>2/1 2/0.125 64/256
S. aureus 0.125/0.125 0.5/>0.125e1 16e>16/2e>8 >512/>512
L. monocytogenes 0.125e0.25/0.25 0.125/0.06e0.125 16e64/32 nd
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for all the Gram-positive strains except for S. aureus. An
overall increase in the MIC values was found for S. aureus and
all the other strains tested. A similar pattern was observed for
peptidomimetic 2 (Supplemental Tables S1 and S2).
Given these preliminary results, subsequent experiments
were aimed at clarifying the possible involvement of com-
plement. Thus, the effect of sodium polyanethole sulfonate
(SPS) was tested, as it is a specific inhibitor of the complement
system [24]. A considerable increase in the MIC values was
observed when SPS was added during the MIC test. Moreover,
SPS alone abolished the activity of peptidomimetics (data not
shown), and therefore it cannot be used in the present exper-
imental setup to address the possible role of complement. MIC
of peptidomimetics was also determined in the presence of
complement C3-depleted serum and complement factor I- and
H-deficient sera, derived from clinical samples. No change in
the MIC was observed compared to non-depleted or non-
deficient sera (data not shown).
3.3. Time-kill assay of E. coli by peptidomimetic 1 in the
presence of human plasma
Peptidomimetic 1 was bactericidal to E. coli, as cell counts
were significantly decreased after incubation for 2e3 h in a
dose-dependent manner (Fig. 2; panel A). After treatment for
2 h, cell numbers (CFU/ml) were reduced with 1.5, 2.5 and 4
log units when treated with peptidomimetic 1 at 16, 32 and
64 mg/ml, i.e. 2 $ MIC to 8 $ MIC, respectively. The bacteria
grew well in the presence of 25% plasma in MHB, and
interestingly, a more rapid killing of E. coli was seen for
peptidomimetic 1 when 25% plasma was added to MHB
(Fig. 2; panel B). The combination of 8 mg/ml peptidomimetic
and 25% plasma led to a cell reduction of 1.5 log units, which
is similar to using 16 mg/ml peptidomimetic in MHB alone. A
similar effect was observed at 16 mg/ml
peptidomimetic þ 25% plasma compared to 32 mg/ml, as well
as 32 mg/ml þ 25% plasma compared to 64 mg/ml (Fig. 2).
After 24 h (data not shown), we observed a synergistic effect
in the killing of E. coli when 25% plasma and peptidomimetic
were used in combination at concentrations up to 16 mg/ml.
Regrowth was observed in all samples treated with peptido-
mimetics only. For the samples treated with 8 and 16 mg/ml
peptidomimetics, growth was comparable to the controls,
while similar samples supplemented with plasma exerted a
killing effect that was maintained after 24 h. Regrowth could
be explained by partial depletion of the compound due to its
binding to dead bacteria. Small-colony variants were observed
in peptidomimetic-treated samples, both in the presence and
absence of plasma; however, this phenotype was not main-
tained after colonies were re-grown on new agar plates.
3.4. Visualization of cell damage caused by human
plasma
Since many AMPs and peptidomimetics act directly on the
bacterial cell envelope, we speculated that human plasma
might also disrupt the envelope and thereby cause potentiation
via an additive effect. Scanning electron microscopy revealed
no cell membrane damage on E. coli exposed to and grown in
the presence of 25% plasma (Fig. 3, B). In contrast, different
degrees of damage to the cell envelope were evident for
samples treated with increasing concentrations of peptidomi-
metic 1 (Fig. 3, CeF). Damage could be seen as the formation
of blebs (Fig. 3, D), which gave rise to protrusions of the outer
cell membrane (Fig. 3, E) and formation of holes in the apical
part of the cells (Fig. 3, C and F). Addition of 25% plasma to
the samples treated with peptidomimetics at 8 mg/ml and
16 mg/ml, respectively, did not produce further damage (Fig. 3,
D and F) compared to samples treated with 16 mg/ml and
32 mg/ml (Fig. 3, C and E). However, addition of plasma
seemed to affect the average length of the cells. In fact, bac-
teria treated with plasma appeared longer (Supplemental
Fig. S1). This cell elongation was observed after treatment
with plasma, but not with peptidomimetics alone. A few
selected samples were observed in an optical microscope as
well (data not shown). Here, cell aggregation was detected in
Fig. 2. Killing of E. coli by peptidomimetic 1 in MHB (A) and in MHB in the presence of 25% human plasma (B). Counts are averages of biological duplicates and
error bars are standard deviations. 0 mg/ml: solid line; 8 mg/ml: dash dot line; 16 mg/ml: round dot line; 32 mg/ml: dash line; 64 mg/ml: square dot line. The
experiment was performed in the absence and presence of plasma on the same day.
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specimens from samples treated with peptidomimetic plus
plasma, whereas this was not observed for the controls, i.e.
specimens not exposed to either compound or plasma and
specimens exposed solely to plasma.
4. Discussion
Here we demonstrate that the antibacterial activity of two
peptidomimetics against several Gram-negative and Gram-
positive human pathogens is enhanced by the presence of
human plasma and, to some extent, by the presence of human
serum. From a clinical perspective, this is a promising finding,
since it is likely that lower concentrations of peptidomimetics
may be used in clinical settings than usually expected based on
testing in laboratory growth media.
For the peptidomimetics investigated in the present study,
the concentration that causes 10% hemolysis (HC10) was
previously found to be above 500 mg/ml [20], indicating low
general cellular toxicity. In addition, peptidomimetic 1 was
previously shown to exert acceptable cell selectivity between
S. epidermidis and HeLa cells (i.e. the ratio between IC50 and
MIC was above 200) [20] despite the fact that this cell line is
more susceptible to these antibacterial peptidomimetics than
other more relevant cell lines (e.g. HepG2, NIH 3T3 and
HUVEC) [19]. Moreover, as shown by Jahnsen et al. [19], this
type of peptidomimetics may be further optimized toward
even lower cytotoxicity by partial hArg/Lys substitution.
Thus, the finding that human plasma potentiates the antibac-
terial effect of compounds 1 and 2 further supports their po-
tential use in vivo, as cytotoxic side effects are highly
concentration-dependent and therefore will decrease signifi-
cantly when the concentration needed for bacterial killing is
lowered 2- to 16-fold.
The potentiation of antibacterial compounds by plasma
could be caused by endogenous blood components such as
complement proteins. Hein-Kristensen et al. [16] suggested
that complement factors might be responsible for the plasma-
enhanced activity of membrane-active AMPs and peptidomi-
metics against E. coli due to the fact that heat inactivation of
complement [25] abolished this synergism, a finding corrob-
orated by the present study in which we extended its validity
to several bacterial species.
Fig. 3. Scanning electron microscopy (SEM) images of E. coli. (A) untreated; (B) untreated þ 25% plasma; upon treatment with peptidomimetic 1: (C) 16 mg/ml,
(D) 8 mg/ml þ 25% plasma, (E) 32 mg/ml, (F) 16 mg/ml þ 25% plasma.
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Activation of complement results in formation of the
membrane attack complex (MAC) that generates pores in
Gram-negative bacterial cell membranes. The role of AMPs
as immune potentiators and signaling molecules is well-
known, and it has recently been found that they share a
number of features with complement [26]. Thus, given the
membrane-perturbing effect of AMPs and antibacterial
peptidomimetics, a synergistic effect between peptidomi-
metics and complement system appeared likely. Neverthe-
less, we observed no visible damage to the envelope when E.
coli was exposed to plasma when examined by SEM. On the
other hand, we found a dramatic increase in MIC in the
presence of heat-inactivated plasma, supporting the
assumption that one or more heat-sensitive protein(s)
involved in the mechanism of plasma potentiation had suf-
fered from denaturation.
Selected factors of the complement cascade such as factor
H, factor I, and complement C3 did not seem, individually, to
be the cause of potentiation based on testing of C3-depleted,
factor H- and factor I-deficient sera. However, since MIC
values were affected significantly more by plasma than by
serum, and since both contain relevant complement proteins,
future experiments should preferably involve purified com-
plement factors and coagulation proteins.
Besides complement proteins, other factors, such as pro-
teins of the coagulation cascade, could contribute to the effect
of potentiation. This would explain why plasma gives rise to
higher potentiation of peptidomimetics than serum. Unlike
serum, the commercial plasma (P9523 www.sigmaaldrich.
com) contains active clotting factors, which may respond to
the presence of microorganisms. Activation of complement
proteins and the coagulation cascade are connected [27], and
complement is known to inhibit anticoagulation factors,
thereby enhancing the coagulation process. Other studies [28]
reported that specific coagulation factors in plasma promote
the release of antimicrobial compounds directed toward the
negatively charged surfaces of bacterial pathogens. From all
these interconnected processes, it is inferred that higher
potentiation of peptidomimetics by plasma could indeed arise
from favorable interactions requiring the presence of both
complement and clotting factors, given that the latter is absent
in serum. However, it is also evident that only whole-blood
models would mirror the cross-talk between the different
systems acting in vivo [27].
Plasma enhanced the antibacterial effect of polymyxin B,
but not that of gentamicin or ampicillin (Table 5). Given the
membrane-perturbing effect of the peptidomimetics, as
revealed by SEM and leakage of intracellular compounds [29],
we conclude that the potentiation by plasma is related to the
finding that the bacterial membrane appears to be the major
target of these peptidomimetics. Other studies have reported
that complement proteins can act in synergy with antibacterial
compounds such as antibiotics [30] and AMPs [12], and for
instance, the activity of polymyxin B is potentiated by serum
[31]. Interestingly, it was found that terminal complement
components are involved in the enhancement of the antibac-
terial effect of polymyxin B. In contrast, no synergistic effects
between serum and b-lactams or aminoglycoside antibiotics
were reported [32].
The activity of a-helical human cathelicidin LL-37 was
decreased in the presence of plasma. Indeed, Wang et al. found
that human plasma inhibits the antibacterial activity of LL-37,
and it was proposed that LL-37 binds to a 30-kDa plasma
protein [33]. LL-37 is a cationic natural human host defense
peptide, and reducing its activity by binding to blood com-
ponents might have evolved as a mechanism to balance its
otherwise cytotoxic effects in vivo [34], whereas synthetic
highly cationic non-helical and/or non-amphipathic com-
pounds may not be bound by blood components. Also, LL-37
can be inactivated after binding to the Lpp receptor in E. coli
[35]. This interpretation may explain the high MICs found for
this AMP when determined in MHB.
The bacterial pathogens differed in their sensitivity to blood
matrices. This could be attributed to differences in their pro-
pensity to interact with the bacteriolytic or bactericidal com-
plement factors [36], since some pathogens are able to survive
in serum or plasma at certain concentrations due to their
natural virulence factors or resistance mechanisms. Staphylo-
cocci [37] and Pseudomonas spp. [38] are more resistant to
blood than other pathogens, which is in accordance with our
results, as Pseudomonas and Staphylococcus were among the
strains that grew well in 25% plasma. In contrast, Vibrio
parahaemolyticus is more sensitive to serum than V. vulnificus
[39], as also seen in the present study for both serum and
plasma.
However, since the killing efficiency of peptidomimetics
was enhanced in the presence of plasma, it is suggested that:
(i) the inherent resistance mechanisms may be impaired by the
peptidomimetics, and/or (ii) potentiation of the peptidomi-
metics involves plasma components that alone do not exert a
killing effect.
Electron microscopy (EM) is a valuable tool for visualizing
the effects of antimicrobial peptides on the bacterial cell en-
velope [40], and here we demonstrate that the membrane-
perturbing effects of a-peptide/b-peptoid peptidomimetics
can also be documented by scanning EM (Fig. 3, CeF). Our
results are consistent with previous studies where AMPs and
peptoid mimics caused formation of blebs, pore formation and
cell lysis [41,42]. In addition, we detected stronger occurrence
of damage to the apical part of the cell, a feature that was
noted earlier by Klainer and Perkins [43]. It is remarkable that
cells treated with peptidomimetics in the presence of plasma
often appeared longer than those treated in the absence of
plasma. This elongation may well be a symptom of delayed or
inhibited cell division, as noticed by Klainer and Perkins [43]
when E. coli was treated with a sub-MIC concentration of
penicillin. Chileveru et al. [44] also reported cell elongation
after treatment of Gram-negative bacteria with human
defensin-5, which was hypothesized to involve inhibition of
cell division.
Overall, the present results show that the activity of
membrane-active peptidomimetics against a range of Gram-
positive and Gram-negative pathogenic bacteria is potenti-
ated by the presence of human plasma. The potentiation effect
80 L. Citterio et al. / Research in Microbiology 167 (2016) 72e82
of plasma is dependent on the mode of action of the anti-
bacterial compound used (as seen for the conventional anti-
biotics tested), since only compounds acting on the cell
membrane or envelope appear to be potentiated by plasma. We
hypothesize, but cannot conclude, that complement factors are
involved in this potentiation. Also, we hypothesize that
coagulation proteins may act in synergy with complement and
increase the bactericidal effect of peptidomimetics, or vice-
versa.
If future studies show that findings from such experiments
may indeed be translated into animal proof-of-concept studies,
a long-term perspective is that decreased dosing of certain
classes of antibiotics might be applied in the treatment of in-
fectious diseases.
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Supplemental Table S1: MIC of peptidomimetic 2 in MHB, MHB supplemented with native serum or plasma as well as with heat-treated serum or 
plasma. Nd = not determined; ng= no growth. 
 
 
Target strain 
MIC for peptidomimetic 2 (µg  ml–1) 
MHB 
Control 
Added serum (%) Added plasma (%) 12.5% heat-treated 
3 6 12.5 25 3 6 12.5 25 serum plasma 
E. coli 4-8 nd nd 4-8 4-8 nd nd 1-2 0.5-1 16-32 16->64 
S. typhimurium 8-16 nd nd 8-16 8-16 nd 4 2-8 ng 64-128 16->64 
S. marcescens 16-512 4-64 1-4 ng-0.125 ng 16-32 ng ng-4 ng >64 >512 
P. aeruginosa 128-512 nd nd 128-256 128-256 nd nd 16-128 16-32 >512 >512 
V. vulnificus cmcP6 4-16 nd nd 4-8 4 nd nd 2-4 0.5-1 4-16 8->64 
V vulnificus DSM 10143 4-16 nd nd 2-4 4-8 nd nd 1-4 ng 16 16 
V. parahaemolyticus R. 4-8 4 8-16 8-16 ng-<0.125 4  2-4  ng ng 32-64 >128 
V. parahaemolyticus A. 4-8 1-4 ng ng  ng ng-2 ng ng ng 32 >64 
S. aureus 8-64 nd nd 8->32 4 nd nd 4-8 2 64-128 >64->512 
S. epidermidis RP62A 4-8 nd nd 4 2 nd  0.25-2   0.5 ng-<0.25 8-16 16->64 
S. epidermidis 1457 2-8 nd nd 4 2 0.5-1 0.5-1 nd ng 8 >128 
L. monocytogenes 2-8 nd nd 8 8 2-4 nd ng ng 8-16 8-16 
B. cereus 2-8 nd nd 4-8 2-4 nd nd 1-2 1 8-16 8 
  
Supplemental Table S2: MBC of peptidomimetic 2 in MHB, MHB supplemented with native serum or plasma as well as with heat-treated 
serum or plasma. Nd = not determined; ng= no growth. 
 
 
Target strain 
MBC for peptidomimetic 2 (µg ×  ml–1) 
MHB 
Control 
Added serum (%) Added plasma (%) 12.5% heat-treated 
   3     6     12.5      25       3        6         12.5         25        serum  plasma 
E. coli 4-16 nd nd 4-16 4-8 nd nd 2-16 0.5-8 32 32->64 
S. typhimurium 8-16 nd nd 4-32 16 nd 4-8 0.5-8 0.25-ng 64 >64 
S. marcescens 16-128 64 4 ng-0.125 ng 16-32 ng ng ng >64 64 
P. aeruginosa 128->512 nd nd >256 >512 nd nd 512 >32-64 >512 >512 
V. vulnificus cmcP6 8-32 nd nd 8-16 4-8 nd nd 4 0.5-2 8-16 16->64 
V vulnificus DSM 10143 4-16 nd nd 2-4 8 nd nd 1 ng-0.125 16 16 
V. parahaemolyticus R. 8-16 4 8-16 16 ng-4 4 2-4 nd ng 32 >64 
V. parahaemolyticus A. 4-8 4 ng ng  ng  2 ng ng     ng 32-64       >64 
S. aureus 8-128 nd nd 16->32 8-16 nd nd 16 4-8 128 >64->512 
S. epidermidis RP62A 4-8 nd nd 4 2-4 nd   0.5-4 1 >0.25 16 >64 
S. epidermidis 1457 4-8 nd nd 4-8 2-4 1 1 nd nd 8 >128 
L. monocytogenes 2-8 nd nd 16 8-16 4 nd nd nd 32 16 
B. cereus 4-8 nd nd 4-16 2-4 nd nd 1-2 1 8-16 4 
 
!
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Supplemental Table S3: Bacterial strains used in the present study and relative reference. 
 
Strain name Reference 
Escherichia coli ATCC 25922 - 
Salmonella typhimurium L354 Wray C. 1978. Experimental Salmonella Typhimurium infection in calves. Res Vet Sci 
25(2):139-143. 
Serratia marcescens Hejazi A, Falkiner FR. 1997. Serratia marcescens J Med Microbiol 46(11):903-912. 
Vibrio vulnificus DSM 10143 Reichelt JL, Baumann P, Baumann L. 1976. Study of genetic relationships among 
marine species of the genera Beneckea and Photobacterium by means of in vitro 
DNA/DNA hybridization. Arch Microbiol 110(1):101-120.  
Vibrio vulnificus cmcP6 Kim YR, Lee SE, Kim CM, Kim SY, Shin EK, Shin DH, Chung SS, Choy HE, 
Progulske-Fox A, Hillman JD, Handfield M, Rhee JH. 2003. Characterization and 
pathogenic significance of Vibrio vulnificus antigens preferentially expressed in 
septicemic patients. Infect Immun 71(10):5461-5471. 
Vibrio parahaemolyticus ATCC 17802 - 
Vibrio parahaemolyticus RimD D2210633 Nasu H. 2000. A filamentous phage associated with recent pandemic Vibrio 
parahaemolyticus O3!: K6 strains. J Clin Microbiol 38(6):2156-2161. 
Pseudomonas aeruginosa PAO1 Holloway B. 1955. Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 
13(3):572-581. 
Listeria monocytogenes EGDe BUG 1600 Glaser P, Frangeul L, Buchrieser C, Rusniok C, Amend A, Baquero F, et al., Cossart P. 
2001. Comparative genomics of Listeria species. Science 294(5543):849-52.  
Bacillus cereus ATCC 11778 - 
Staphylococcus aureus 8325 Novick R. 1967. Properties of a cryptic high-frequency transducing phage in 
Staphylococcus aureus. Virology 33(1):155-166.  
Staphylococcus epidermidis RP62A Christensen GD, Simpson WA, Bisno AL, Beachey EH. 1982. Adherence of slime-
producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun 
37(1):318-326.   
Staphylococcus epidermidis 1457 Rupp ME, Ulphani JS, Fey PD, Mack D. 1999. Characterization of Staphylococcus 
epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of 
intravascular catheter-associated infection in a rat model. Infect Immun 67(5):2656-
2659. 
 
 
Supplemental Table S4: MIC and MBC of peptidomimetic 1 (1) and polymyxin B (PMB) against E. coli in absence and presence of 25% 
plasma. MIC was assessed in the listed materials. Polypropylenea: plates sterilized by autoclave; polypropyleneb: UV-sterilized plates. The 
experiments were run on the same day in two independent replicates. 
 
 
Material 
MIC/MBC (µg/ml) 
1 1 + 25% plasma PMB PMB + 25% plasma 
Polypropylenea  4-8 / 4-16 0.5-1 / 2-4 0.5 / 0.5 0.007-0.03 / 0.007-0.125 
Polypropyleneb 2-4 / 4-8 0.125-0.25 / 0.5-1 0.5-1 / 0.5-1 0.007-0.015 / 0.007-0.06 
Polystyrene 16 / 16 4-8 / 16 2-4 / 2-4 >0.5-0.5 / >0.5-0.5   
Glass  16 / 64 8-16 / >32 1 / 1 0.5 / 0.5-1 
 
 
 
 
 
 
Supplemental Figure S1: Number of cells with relative length for MHB-treated sample (blue bars) and sample treated with MHB + 25% 
plasma (red bars). For each sample 44 cells were measured.  
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Antimicrobial peptides (AMPs) have for long been considered as potential new antimicrobials since resistance appears not to evolve
readily in nature. However, adaptive laboratory evolution experiments (ALE) have demonstrated that bacteria may develop
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Surprisingly, none of the lineages exposed to P9‐4 adapted to a 32‐fold higher MIC, while all lineages exposed to H‐[Lys‐βNSpe‐
hArg‐βNSpe]3‐NH2 and three out of four lineages exposed to novicidin adapted to a 32‐fold higher MIC than the wild type MIC, after
passaging through approx. 350 generations. Only one out of four lineages exposed to the combination reached a 32-fold higher MIC
of 256 μg/ml. The whole genomes of adapted lineages and individual clones were sequenced and analyzed, and an average of 6
single-nucleotide variants causing amino acid change were detected in the peptide-adapted lineages, while an average of 5 single-
nucleotide variants were found in the control lineages. The most common variants in adapted lineages (and derived clones) were
deletions in the gene encoding the enzyme CDP-glycerophosphotransferase, present in six out of eight adapted lineages and in
eleven clones. The zeta potential of adapted lineages was less negative than that of the wild type, suggesting that a contributing
factor to the gained resistance involve modification of the surface charge.
The results indicate that a common evolutionary trajectory has led to development of resistance both to the individual compounds
and to a combination of all three compounds. The short antimicrobial peptide P9-4, giving rise to a slow resistance development
rate, may be considered a promising candidate for further optimization and future application in clinical settings.
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Abstract 22 
 23 
Antimicrobial peptides (AMPs) have for long been considered as potential new antimicrobials since 24 
resistance appears not to evolve readily in nature. However, adaptive laboratory evolution 25 
experiments (ALE) have demonstrated that bacteria may develop resistance also to AMPs. We, as 26 
others, hypothesize that the risk of resistance development decreases when two or more compounds 27 
are combined as compared to single-drug treatment. The purpose of the study was to investigate 28 
resistance development in E. coli ATCC 25922 when exposed to a combination of three compounds 29 
and to each of the compounds separately (peptidomimetic H-[Lys-βNSpe-hArg-βNSpe]3-NH2 and 30 
the AMPs novicidin and P9-4). 31 
 32 
Surprisingly, none of the lineages exposed to P9-4 adapted to a 32-fold higher MIC, while all 33 
lineages exposed to H-[Lys-βNSpe-hArg-βNSpe]3-NH2 and three out of four lineages exposed to 34 
novicidin adapted to a 32-fold higher MIC than the wild type MIC, after passaging through approx. 35 
350 generations. Only one out of four lineages exposed to the combination reached a 32-fold higher 36 
MIC of 256 µg/ml. The whole genomes of adapted lineages and individual clones were sequenced 37 
and analyzed, and an average of 6 single-nucleotide variants causing amino acid change were 38 
detected in the peptide-adapted lineages, while an average of 5 single-nucleotide variants were 39 
found in the control lineages. The most common variants in adapted lineages (and derived clones) 40 
were deletions in the gene encoding the enzyme CDP-glycerophosphotransferase, present in six out 41 
of eight adapted lineages and in eleven clones. The zeta potential of adapted lineages was less 42 
negative than that of the wild type, suggesting that a contributing factor to the gained resistance 43 
involve modification of the surface charge. 44 
 45 
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The results indicate that a common evolutionary trajectory has led to development of resistance 46 
both to the individual compounds and to a combination of all three compounds. The short 47 
antimicrobial peptide P9-4, giving rise to a slow resistance development rate, may be considered a 48 
promising candidate for further optimization and future application in clinical settings. 49 
1 Introduction 50 
Development of bacterial resistance to conventional antibiotics is a global concern (Fair and Tor, 51 
2014), and it has recently been highlighted as one of the major challenges facing mankind (WHO 52 
Report, 2014). Consequently, there is an urgent need for exploration of new antibacterial 53 
compounds as well as more effective regimens for use of both existing and novel antibiotics. 54 
Antimicrobial peptides (AMPs) have been suggested as such novel antibacterial agents (Hancock 55 
and Sahl, 2006), despite common limitations such as cytotoxic side effects or sensitivity to 56 
proteolytic degradation (Chongsiriwatana et al., 2008). Peptidomimetics mimicking the biological 57 
activity of AMPs have been investigated, and some subclasses have proved to overcome these 58 
shortcomings of AMPs (Jahnsen et al., 2012).  59 
 60 
AMPs have evolved to constitute an essential part of the antimicrobial defense system of most 61 
living organisms, and AMP resistance in natural innate immune system settings has not been 62 
reported (Malmsten, 2014). AMPs typically act as detergent-like compounds causing either pore 63 
formation or disruption of the cell envelope (Brogden, 2005), and it has been stated that resistance 64 
to AMPs will not develop as readily as it develops toward conventional antibiotics (Marr et al., 65 
2006). Also, it is believed that development of resistance to AMPs is impeded by their rapid 66 
bactericidal activity (Fox, 2013).  67 
 68 
However, since AMPs target conserved structures in the bacterial cell envelope, bacterial evolution 69 
have resulted in systems that circumvent their action, i.e. a parallel evolutionary race exists between 70 
pathogens and their hosts (Peschel and Sahl, 2006). Several authors (Devine and Hancock, 2002) 71 
(Nizet, 2006; Maria-Neto et al., 2015) have described a series of bacterial mechanisms of intrinsic 72 
resistance against AMPs. Also, for some compounds, resistant mutants are selected for when 73 
bacteria are exposed to sub-lethal concentrations (Cassone and Otvos, 2010) or when allowed to 74 
adapt over longer periods to AMPs (Perron et al., 2006) or peptidomimetics (Hein-Kristensen et al., 75 
2013). Mutations leading to cell membrane modifications are likely to confer resistance to AMPs; 76 
however, the exact mechanisms of resistance to AMPs are not fully understood (Maria-Neto et al., 77 
2015). Whole-genome sequencing of the end-point resistant lineages selected for may provide a 78 
more detailed insight into the molecular mechanisms underlying resistance (Köser et al., 2014). The 79 
pattern of mutation events may thus clarify whether resistance development involves a particular 80 
evolutionary trajectory (de Visser and Krug, 2014). Also, the understanding of resistance 81 
mechanisms is essential for discovery of potential targets useful for treatment of drug-resistant 82 
bacteria (Punina et al., 2015) (Cole and Nizet, 2016). 83 
 84 
Most studies on AMPs and peptidomimetics have focused on their spectrum of activity, cost of 85 
production, the dose needed, and their efficacy in clinical trials (Brogden and Brogden, 2011). 86 
However, assessing the potential for resistance development is an important part of the evaluation 87 
of novel antibacterial compounds. All antimicrobials must be used in ways that optimize their effect 88 
at the lowest possible concentration and reduce the risk of resistance development. One strategy is 89 
to apply combination therapy that may provide an enhanced antibacterial effect in vitro via 90 
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synergistic effects (Zhuang et al., 2015; Galani et al., 2014). Thus, by combining drugs, the dose of 91 
each compound may be reduced whereby potential toxicity in vivo may be abolished (Pirrone et al., 92 
2011). Further, a combination of several antibiotics may impose additional evolutionary restraints 93 
on the bacterial population (Lindsey et al., 2013) thereby suppressing the viability of mutants that 94 
otherwise might overcome the mode of action of the individual drugs. 95 
 96 
Combination treatment has been successfully applied for HIV treatment (Lennox et al., 2009), 97 
malaria (Nyunt and Plowe, 2007), tuberculosis (Ortona et al., 1998), and it is used for treatment of 98 
severe infections with carbapenemase-producing Enterobacteriaceae (Qureshi et al., 2012). Several 99 
in vitro studies have shown the potential of combination treatment based on AMPs 100 
(Chongsiriwatana et al., 2011; Yu et al., 2016) and AMPs together with conventional antibiotics 101 
(Hindler et al., 2015). In fact, AMPs have the advantage of acting in synergy in the natural host 102 
environment (Cassone and Otovs, 2010). 103 
 104 
AMPs act mainly by binding to different macromolecules in the bacterial cell membrane, and 105 
therefore typically have multiple low-affinity targets in contrast to conventional antibiotics. When 106 
the bacterial cell is targeted in a multi-mode way, resistance development is slowed down due to 107 
increased cost of fitness for the induced mutations. Hence, simultaneous alteration of several targets 108 
would appear less probable than it would be for single-target molecules (Sallum and Chen, 2008). 109 
In a combination approach, such multiple mutations would be of less probability due to an even 110 
higher number of potential target molecules.  111 
 112 
The purpose of the present study was to assess the risk of resistance development to two AMPs and 113 
a peptidomimetic. We also addressed the hypothesis that resistance to a cocktail of compounds 114 
would develop slower than against each compound alone.  115 
 116 
2 Material and methods 117 
 118 
2.1 Bacterial strain and culture conditions.  119 
 120 
Escherichia coli ATCC 25922 was grown in cation-adjusted Müller Hinton II broth (MHB) (Becton 121 
Dickinson 212322) adjusted to pH 7.4 and supplemented with 1.5% agar (Oxoid, CM0471) for 122 
culturing on solid medium. Stock cultures of this strain and resulting adapted lineages were stored 123 
at –80 ⁰C in 25% glycerol. 124 
 125 
2.2 Synthesis of peptidomimetics and AMPs.  126 
 127 
The potential development of resistance was tested by using three compounds: the peptidomimetic 128 
H-[Lys-βNSpe-hArg-βNSpe]3-NH2 that displays an unnatural backbone with some degree of a non-129 
helical secondary structure (Jahnsen et al., 2014; Figure 1), the AMP novicidin 130 
(KNLRRIIRKGIHIIKKYF-NH2), a typical α-helical arginine/lysine-rich peptide (Nielsen and 131 
Otzen, 2010), and the AMP P9-4 (KWRRWIRWL) that most likely does not form a secondary 132 
structure due to its short length (Qi et al., 2010). H-[Lys-βNSpe-hArg-βNSpe]3-NH2, novicidin and 133 
P9-4 were used in the adaptation and were abbreviated as “1”, “2”, “3”, respectively. Compounds 134 
used for assessment of cross resistance were the following: 5 (Ac-[hArg-βNSce-Lys-βNSpe]3-NH2), 135 
6 (Ac-[Lys-βNphe]8-NH2), 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2) as shown in 136 
Figure 1. 137 
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All the compounds were prepared by solid-phase synthesis as previously described (Bonke et al., 138 
2008; Olsen et al., 2010). The resulting lyophilized peptidomimetics and AMPs were dissolved in 139 
10 mg/ml sterile MilliQ water and stored at –20 ⁰C.  140 
 141 
2.3. Determination of Minimum Inhibitory Concentration (MIC).  142 
 143 
MIC of each compound alone, combinations of each of two compounds and of all three was 144 
determined. When testing mixtures of two compounds, each was included at 50% and when testing 145 
the combination of three, each was included at 33% of the total (Table 1). MIC was determined as 146 
described in (Citterio et al., 2016) in accordance with the CLSI guidelines (2012). Microdilution 147 
series of the compounds were prepared in UV-sterilized 96-well polypropylene plates (Thermo 148 
Scientific Nunc, 267334) with sterile polystyrene lids (Sigma Aldrich, CLS3930-100EA). Stock 149 
solutions of peptidomimetics and AMPs were prepared in MilliQ water. Fifty µl of compound 150 
solution and 50 µl of MHB were dispensed into the first well of each row, followed by two-fold 151 
dilutions giving a final concentration range of 128-0.25 µg/ml. Overnight culture of the strain was 152 
diluted in sterile 0.9% NaCl to OD546 0.2 (accepted range: 0.195-0.210) corresponding to 153 
approximately 1 × 108 CFU/ml. This suspension was further diluted 1:100 in MHB and 50 µl of this 154 
culture were inoculated into microtiter plates to reach a final concentration of 5 × 105 CFU/ml in a 155 
final volume of 100 µl. Plates were incubated for 20 h at 37 °C. Growth was determined visually 156 
either as turbidity or as formation of a pellet. MIC was the lowest concentration of peptidomimetics 157 
or AMPs where no growth was observed. All MIC assays were performed as two independent 158 
replicates. 159 
 160 
2.4 Adaptive Laboratory Evolution (ALE).  161 
 162 
Adaptive laboratory evolution of E. coli was carried out as previously described (Perron et al., 163 
2006) in presence of each compound alone and in a combination of all three compounds. An 164 
overnight culture of the strain was grown on MHB agar at 37 °C. A single colony was inoculated in 165 
liquid MHB and grown overnight at 37 °C at 250 rpm on orbital shaker. The initial culture was 166 
adjusted to OD546 = 0.2 and 10 µl were inoculated into 990 µl MHB giving 1 ml of final volume. 167 
Cultures were grown in Sterilin tubes (VWR, 212-7400) at 37 °C at 250 rpm. Throughout the 168 
experiment serial transfers of 10 µl of bacterial culture to fresh medium were performed when 169 
growth was visible as turbidity. After five transfers in un-supplemented medium, four different 170 
peptide treatments were tested: H-[Lys-βNSpe-hArg-βNSpe]3-NH2, novicidin, P9-4, and the 171 
combination of the three (mixed 1:1:1). Four replicates (lineages) were prepared for each treatment, 172 
with the addition of four un-supplemented cultures (i.e. non-exposed lineages), giving a total of 20 173 
parallel lineages. As a simplification, the four lineages adapted to H-[Lys-βNSpe-hArg-βNSpe]3-174 
NH2 (1) were referred to as “1a”, 1b”, “1c” and “1d” through the course of the manuscript. Lineages 175 
adapted to novicidin (2) were referred to as “2a”, 2b”, “2c” and “2d”, lineages adapted to P9-4 (3) 176 
were indicated as “3a”, 3b”, “3c” and “3d”, and lineages adapted to the combination of three were 177 
designated “4a”, 4b”, “4c” and “4d”. Among non-exposed lineages, we selected lineages “0a” and 178 
“0b”, that were transferred until the adaptation experiment was ended, and lineages “0c” and “0d” 179 
that were transferred until the first adaptation to 32-fold of the initial MIC was completed. 180 
Adaptation started from 1/16 of the wild type MIC (i.e. 0.25 µg/ml for 1a, 1b, 1c and 1d; 0.5 µg/ml 181 
for lineages 2a, 2b, 2c and 2d and 3a, 3b, 3c and 3d; and 0.5 µg/ml for 4a, 4b, 4c and 4d). Five 182 
transfers at constant concentration were performed. Then the concentration was doubled and the 183 
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experiment continued until a level of 32-fold higher MIC than wild type MIC was reached for most 184 
of the lineages. After each adaptation step, frozen stocks of the adapted culture were prepared. 185 
 186 
Purity of the lineages was checked at each transfer by streaking on MHB agar plate. The total 187 
number of passages in presence of compound was 50, equivalent to approximately 350 generations. 188 
Re-inoculations were performed twice a day during the sub-MIC treatment and then reduced to 189 
once per day when growth became slower, as the concentration of compound was increased. In case 190 
no growth was observed the next day, the tube was left for another day. If growth still did not occur, 191 
the re-inoculation step was repeated in the same concentration as used in the previously grown 192 
culture. If still no growth was seen, concentration was halved. End of a lineage was considered to be 193 
reached when no growth was observed upon five consecutive re-inoculations. 194 
 195 
To determine stability of the resistance, MIC was determined for each adapted lineage. Overnight 196 
cultures for this assay were prepared in presence of compound at the concentration each lineage was 197 
adapted to. For lineages that did not grow overnight under these conditions the compound 198 
concentration was decreased. Furthermore, the adapted lineages were re-inoculated five times in un-199 
supplemented medium, and MIC was determined for all of them. To assess homogeneity of the 200 
lineage community, the lineages were streaked on agar plates, and then five individual clones 201 
(colonies) were isolated after overnight growth on solid medium. Clones were enumerated from 1 to 202 
5. As an example, clone 1 isolated from the novicidin-adapted lineage “a” was indicated as 2a-1. 203 
MIC was also determined for all the clones.  204 
 205 
2.5 Whole-genome sequencing and variant calling. 206 
 207 
Lineages for whole-genome sequencing were chosen based on the results from the MIC assay 208 
performed on the adapted cultures and the respective clones. Two replicates of two control lineages 209 
and four adapted lineages were selected, giving a number of 12 genomes. Also, two out of five 210 
individual clones were considered for each replicate, giving a number of 24 genomes. Of the control 211 
lineages, half was derived from un-supplemented cultures that were transferred until the first 212 
adaptation to a 32-fold higher MIC had occurred; the other half was derived from un-supplemented 213 
cultures that were serially transferred until the experiment was completed. The wild type ancestral 214 
strain (E. coli ATCC 25922) was sequenced as well. Hence, a total number of 37 lineages and 215 
clones were whole-genome sequenced.  216 
 217 
An overnight culture of E. coli (1.5 ml) was grown to stationary phase and genomic DNA was 218 
extracted with the NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany). Quality of extracted 219 
DNA was assessed by 1% agarose gel electrophoresis and absorbance measurement at DeNovix 220 
DS-11 Spectrophotometer. Quantification was done by Qubit 2.0 Fluorometer (Invitrogen, United 221 
Kingdom). Preparation of genomic DNA libraries and sequencing was performed at the Novo 222 
Nordisk Foundation Center for Biosustainability (Hørsholm, Denmark). Libraries were prepared 223 
with TruSeq Nano HT (Illumina, San Diego, USA) and fragmented to an average size of 350-400 224 
bp with CovarisE220. Average library size after adapter ligation was 500-550 bp, determined by 225 
Fragment Analyzer and Standard Sensitivity NGS kit. Concentrations of the final libraries were 226 
measured by Qubit, dsDNA broad range assay. Libraries were used for paired-end sequencing of 227 
genomes using the Illumina sequencing technology on a NextSeq v2 Mid Output 300 cycles 228 
(2x150). The obtained sequence reads of the wild type strain were de novo assembled in CLC 229 
Genomics Workbench, version 8 (CLC Bio, Aarhus, Denmark) resulting into 156 contigs, 230 
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comprising a total number of 5122028 bases, with a genome coverage of 89×. The assembled 231 
genome has been deposited at GenBank under the BioProject PRJNA309047. All other 36 genome 232 
sequences were submitted to the Sequence Read Archive (SRA) database under the accession 233 
number SRP075796. All the sequenced genomes from adapted and control lineages were mapped 234 
with the 156 contigs as a reference. Average genome coverage was 104×. The 156 contigs were 235 
annotated by Rapid Annotation using Subsystem Technology (Aziz et al., 2008). Variants were 236 
called by fixed ploidy variant detection in CLC Genomics Workbench, in order to identify point 237 
mutations such as Single Nucleotide Polymorphisms (SNPs) and deletion-insertion-polymorphism 238 
(DIPs). Variants with a frequency above 60% were considered for further analysis. Functional 239 
consequences were predicted by searching for amino acid changes, and then filtering non-240 
synonymous mutations.  241 
The analysis was repeated by assembling the wild type contigs to the previously annotated genome 242 
of E. coli ATCC 25922, available at GenBank with the accession number CP009072 (Minogue et 243 
al., 2014). Wild type variants, in comparison to this genome, were detected and shown in 244 
Supplementary Table 2. All the adapted lineages were then mapped to the annotated genome. 245 
Variants were detected and filtered against the known ones, already found in the wild type.  246 
 247 
2.6 Measurement of Zeta potential.  248 
 249 
The wild type strain, an adapted lineage (3c) and a clone (1a-1) were grown overnight in 2 ml liquid 250 
MHB at 37 °C at 250 rpm on an orbital shaker. Cultures were grown both in presence and absence 251 
of compound. Cells were harvested in Eppendorf 5810R centrifuge at 2250 × g for 20 min. Cell 252 
pellets were washed five times in 0.5 mM potassium phosphate buffer solution (pH 7.4), in 253 
Eppendorf 5417R centrifuge at 3000 × g for 5 min, as described in Halder et al., (2015). OD600 was 254 
adjusted to 0.2 (corresponding to approximately 1 × 108 CFU/ml). Zeta potential was measured 255 
with a Zetasizer Nano ZS90 device (Malvern, UK). The given values resulted from the average of 256 
three technical replicates, each of them consisting of 20 measurements. The experiment was 257 
repeated a second time on a separate day. Statistical significance was assessed by One-way analysis 258 
of variance (ANOVA) with statistical F test.  259 
 260 
3 Results  261 
 262 
3.1 Adaptive laboratory evolution.  263 
All four lineages exposed to H-[Lys-βNSpe-hArg-βNSpe]3-NH2 (1a to 1d) and three out of four 264 
lineages exposed to novicidin (2b 2c, 2d) were adapted to a 32-fold higher MIC (128 and 256 265 
µg/ml, respectively) after passaging through approximately 350 generations (Figure 2). 266 
Unexpectedly, none of the lineages exposed to P9-4 (3a to 3d) adapted to a 32-fold higher MIC, but 267 
only one of four lineages (3c) tolerated a 16-fold higher MIC of 128 µg/ml), whereas the other three 268 
i.e. 3a, 3b, 3d remained at 8-, 4- and 4-fold higher MIC (64 and 32 µg/ml, respectively) as shown in 269 
Figure 2. Only 4a out of four lineages exposed to the three-compound combination adapted to a 32-270 
fold higher MIC of 256 µg/ml), whereas the other three i.e. 4b, 4c and 4d remained at 4-, 8- and 8-271 
fold higher MIC (32 and 64 µg/ml, respectively) as shown in Figure 2. 272 
 273 
3.2 Re-growth of adapted lineages in presence of compound. 274 
All adapted lineages were revived from frozen stocks and re-grown at the compound concentration 275 
that they were adapted to. All four 1-adapted lineages, 3c, and 4a (Table 2) were able to re-grow at 276 
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the concentration that they were adapted to, as opposed to the remaining lineages. The 2-adapted 277 
lineages were only able to re-grow at ¼ of the MIC that they were originally adapted to, and similar 278 
results were seen for 3a and 3b as well as for 4c. Lineages 3d, 4b and 4d were all able to re-grow at 279 
½ of the MIC that they were originally adapted to (Table 2). 280 
 281 
3.3 Assessment of resistance in adapted lineages. 282 
Stability of resistance was tested by determining MIC after five transfers, corresponding to 283 
approximately 35 generations, in absence of compound (Table 2). Lineage 2a had a MIC of 4 µg/ml 284 
when re-tested, despite being adapted to 64 µg/ml. Only one of five clones i.e. 2d-4 had a high MIC 285 
of 64 µg/ml (Table 3) while for all the other clones MIC was comparable to wt MIC, i.e 4-16 µg/ml. 286 
2a and 2d and selected derived clones were whole-genome sequenced, as they were found to be the 287 
most susceptible and resistant, respectively.  288 
 289 
In the 1-adapted lineages the measured MIC was equivalent to a 32-fold higher MIC than the wt 290 
MIC (128 µg/ml) or even higher (256-512 µg/ml). Also, the high MIC was maintained in clones 291 
isolated from three out of four lineages, except for 1b-4 (Table 3). The lineages with the highest and 292 
lowest MIC values, respectively, 1a and 1c, were whole-genome sequenced as were two clones for 293 
each lineage.  294 
 295 
MIC for 3c, originally evolved to a 16-fold higher MIC of 128 µg/ml, remained high (64-128 296 
µg/ml) after re-growth in presence of compound and upon five subsequent re-inoculations in 297 
absence of compound. In the five isolated clones, the measured MIC varied from a lower limit equal 298 
to the wt MIC (8-16 µg/ml) to an upper limit of 64 µg/ml (Table 3).  299 
MIC for 4a (adapted to 256 µg/ml) was 32-128 µg/ml after re-growth in presence of compound, and 300 
reached 16-32 µg/ml after five subsequent re-inoculations in absence of compound. In the isolated 301 
clones, a MIC range up to 128 µg/ml was found only in two out of 20 clones (Table 3). These 302 
results indicate that the resistance trait decreased in absence of compound, even though 3c and 4a 303 
previously adapted to a 16-fold higher MIC of 128 µg/ml and a 32-fold higher MIC of 256 µg/ml, 304 
respectively).  305 
Lineages 3c and 4a were whole-genome sequenced as representatives of resistant lineages, along 306 
with two clones from each of them. 307 
 308 
Lineage 4b (adapted to a 4-fold higher MIC of 32 µg/ml) and 4c and 4d (adapted to an 8-fold higher 309 
MIC of 64 µg/ml) as well as clones derived from these lineages displayed generally higher MIC 310 
than 3a (adapted to an 8-fold higher MIC of 64 µg/ml), 3b and 3d (both adapted to a 4-fold higher 311 
MIC of 32 µg/ml). In fact, 4c and 4d had MIC of 16-64 and 32 µg/ml, respectively, when grown in 312 
presence of compound (Table 2). In the clones isolated from such lineages, MIC values were 313 
between 8 and 128 µg/ml, while in all clones, isolated from 4a, 4b and 4d, MIC values did not 314 
exceed the wt MIC (8-16 µg/ml). Given these data, 4b and 3d were whole-genome sequenced as 315 
representatives of susceptible lineages. 316 
 317 
Cross resistance was assessed in the lineages where resistance persisted to the highest degree (1a, 318 
3c, 4a, 2d). MIC of peptidomimetics displaying structural variations as compared to 1 was also 319 
assessed (Table 4). Resistance was maintained toward compounds 5 and 6. It is noticeable that the 320 
lipidated compound 7 retained almost full activity against 1a (MIC was 16 µg/ml as compared to 4-321 
8 µg/ml in the wild type) but not against the other resistant lineages. Compound 2 retained full 322 
activity against 1a and 3c, but not against 4a. This was also reflected in the MIC values of 2 in 323 
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combination with 1. In lineage 1a, resistance was retained toward 1 and 3. The two-compound 324 
combinations seemed to be less effective than the combination of three compounds. Compound 2 325 
alone showed the best activity on resistant lineages adapted to the other two compounds.   326 
 327 
3.4 Whole-genome sequencing. 328 
 329 
The wild type E. coli ATCC 25922 genome was assembled into 156 contigs with 89× coverage. A 330 
fully closed genome is available at NCBI; however, we chose to genome-sequence the actual strain 331 
we worked with. The wild type genome showed 30 variants with frequencies above 60%, with 332 
fourteen of them occurring in coding regions (Supplementary Table 2), as compared to the fully 333 
closed genome. This number indicated that comparison of the adapted strains to the de novo 334 
sequenced wild type was justified. 335 
 336 
Sequences from the adapted lineages and clones were mapped to the wild type contigs, and an 337 
average number of 26 variants per genome with a frequency above 60% were found. Variants in 338 
coding regions were on average 14. Among these, an average of 6 variants caused an amino acid 339 
change in proteins. In non-exposed lineages, we found an average number of 24 variants per 340 
genome with a frequency above 60%. Among these, an average of 14 were located in coding 341 
regions, and 5 variants caused amino acid changes in encoded proteins (Table 5; Supplementary 342 
Table 1).  343 
 344 
Deletions in the CDP-glycerophosphotransferase (CDP-glycerol: N-acetyl-β-D-mannosaminyl-1,4-345 
N-acetyl-D-glucosaminyldiphosphoundecaprenyl glycerophosphotransferase) were seen in 6 out of 346 
8 exposed lineages and in 11 clones. Interestingly, deletions were seen in clone 3c-4, but not in its 347 
parent lineage (3c). The deletions occurred in different regions of the same protein (Figure 3). 348 
However, there was no pattern between variant type, peptide and lineage, except for 2d, where the 349 
same deletion type was found both in the community and in the clones. 350 
 351 
Lineages that, based on MIC assessment, showed the highest level of resistance (the 1-adapted 352 
lineages as well as 3c and 4a) did not share the same variant pattern. In fact, 1a had a deletion in the 353 
genes encoding CDP-glycerophosphotransferase while its two isolated clones also showed a 354 
mutation in the outer-membrane protein assembly factor YaeT precursor. By contrast 1c displayed a 355 
mutation in three different proteins besides a deletion in the CDP-glycerophosphotransferase that 356 
was different from the one acquired by lineage a. In 4a, the highest number of variants was found 357 
(55 with a frequency above 60%). Among these, ten variants corresponded to non-synonymous 358 
mutations in coding regions, and three of these may be suggested to be involved in the resistance 359 
genotype: a deletion in the CDP-glycerophosphotransferase (present in 3d-4, 1a-1 and 1a-5), and 360 
mutations in the respiratory nitrate reductase δ chain and in the GTP pyrophosphokinase 361 
bifunctional (p)ppGpp synthase/hydrolase SpoT, respectively. 362 
 363 
In 2a, which was less resistant than the other three lineages, a mutation in the diguanylate cyclase 364 
domain protein and one in the Zinc ABC transporter ZnuA were found in both the lineage 365 
community and in the derived clones. These mutations did not appear in any of the other adapted 366 
lineages. Also, this lineage, and its derived clones, did not show any deletion in the CDP-367 
glycerophosphotransferase. By contrast, in 2d a deletion in the same region of the CDP-368 
glycerophosphotransferase was present in both the lineage community and in the derived clones. 369 
Some of the mutations found in 3d-4, such as the ones in the CDP-glycerophosphotransferase, 370 
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respiratory nitrate reductase δ chain and GTP pyrophosphokinase, were also present in 4a and 4a-1. 371 
A mutation in the phage major capsid protein was found in both 3d and 4b-1.   372 
 373 
The mutational events, common to both adapted and non-exposed lineages, are shown in 374 
Supplementary Table 1. A mutation in the YeeV toxin protein arose in one exposed lineage and two 375 
clones (3c, 3c-1 and 4a-1). A different mutation in the same protein was seen in non-exposed clone 376 
0a-2. Interestingly, none of the 3-adapted lineages and clones had a mutation in the 377 
dihydrolipoamide acetyltransferase.  378 
 379 
A few mutational events were typical for the non-exposed lineages, such as mutations in the LysR 380 
transcription regulator LrhA, the mannose-specific adesin FimH, the phosphatase CheZ, involved in 381 
chemotaxis response and the arginine pathway regulatory protein ArgR2C (Supplementary Table 382 
1). 383 
 384 
3.5 Measurement of Zeta potential.  385 
 386 
The impact of the deletion in the CDP-glycerophosphotransferase gene on the resistance phenotype 387 
was assessed by measuring the Zeta potential of selected adapted lineages and clones. Average 388 
values for 3c and 1a-1 were –33 mV and –28 mV, respectively, both significantly higher than that 389 
found for the wild type (–48 mV).  390 
 391 
4 Discussion 392 
 393 
E. coli adapted readily to the peptidomimetic H-[Lys-βNSpe-hArg-βNSpe]3-NH2 (1) and the AMP 394 
novicidin (2). Indeed most of the lineages became resistant during the course of the adaptive 395 
evolution experiment. In contrast, resistance did not readily develop toward the P9-4 peptide (3), 396 
which differs from the other two compounds by displaying an arginine-tryptophan (RW) motif 397 
twice. This motif has been shown to increase the interaction of AMPs with membranes. In fact, for 398 
short peptides (6-12 residues) the presence of RW motifs has been highlighted as promoting 399 
membrane interactions, since arginine preferentially forms bidentate hydrogen bonds with the polar 400 
headgroups of phosphatidylglycerol, while tryptophan traverse the membrane by intercalation (Liu 401 
et al., 2007). Hence, the delayed resistance development may be related to the strongly membrane-402 
disruptive mode of action that also confers some concomitant toxicity toward human cells. In 403 
addition, RW motifs preferentially induce inter-peptide rather than intra-peptide interactions (Liu et 404 
al., 2007). This latter feature may increase the number of molecular targets in the bacterial cell 405 
membrane, thereby delaying resistance development.  406 
Common mutations were identified in the gene CDP-glycerophosphotransferase encoding an 407 
enzyme consisting of 1266 amino acids. Single-nucleotide deletions were found in three different 408 
regions of this gene (Figure 3). A deletion (found in the genomes of 1a, 3c-1, 3d and 3d-1) was 409 
located in a region encoding the tetratricopeptide (TPR) domain, which is a putative protein-binding 410 
surface. A second deletion type, found in the genomes of 1c, 1c-1, 2d, 2d-1 and 2d-4, had occurred 411 
in a domain putatively involved in outer membrane biosynthesis, as previously shown in Klebsiella 412 
pneumoniae (Frirdich et al., 2004). The third deletion type (present in 1a-1, 1a-5, 3d-4, 4a and the 413 
derived clones as well as in 4b and the derived clone 4b-1), was in a domain functionally related to 414 
cell wall biogenesis as well as lipid transport and metabolism. The second and third deletion types 415 
were located in the region responsible for the phosphotransferase activity thus inferring a putative 416 
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resistance mechanism based on deficient introduction of negative charge to the membrane. Such 417 
mutations are likely to inhibit phosphorylation, thereby reducing the negative charge of the 418 
membrane, and limiting the interaction with positively charged AMPs. We hypothesized that 419 
lineages and clones which acquired a deletion that decreased the phosphotransferase activity would 420 
possess less negative membranes. Indeed, higher zeta potential (–28 mV) was measured for clone 421 
1a-1 as compared to both wild type (–48 mV) and 3c (–33 mV). The latter also possessed 422 
significantly increased surface charge as compared to the wild type, indicating that it had acquired a 423 
surface charge modification arising from deficiencies in at least one other membrane-related 424 
maintenance system. This result suggests that for clone 1a-1 the mutation in CDP-425 
glycerophosphotransferase may affect the bacterial surface charge resulting in a less negative 426 
membrane. This mechanism seems to constitute a novel variation as compared to the known 427 
strategies of limiting the attraction of cationic compounds (Band and Weiss, 2015). Occurrence of 428 
the same variant across lineages exposed to distinct compounds appears to be linked to the similar 429 
nature of the antibacterial agents giving rise to the selection pressure (Band and Weiss, 2015). It is 430 
unclear whether the distinct deletion types confer different levels of resistance. However, 1c 431 
exhibited the same deletion in the CDP-glycerophosphotransferase as also found in 2d, and for both 432 
the MIC values suggest that resistance was probably induced by activation of preexisting adaptive 433 
systems, unlike the other 1-adapted lineages, where resistance was maintained. This shows that 434 
diversification into different genotypes occurs both within lineages adapted to the same compound 435 
and across lineages exposed to different compounds.   436 
Despite the heterogeneity, the variants can be divided into four distinct groups, which represent 437 
genotypes that have followed parallel evolutionary trajectories. The deletion in the CDP-438 
glycerophosphotransferase was not present in 2a, which instead had acquired mutations in the 439 
diguanylate cyclase domain protein and in the periplasmic zinc transporter ZnuA. The former seems 440 
to be involved in phosphorylation (like the CDP-glycerophosphotransferase), the latter in zinc 441 
uptake (Hantke, 2005; Ammendola et al., 2007). A mutation in the zinc uptake system protein 442 
ZnuA may be related to a known mechanism of resistance based on peptide degradation by zinc-443 
dependent metalloproteases (Kooi and Sokol, 2009). 444 
 445 
Three genomes (3d-4, 4a and 4a-1) had acquired mutations in the respiratory nitrate reductase δ 446 
chain, in the GTP pyrophosphokinase, alongside a deletion in the same region of the CDP-447 
glycerophosphotransferase. The respiratory nitrate reductase δ chain is essential for assembly of the 448 
whole enzyme; hence, a mutation in this subunit may affect the overall function of the protein if the 449 
assembly itself is compromised. Yet, the consequence of these mutations on resistance development 450 
remains unclear.  451 
 452 
Lineage 3c, the most resistant among the 3-adapted lineages, did not have a deletion in the CDP-453 
glycerophosphotransferase. Remarkably, despite the absence of a deletion in the CDP-454 
glycerophosphotransferase, this specific lineage developed stable resistance. In contrast, 2a, also 455 
lacking this deletion, was less resistant than 3c. These findings may be related to the different 456 
variant patterns that the lineages have acquired in presence of different compounds. However, the 457 
deletion in the CDP-glycerophosphotransferase was present in 3c-4, inferring that there has been 458 
more than one mutational trajectory within the same lineage community exposed to the same 459 
compound. In fact, this selected clone may merely represent a rarely occurring genotype in the 460 
lineage population. Nevertheless, 3c may represent a special case where the previously acquired 461 
mutations were lost in the next generations, because they were deleterious (Török et al., 2012). 462 
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Potential loss of the mutations in the CDP-glycerophosphotransferase may be responsible for the 463 
prolonged period needed to reach adaptation to the highest concentration of exposure (128 µg/ml).  464 
 465 
In conclusion, the four main mutational trajectories may be summarized as: a first one can be 466 
identified in the acquisition of a deletion in the CDP-glycerophosphotransferase, a second one in the 467 
diguanylate cyclase domain protein and in the periplasmic zinc transporter protein ZnuA, a third 468 
one had no deletion in the CDP-glycerophosphotransferase, while a fourth trajectory resulted in 469 
mutations in the respiratory nitrate reductase δ chain, in the GTP pyrophosphokinase, alongside a 470 
deletion in the CDP-glycerophosphotransferase.     471 
 472 
The presence of the short peptide P9-4 in the combination appears to have slowed down the 473 
resistance development in three out of four lineages exposed to the combination. Nevertheless, the 474 
simultaneous exposure to three compounds may account for the decreased rate of resistance 475 
development, as inferred by the work of Pirrone et al. (2011). However, it has been highlighted  that 476 
in clinical studies of Gram-negative infections there was no difference in emergence of resistance 477 
during combination therapy versus monotherapy (Tamma et al., 2012). 478 
 479 
For lineage 4a resistance development was faster than for the other three 4-adapted lineages. 480 
However, despite adaptation to a 32-fold higher MIC of 256 µg/ml, this lineage proved incapable of 481 
retaining a high level of resistance as opposed to 1a, 1b and 1d. MIC results performed on adapted 482 
lineages and derived clones may overall indicate that for the three 1-adapted lineages as well as for 483 
3c and 4a, resistance was relatively stable, and hence arises from genetic mutations, while for the 484 
others resistance may be a phenotypic switch trait, caused by inducible preexisting adaptive 485 
systems. In fact, exposure to sub-MIC concentrations may lead to upregulation of efflux pumps or 486 
simply decreased membrane permeability due to LPS modification with additional fatty acid chains 487 
(Nizet, 2006).  488 
Overall, the resistant genotypes had acquired a few distinct but non-identical mutations that appear 489 
to be correlated to the mechanism of the evolved resistance.  490 
We conclude that mutations in CDP-glycerophosphotransferase may be a prime contributing factor 491 
in the adaptation to the investigated compounds. On the other hand, the zeta potential measurement 492 
is not an exhaustive method for confirming this hypothesis. We envision that only the construction 493 
of wild type mutants with deletions in the CDP-glycerophosphotransferase would unequivocally 494 
confirm whether this indeed is the primary cause of the observed resistant phenotype. 495 
It is not known whether independent mutations or rather the interplay between different cooperative 496 
mutations is responsible for resistance. As pointed out by Martinez and Baquero (2000), the 497 
emergence of independent or cooperative mutations depends on the specific bacterium-compound 498 
interaction. Also, it is known that a change of a single residue in an encoded protein may not 499 
interfere with its activity, unless the change occurs in the active site of an enzyme or in a residue 500 
that is involved in folding of the protein (Studer et al., 2013).  501 
The three antibacterial compounds investigated for their potential risk of inducing resistance were 502 
selected to represent distinct structural differences, and thus comprised a non-helical 12-residue 503 
peptidomimetic H-(Lys-βNphe-hArg-βNphe)3-NH2 (denoted 1), with an alternating design of 504 
cationic Lys/hArg and aromatic peptoid residues, a typical 18-mer α-helical highly cationic AMP 505 
(i.e. novicidin also denoted 2) as well as a very short 9-residue Arg/Trp-rich AMP (i.e. P9-4 also 506 
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denoted 3). Interestingly, lineage 1a exhibited cross resistance to both peptidomimetics 6 and 8 (Ac-507 
[Lys-βNphe]8-NH2 and Ac-[hArg-βNSpe]6-NH2) displaying only Lys or hArg residues, 508 
respectively, together with aromatic peptoid units, while susceptibility to the lipidated Lys-based 509 
analogue 7 was almost fully retained inferring that this structural modification most likely is 510 
associated with an altered mode of action. Nevertheless, this seems not just to be correlated with an 511 
increased overall lipophilicity of compound 7, since cross resistance to the hydrophobic analogue 5 512 
had evolved also. Analogue 5 resembles compound 1 with respect to cationicity, but contains 513 
additional α-methyl groups in the peptoid side chains as well as a significant content of aliphatic 514 
cyclohexyl peptoid side chains, which collectively confer similar enhanced hydrophobicity as the 515 
single fatty acid in compound 7. Noticeably, the structurally most different compounds, 1 and 2, 516 
displayed less and no cross resistance, respectively. Somewhat surprisingly the combination of three 517 
and the 1+2 pair displayed similar activity against all resistant strains tested, whereas other two-518 
compound combinations were less effective than the individual compounds. Compound 2 alone in 519 
fact showed unchanged activity on resistant lineages adapted to other compounds inferring that its 520 
killing mechanism appears to deviate significantly from those of 1 and 3.   521 
We show that resistance development toward a combination of three AMPs was slower than to two 522 
of the three compounds when used alone. However, resistance to one of the peptides (P9-4) alone 523 
was surprisingly difficult to evolve. These findings indicate that resistance development is 524 
compound-dependent rather than combination-dependent. We propose that constrained evolutionary 525 
resistance-inducing trajectories are compound-dependent. Also, it is suggested that the influence of 526 
certain mutations can be explained, as they occurred in lineages upon exposure to different 527 
compounds. Our results infer that P9-4 may constitute a potential lead for a future drug candidate, 528 
and we encourage early-stage investigation of resistance development for all promising novel 529 
antibacterial compounds. In addition, the issue of the potential risk of cross-resistance seems to be 530 
quite complex as no clear-cut conclusions can be made from this limited study. However, more 531 
detailed studies comprising a larger number of AMPs are warranted in order to assess to which 532 
degree activity of other subclasses of AMPs will be compromised by resistance development to a 533 
single AMP or to a combination of antibacterials.   534 
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Table 1: MIC of the compounds used in the present study against E. coli ATCC 25922.  737 
 738 
Compound MIC (µg/ml)  
1 4-8 
2 4-16 
3 8-16 
4 8 
5 
6 
7 
8 
8-16 
8 
4-8 
4-8 
1+2 4-8 
1+3 8 
2+3 8 
1 (H-[Lys-βNSpe-hArg-βNSpe]3-NH2), 2 (novicidin), 3 (P9-4), 4 (1+2+3), 5 (Ac-[hArg-βNSce-Lys-739 
βNSpe]3-NH2), 6 (Ac-[Lys-βNphe]8-NH2), 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2).  740 
 741 
 742 
 743 
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Table 2: Fold change in adapted lineages as compared to wt MIC of the compounds used in the 757 
adaptation. 758 
  
Fold increase as compared to wt MIC 
 
Lineage At the end of ALE At re-growth upon 
freeze storage  
After 
ALE 
and re-
growth 
After 5 re-
inoculations  
in absence of 
compound 
1a 16-32 16-32 64 16-32 
1b 16-32 16-32 64 16 
1c 16-32 16-32 64 32 
1d 16-32 16-32 32-64 32 
     
2a * 4-16 1-4 1 1 
2b * 16-64 4-16 1 2-4 
2c* 16-64 4-16 2-4 1-2 
2d* 16-64 4-16 4-16 2-8 
     
3a * 4-8                1-2 1 1 
3b * 2-4 1 1 1 
3c  8-16 8-16 8 4-8 
3d * 2-4 1-2 1 1 
     
4a  32 32 4-16 2-4 
4b * 4 2 1-2 1-2 
4c * 8 2 2-8 2 
4d * 8 4 4 2 
 759 
Note: the fold increase presented in the first two columns refers to MIC values reported in Table 1. The 760 
actual concentration of adaptation is reported in Figure 2. *Lineages that did not grow at the concentration of 761 
adaptation and therefore were grown in lower concentration. Lineages in bold were whole-genome 762 
sequenced. Experiments were done in independent duplicates.  763 
 764 
 765 
 766 
 767 
 768 
 769 
 770 
 771 
 772 
 773 
 774 
In revi
ew
  Adaptive Resistance to Antimicrobial Peptides 
19 
 
 
Table 3: Fold change in MIC of the compounds in five clones isolated from each adapted lineage.  775 
 776 
 Fold change in MIC of the respective compound for each clone (1-5) 
Lineage 1 2 3 4 5 
1a 32-64 32-64 32-64 32-64 32 
1b 16 16 16 1 16 
1c 2 4 2-8 4-8 4-8 
1d 32 8-32 16-32 32 64 
      
2a 1 1 1 1 1 
2b 1 1 1 1 1 
2c 1 1 1 1 1 
2d 1 1 1 4-16 1 
      
3a 1 1 1 1 1 
3b 1 1 1 1 1 
3c 4 2-4 4 2-4 4 
3d 1 1 1 1 1 
      
4a 2-4 4 4 4 2-4 
4b 1-2 2 1-4 2-4 1-2 
4c 2 1-2 1-8 1 1 
4d 1 2-16 2-4 8-16 2 
 777 
All clones were tested against the respective compound used for adaptation. Fold changes in bold relate to 778 
the clones that were whole-genome sequenced. Experiments were done in independent duplicates. 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
 788 
 789 
 790 
 791 
 792 
 793 
 794 
 795 
 796 
 797 
 798 
 799 
 800 
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Table 4: Cross resistance in selected resistant lineages. 801 
 802 
Compound  Fold change in MIC (µg/ml) in adapted lineages 
  1a 3c 2d 4a 
1  32-64 16 4-8 64-128 
2  1 1 4-16 2-8 
3  2-4 8-16 2-4 8-16 
4  1-2 2-4 4 8 
5 
6 
7 
8 
 8-16 
64 - > 64 
2-4 
8-16 
16 
64 
8 
4-8 
8 
32 
4-8 
2 
32 
>64 
16-32 
16-32 
1 + 2  1 4 2-4 8 
1 + 3  8 16 4 32 
2 + 3  2 4-8 4-8 8 
 803 
1 (H-[Lys-βNSpe-hArg-βNSpe]3-NH2), 2 (novicidin), 3 (P9-4), 4 (1+2+3), 5 (Ac-[hArg-βNSce-Lys-804 
βNSpe]3-NH2), 6 (Ac-[Lys-βNphe]8-NH2), 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2).  805 
  806 
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Table 5: Single-nucleotide variants (frequency >60%) causing amino acid change in adapted lineages and respective clones. In italic: variant causing 807 
synonymous mutations. 808 
 809 
    Mutations in adapted lineages and clones 
 1  2  3  4 
Gene product a a-
1 
a-
5 
c c-
1 
c-
5 
 a a-
1 
a-
3 
d d-
1 
d-
4 
 c c-
1 
c-
4 
d d-
1 
d-
4 
 a a-
1 
a-
2 
b b-
1 
b-
4 
CDP-glycerophosphotransferase  x x x x x      x x x    x x x x  x x x x x  
Respiratory nitrate reductase δ 
chain  
                   x  x x     
GTP pyrophosphokinase                     x  x x     
Unsaturated fatty acid biosynthesis  
repressor FabR2C TetR  
                        x   
Diguanylate cyclase         x x x                  
Outer membrane protein assembly 
factor YaeT precursor  
 x x                         
Uncharacterized Yrbk             x                
S-formylglutathione hydrolase              x               
Transcriptional activator  
of maltose regulon 2C MalT  
            x               
Zinc ABC transporter ZnuA        x x x                  
Phage major capsid protein                  x        x  
T1SS secreted agglutinin RTX          x                 x x 
Mobile element protein         x  x                 
Antirestriction protein klcA     x    x   x x           x    
Exopolygalacturonate lyase           x x x               
FecD (Iron transport protein)     x                     x  
Glutamate decarboxylase                 x  x    x     
Ferredoxin reductase                    x        
Periplasmic binding protein                         x   
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 810 
We show lineages 1a and 1c and clones 1a-1, 1a-5, 1c-1, 1c-5 for H-[Lys-βNSpe-hArg-βNSpe]3-NH2, lineages 2a and 2d and clones 2a-1, 2a-3, 2d-1, 2d-4 for novicidin, 811 
lineages 3c and 3d and clones 3c-1, 3c-4, 3d-1, 3d-4 for P9-4, lineages 4a and 4b and clones 4a-1, 4a-2, 4b-1, 4b-4 for the combination. We report only variants that were not 812 
also present in non-exposed lineages. We do not show variants occurring in hypothetical proteins.813 
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12 Figure legends 814 
 815 
Figure 1: Structure of the peptidomimetics used in the present study. From the top left, 816 
clockwise: compound 1 (H-[Lys-βNSpe-hArg-βNSpe]3-NH2) 5 (Ac-[hArg-βNSce-Lys-βNSpe]3-817 
NH2) 6 (Ac-[Lys-βNphe]8-NH2) 7 (Lau-[Lys-βNphe]6-NH2) and 8 (Ac-[hArg-βNSpe]6-NH2).  818 
 819 
Figure 2: Adaptive laboratory evolution of E. coli to the single compounds and the 820 
combination. Four independent lineages (black line: lineage a, red line: lineage b, blue line: lineage 821 
c, green line: lineage d) were adapted for each treatment: H-[Lys-βNSpe-hArg-βNSpe]3-NH2 822 
(compound 1), novicidin (2), P9-4 (3), and the combination of the three compounds (4). 823 
 824 
Figure 3: Location of the three deletion types in the gene encoding for the CDP-825 
glycerophosphotransferase. The precise location of the deletions is marked with a purple bar. 826 
The deletions were found in a region encoding for the TPR domain (yellow) and in two distinct 827 
regions related to the phosphotransferase activity (light orange and orange).  828 
 829 
Figure 1.TIF
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Supplementary Table 1: Single nucleotide variants (frequency >60%) causing amino acid change in both adapted and non-exposed lineages. 
 
 Adapted lineages and clones   
 1 2 3 4  0 
 
Gene product 
a a-
1 
a-
5 
c c-
1 
c-
5 
a a-
1 
a-
3 
d d
-1 
d
-4 
c c-
1 
c-
4 
d d
-1 
d
-4 
a a-
1 
a-
2 
b b
-1 
b
-
4 
 a a-
1 
a-
2 
b b
-1 
b
-2 
c c-
1 
c-
2 
d d
-1 
d
-2 
Mannose-specific 
adesin FimH 
                          x     x x x    
phosphatase CheZ                            x  x    x  x 
Arginine pathway  
regulatory protein 
ArgR2C 
                                  x  
LysR family 
transcription 
regulator lrhA 
                         x     x x x    
                                     
YeeV toxin protein              x x      x       x          
Mobile element 
protein  
x   x x x x  x x  x x x  x x  x x   x x x x x x x x x x x  x x 
DNA repair protein 
RadC  
x x x  x x x x x x x x x x x x x x x x x x x  x x x x x x x x x x x x 
Dihydrolipoamide  
acetyltransferase  
x x    x x x x x  x   x  x  x x x x x x     x x  x x   x 
Membrane protein 
b2001 
    x       x       x         x         
BigB  x                         x          
Uncharacterized 
YkfH 
x x x x x x x x x x x x x x x x x x x x x x x x  x x x x x x x x x x x x 
 
 3 
Variants typical of non-exposed lineages (0) are shown in the upper part of the table. In non-exposed lineages, 0a, 0b and respective clones were transferred 
until the adaptation experiment was ended while lineages 0c, 0d and respective clones were transferred until the first adaptation to 32× was completed. Single 
nucleotide variants detected both in adapted and in non-exposed lineages and clones are shown in the lower part of the table. 
 
Supplementary Table 2: Single nucleotide variants (frequency >60%) occurring in coding regions of the wild type genome used in the present study, as 
compared to the reference strain Escherichia coli ATCC 25922.  
 
Gene product Number of variants in coding regions 
LPS-assembly protein lptD 1 
Rhs element Vgr family protein 3 
Phage major capsid E family protein 1 
deoR C term sensor domain protein 2 
Glycosyl transferase 21 family protein 1 
Integrase core domain protein 1 
Putative membrane protein 1 
Putative entS/YbdA MF S transporter 1 
Propionate CoA ligase 1 
Hypothetical proteins 2 
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Introduction**
*
The&rapid&emergence&and&spreading&of&bacterial&antibiotic&resistance&highlight&the&urgent&
demand& for& discovery& and& development& of& novel& antimicrobial& compounds& and& treatment&
strategies.& In& the& last& two& decades,& antimicrobial& peptides& (AMPs)& have& been& considered& as&
potential& novel& antibiotics& due& to& the& lack& of& widespread& coGevolution& of& resistance& in& nature&
(Ulvatne,&2003;& Zaiou,&2007).& Initially,& emergence&of& resistance& toward&AMPs&was&assumed& to&be&
low&due& to& their& rapid&bactericidal&activity& (Wimley&and&Hristova,&2011;&Fox,&2013).&Nevertheless,&
development& of& resistance& to& AMPs& has& been& raised& as& a& potential& risk& as& general& resistance&
mechanisms&might& compromise& the& innate& immune& defense& in& humans& (Bell& and& Gouyon,& 2003;&
Perron& et& al.,& 2006).& Resistance& is& a& natural& phenomenon& that& depends& on& the& environmental&
stimuli,&and&e.g.&stress&induced&by&AMPs&under&laboratory&conditions&may&exert&a&selection&pressure&
that&confers&bacterial&adaptive&resistance&(Hong&et&al.,&2016).&&
By& using& an& adaptive& laboratory& evolution& approach,& resistant&E.# coli& lineages,& exhibiting&
substantially& increased& minimal& inhibitory& concentrations& (MICs)& toward& AMPs& and&
peptidomimetics,& were& readily& developed& (Citterio& et& al.,& 2016,& submitted).& Hence,& any& AMP& or&
synthetic&analogue&may&select&for&resistant&mutants&present&(or&evolving)&in&a&bacterial&population.&
In&addition,&it&has&been&found&that&AMPGresistant&bacterial&mutants&can&display&crossGresistance&to&
other&AMPs&with&different&structures&and&modes&of&action&(Andersson&et&al.,&2016).&Thus,&it&is&crucial&
to& investigate& the&potential&of& such& crossGresistance&as& it& represents& a&possible& risk& for& any&novel&
antibacterial& compound.& Interestingly,&Baym&et&al.,& (2016)& recently& reported& that& inversion&of& the&
selective&advantage&of&resistance&could&turn&a&resistant&population&susceptible&again.&Such&inversion&
of& the&selective&advantage& is& triggered&by&suppressive&drug& interactions.& In& fact,& resistance& to& the&
first& applied& drug& can& increase& the& sensitivity& to& a& second& applied& drug& (Imamovic& and& Sommer,&
2013).& The& latter& creates& a& concentration& regime& that& inhibits& the& growth& of& resistant& bacteria,&
hence& selecting& for& the& sensitive& part& of& the& population& (Baym& et& al.,& 2016).& Based& on& these&
observations,&we&hypothesized&that&suppressive&drug&interactions&can&select&against&AMPGresistant&
mutants,&hence&inducing&susceptibility&in&a&resistant&population.&
CrossGresistance& and& susceptibility& patterns& were& difficult& to& explain& when& only& a& few&
compounds& were& included& in& the& studies& (HeinGKristensen& et& al.,& 2013;& Citterio& et& al.,& 2016,&
submitted).&Hence,&the&present&purpose&was&to&assess&whether&previously&evolved&AMPGresistant&E.#
coli&clones&were&resistant&or&susceptible&to&a&structurally&more&diverse&range&of&compounds.&Thus&
we& selected& an& array& of& synthetic& AMPs& and& peptidomimetics& for& an& extended& study& of& crossG
resistance.& These& compounds& represent& a& variety& of& structural& features& such& as& length,&
hydrophobicity,& lipidation,& incorporation& of& DGamino& acids,& and& presence& of& characteristic& motifs&
(e.g.&RW&or&IR)&or&high&abundance&of&certain&amino&acids.&&
Our&hypothesis&was&that&combinations&of&compounds&displaying&different&typical&features&
of&synthetic&AMPs&might&give&rise&to&drugGsuppressive&interactions&in&AMPGresistant&clones.&Clones&
derived&from&lineages&adapted&in&the&laboratory&upon&exposure&to&subGlethal&concentrations&of&the&
AMPs&P9G4&and&novicidin& as&well& as&peptidomimetic&HG[LysGβNSpeGhArgGβNSpe]3GNH2& (HFG1002G2)&
individually& and& in& a& combination& of& all& three& compounds& were& examined& (Citterio& et& al.,& 2016,&
submitted).&From&wholeGgenome&sequence&analysis&of&these&AMPGadapted&clones,&we&identified&a&
novel& putative& distinct& mode& of& resistance& leading& to& an& overall& loss& of& negative& charge& of& the&
bacterial&membranes.&We&hypothesized&that&this&mechanism&of&resistance&was&genetically&encoded;&
hence& it& would& be& maintained& in& absence& of& the& selective& pressure& exerted& by& the& compound.&
Therefore& we& reGcultivated& highly& resistant& clones& in& absence& of& compound& and& investigated&
whether& the& single& nucleotide& variants,& identified& immediately& after& the& adaptive& evolution&
experiments,&were&still&present&in&the&populations&of&these&clones&after&fifteen&reGinoculation&steps.&&
The&primary&purpose&of&the&present&study&was&to&investigate&the&stability&of&resistance&in&
AMPGresistant&mutants&as&well&as&estimating&the&degree&of&and&trends&for&crossGresistance&in&such&
highly&resistant&clones.&
!
Methods*
*
Bacterial*strain*and*culture*conditions.!#
Escherichia#coli&ATCC&25922&was&grown&in&cationGadjusted&Müller&Hinton&II&broth&(MHB)&(Becton&
Dickinson&212322)&adjusted&to&pH&7.4&and&supplemented&with&1.5%&agar&(Oxoid,&CM0471)&for&
culturing&on&solid&medium.&Stock&cultures&of&this&strain&and&reGcultivated&clones&were&stored&at&G80&
⁰C&in&25%&glycerol.&
&
Synthesis*of*peptidomimetics*and*AMPs.*&
The&compounds&(peptidomimetics&and&AMPs)&were#prepared&by&solidGphase&synthesis&as&previously&
described&(Bonke&et&al.,&2008;&Olsen&et&al.,&2010).&The&resulting&lyophilized&compounds&and&the&
antibiotic&polymyxin&B&(Sigma&Aldrich,&P4932)&were&dissolved&in&10&mg/mL&sterile&MilliQ&water&and&
stored&at&G20&⁰C.&&
&
Stability*of*resistance.**
A&number&of&lineages&of&E.#coli&were&previously&adapted&to&three&compounds,&alone&and&in&a&
combination&of&three&(Citterio&et&al.,&2016,&submitted).&Seventeen&clones&were&isolated&from&these&
lineages&and&reGcultured&in&absence&of&compound&for&five,&ten&and&fifteen&reGinoculation&steps.&An&
overnight&culture&of&the&strain&was&inoculated&in&liquid&MHB&and&grown&overnight&at&37&⁰C&at&250&
rpm&on&orbital&shaker.&Cultures&were&grown&in&Sterilin&tubes&(VWR,&212G7400)&at&37&⁰C&at&250&rpm.&
An&amount&of&10&µl&was&inoculated&into&990&µl&MHB&giving&1&ml&of&final&volume.&Throughout&the&
experiment&serial&transfers&of&10&µl&of&bacterial&culture&to&fresh&medium&were&performed&when&
growth&was&visible&as&turbidity.&Purity&of&the&lineages&was&checked&by&streak&on&MHB&agar&plates.&
The&total&number&of&passages&in&absence&of&compound&was&fifteen,&equivalent&to&approximately&
105&generations.&Frozen&stock&cultures&were&prepared&after&five,&ten&and&fifteen&reGinoculation&
steps,&respectively.&
*
Determination*of*Minimum*Inhibitory*Concentration*(MIC).&&
MIC&of&the&compounds&or&MIC&of&the&combination&toward&which&they&were&adapted&to&was&tested&
after&the&five,&ten&and&fifteen&reGinoculation&steps,&respectively&(Table&2).&When&testing&the&
combination&of&three,&each&was&included&at&33%&of&the&total.&MIC&was&determined&as&described&in&
(Citterio&et&al.,&2016)&in&accordance&with&the&CLSI&guidelines&(2012).&Microdilution&series&of&the&
compounds&was&prepared&in&UVGsterilized&96Gwell&polypropylene&plates&(Thermo&Scientific&Nunc,&
267334)&with&sterile&polystyrene&lids&(Sigma&Aldrich,&CLS3930G100EA).&Working&solutions&of&
peptidomimetics&and&AMPs&were&prepared&in&MilliQ&water.&Fifty&µl&of&compound&solution&and&50&µl&
of&MHB&were&dispensed&into&the&first&well&of&each&row&and&then&twoGfold&diluted&giving&a&final&
concentration&range&of&128G0.25&µg/ml.&Starting&concentration&was&increased&to&1024&µg/ml&for&the&
most&resistant&clones.&Overnight&culture&of&the&strain&was&diluted&in&sterile&0.9%&NaCl&to&OD546&0.2&
(accepted&range:&0.195G0.210)&corresponding&to&approximately&1&x&108&CFU/ml.&This&suspension&was&
further&diluted&1:100&in&MHB&and&50&µl&of&this&culture&were&inoculated&into&microtiter&plates&to&
reach&a&final&concentration&of&5&x&105&CFU/µl&in&a&final&volume&of&100&µl.&Plates&were&incubated&for&
20&h&at&37&⁰C.&Growth&was&determined&visually&either&as&turbidity&or&as&formation&of&a&pellet.&MIC&
was&the&lowest&concentration&of&peptidomimetics&or&AMPs&where&no&growth&was&observed.&All&MIC&
assays&were&performed&as&two&independent&replicates.&
!
WholeFgenome*sequencing*and*variant*calling.*
Twelve&clones&were&whole&genome&sequenced&immediately&after&adaptation&(Table&4);&five&of&these&
have&been&published&in&Citterio&et&al.,&(2016,&submitted)&whereas&seven&genomes&were&sequenced&
de#novo&as&part&of&the&present&study.&Of&the&twelve&clones,&six&that&retained&high&MIC&after&fifteen&
reGinoculation&steps&were&selected&for&wholeGgenome&sequencing&along&with&two&clones,&for&which&
MIC&have&decreased&to&MIC&in&wild&type&E.#coli&(Table&5).&An&overnight&culture&of&E.#coli#(1.5&ml)#was&
grown&to&stationary&phase&and&genomic&DNA&was&extracted&with&the&NucleoSpin&Tissue&kit&
(MachereyGNagel,&Düren,&Germany).&Quality&of&extracted&DNA&was&assessed&by&1%&agarose&gel&
electrophoresis&and&absorbance&measurement&at&DeNovix&DSG11&Spectrophotometer.&
Quantification&was&done&by&Qubit&2.0&Fluorometer&(Invitrogen,&United&Kingdom).&Preparation&of&
genomic&DNA&libraries&and&sequencing&was&performed&at&the&Novo&Nordisk&Foundation&Center&for&
Biosustainability&(Hørsholm,&Denmark).&Libraries&were&prepared&with&TruSeq&Nano&HT&(Illumina,&San&
Diego,&USA)&and&fragmented&to&an&average&size&of&350G400&bp&with&CovarisE220.&Average&library&size&
after&adapter&ligation&was&500G550&bp,&determined&by&Fragment&Analyzer&and&Standard&Sensitivity&
NGS&kit.&Concentrations&of&the&final&libraries&were&measured&by&Qubit,&dsDNA&broad&range&assay.&
Libraries&were&used&for&pairedGend&sequencing&of&genomes&using&the&Illumina&sequencing&
technology&on&a&NextSeq&v2&Mid&Output&300&cycles&(2x150).&Average&genome&coverage&was&104×.&
All&the&sequenced&genomes&from&adapted&clones&were&mapped&with&the&wild&type&strain&
(Escherichia#coli&ATCC&25922)&as&reference.&The&obtained&sequence&reads&of&the&wild&type&strain&
were&de#novo&assembled&in&CLC&Genomics&Workbench,&version&8&(CLC&Bio,&Aarhus,&Denmark)&
resulting&into&156&contigs,&comprising&a&total&number&of&5122028&bases,&with&a&genome&coverage&of&
89×.&The&assembled&genome&has&been&deposited&at&GenBank&under&the&BioProject&PRJNA309047.&
The&156&contigs&were&annotated&by&Rapid&Annotation&using&Subsystem&Technology&(Aziz&et&al.,&
2008).&Variants&were&called&by&fixed&ploidy&variant&detection&in&CLC&Genomics&Workbench,&in&order&
to&identify&point&mutations&such&as&Single&Nucleotide&Polymorphisms&(SNPs)&and&deletionGinsertionG
polymorphism&(DIPs).&Variants&with&a&frequency&above&60%&were&considered&for&further&analysis.&
We&inferred&functional&consequences&by&searching&for&amino&acid&changes,&and&then&filtering&nonG
synonymous&mutations.&&
*
Results*
We&selected&a&number&of&clones&from&an&adaptive&evolution&experiment,&which&were&
highly& resistant& to& peptoids/AMPs& (Citterio& et& al.,& 2016,& submitted).& In& the& present& work& these&
clones& were& subGcultured& for& several& generations& in& order& to& determine&whether& resistance& was&
maintained&in&absence&of&a&selection&pressure&exerted&by&the&respective&compounds.&&A&reduction&in&
MIC& following& this& prolonged& culturing& in& absence& of& peptide& was& observed& for& six& out& of& the&
seventeen&original&clones&upon&the&5th&reGinoculation&(nGiv4,&P94Giii1,&P94Giii4,&cGi2,&cGii4,&cGiv4).&Only&
slight&additional& reduction&of&MICs&was& seen&after& the&10th& reGinoculation.& Interestingly,& for& three&
clones&(nGiv4,&P94Giii1,&cGi2)&MIC&values&were&even&higher&than&they&were&after&the&5th&reGinoculation.&
Upon&the&15th&reGinoculation,&eight&of&17&clones&still&retained&resistance,& i.e.& there&was&a&8G&to&64G&
fold&increase&in&their&MICs&as&compared&to&the&original&MIC&in&wildGtype&E.#coli#(Table&2).&
After&fifteen&reGinoculation&steps,&we&selected&six&clones&with&retained&elevated&MICs&
along&with& two&clones& (P94Giii4&and&cGiv4),& for&which&MIC&had& reverted& to& the&original&MIC& in& the&
wildGtype&E.#coli#(Table&2;&depicted&in&bold).&MIC&of&eleven&compounds&along&with&the&wellGknown&
peptide&antibiotic&polymyxin&B&was&assessed&in&the&same&clones&in&order&to&determine&susceptibility&
and&potential&crossGresistance&(Table&3).&Almost&all&clones,&retaining&resistance&to&P9G4,&HFG1002G2,&
novicidin,& and& to& the& combination&of&all& three,&were&also& resistant& to& compounds&1,&3& (both&with&
intracellular&targets)&and&to&some&extent&to&compound&6&(LysGrich,&20&amino&acid&long,&membraneG
active).&By&contrast,&the&resistant&clones&were&sensitive&to&compounds&9&(ArgGrich;&with&IR&motifs;&8&
amino&acid& long),&11& (DGpeptide,& Lys/PheGrich,&15&amino&acids& long)&and&8& (LysGrich;&4&amino&acid&
long),&all&assumed&to&be&membraneGactive&compounds.&The&resistant&clones&were&also&moderately&
sensitive&to&compound&2& (ArgGrich;&with&RW&motifs;&12&amino&acid& long).&There&was&a&similar&MIC&
pattern&of&the&membraneGactive&compounds&5&and&6&(both&LysGrich)&for&all&the&resistant&clones&(nG
iv4;&cGi2;&P94Giii5;&HFGi5;&HFGiii5;&HFGiv5).&
Clone&P94Giii4&was&susceptible&to&all& the&compounds,&as&opposed&to&clone&cGiv4,& that&
showed&resistance&to&compounds&1&and&3,&despite&the&fact&that&resistance&to&the&combination&was&
lost&after&the&fifteen&reGinoculation&steps.&&
MIC& of& polymyxin& B& (PmB)& was& higher& than& the& wildGtype& E.# coli& for& all& the& tested&
clones.&In&particular&the&MIC&of&PmB&against&cGi2,&HFGi5&and&HFGiv5GPMB&was&16Gfold&higher&than&MIC&
of&PmB&against&wildGtype&E.#coli.&
The&clones&tested&for&crossGresistance&were&also&wholeGgenome&sequenced&in&order&to&
determine&whether&the&mutations&acquired&after&adaptation&to&P9G4,&novicidin,&HFG1002G2&and&the&
combination&of&all& three&compounds,& respectively,&were&preserved&after& continued&culturing&with&
fifteen&reGinoculation&steps&in&absence&of&compound.&
*
Discussion*
All&clones&that&were&evolved&to&gain&resistance&against&novicidin,&P9G4,&HFG1002G2&and&
the&combination&of&all& three&compounds,&were&also& resistant& to&compounds&1,&3& and&6& indicating&
that& they& share& a& common& mode& of& action,& and& thus& may& be& susceptible& to& similar& resistance&
mechanisms.&This&evolved&resistance&in&these&clones&comprises&compounds&1&and&3&that&both&have&
intracellular&activity&(Zhu&et&al.,&2007;&Lele&et&al.,&2013),&and&this&may&indicate&that&compound&6&also&
act& via&an& intracellular& target.&AMPs&with& intracellular&mechanisms&are&known& to&act& slower& than&
membraneGactive& AMPs& (Giacometti& et& al.,& 1998).& The& killing& mechanism& of& membraneGactive&
compounds& is&known&to& involve&multiple&possible& target&molecules,&while&AMPs&with& intracellular&
activity& are& more& likely& to& have& a& specific& target& (Jenssen& et& al.,& 2006).& Hence,& AMPGresistant&
mutants&may& be& able& to& evolve& resistance& to& such& compounds&more& readily& than& to&membraneG
active&AMPs.&For&some&novel&synthetic&AMPs& it&has&been&found&that&their&mechanism&of&action& is&
not&clarified&as&yet,&and&it&may&involve&a&combination&of&both&membrane&activity&and&intracellular&
targets&(Cassone&and&Otvos,&2010).&However,&so&far&there&have&been&no&previous&reports&with&clear&
evidence& supporting& that& crossGresistance& to& intracellularly& acting& compounds& occurs&more& likely&
than&to&membrane&active&ones,&as&our&study&infers.&Also,&proteolysis&and&extrusion&by&efflux&pumps&
are&very&common&means&by&which&bacteria&adapt&to&AMPs&(Band&and&Weiss,&2015;&Andersson&et&al.,&
2016).& Hence,& the& specific& structure& (i.e.& sequence)& of& an& AMP& may& be& responsible& for& its&
susceptibility&toward&proteolytic&degradation.&In&order&to&investigate&this,&the&array&of&AMPs&might&
be&tested&against&a&few&selected&known&mutant&strains&with&characteristic&resistance&patterns.&&
The&specific&subclasses&of&AMPs&included&in&the&test&array&were&initially&chosen&based&
on&previous&studies&on&rational&design&of&AMPs.&Interestingly,&the&subtypes&comprised&by&this&array&
appear&to&correlate&well&with&susceptibility&of&resistant&clones.&There&was&susceptibility&in&all&tested&
clones& toward& compounds& 2& and& 9& (which& both& are& ArgGrich),& and& the& ultraGshort& lipidated&
compound&8&as&well&as&the&Lys/PheGrich&DGpeptide&11.&These&four&compounds&may&have&a&number&
of& targets& within& the& bacterial& membrane& that& allows& them& to& overcome& the& mechanisms& of&
resistance& acquired& by& all& tested& evolved& clones.& In& this& respect,& it&was& already& pointed& out& that&
small&differences& in&the&mechanism&of&action&might&conserve&the&activity&of&a&compound& in&AMPG
resistant&clones&(Macwana&and&Muriana,&2012).&Compound&2&is&a&12Gresidue&peptide;&compound&8&
is& LysGrich& (consisting& of& 4& amino& acids).& The& 8Gresidue& compound& 9& contains& IR& motifs& and&
represents&an&analogue&of&an&octapeptide&previously&highlighted&for&its&broadGspectrum&and&lack&of&
toxicity& (Ong& et& al.,& 2013;& Lau& et& al.,& 2015).& Hence,& these& structural& features& might& be& further&
explored&in&order&to&confirm&their&advantages&in&synthetic&drugs&for&which&resistance&development&
is&a&prominent&concern.&&
Other& experimentally& adapted& clones& could& be& tested& or,& even& better,& naturally&
resistant&bacteria&or&clinical&resistant&isolates.&&
This&study&highlights&that&AMPGresistant&mutants&become&susceptible&as&the&wildGtype&strain&upon&
prolonged& exposure& to& subGlethal& concentrations& of& compounds& with& certain& features.& The&
relevance&of&this&discovery&will&be&further&acknowledged&once&natural&human&AMPs&such&as&LLG37&
are&tested&towards&AMPGresistant&mutants.**
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Table&1:!Characteristics!of!the!compounds!used!in!the!present!study!and!their!MIC!in!E.#coli!ATCC!25922.!!
c*!=!combination!of!novicidin!+!P9A4!+!HFA1002A2.!PMB!=!polymyxin!B.!
&
Predicted&
mechanism&of&
action&
Sub7class& No/name& Amino&acid/chemical&sequence& Length&
(aa)&
Charge& MW&
(g/mol)&
MIC&in&E.#coli&
&µg/ml& &µM&
Intracellular!
target!
!
Arg/ProArich& 3! RRIRPRPPRLPRPRPRPANH2!!!! 17! +9! 3198.89! 4! 1.25!
Trp/ArgArich& 1! VRRFkWWWkFLRRANH2!!!!!
13! +7! 2761.55! 8! 2.89!
!
!
!
!
!
!
Membrane!
active!
!
Lys/TrpArich& 10! (KW)4ANH2! 8! +5! 1844.68! 16! 8.67!
Trp/ArgArich& P9A4! KWRRWIRWLANH2!!! 9! +5! 1968.85! 8A16! 6.09!
ArgArich& 2! RRWRIVVIRVRRANH2!! 12! +7! 2462.26! 2A4! 1.21!
ArgArich;!β–sheet& 9! (IRIR)!2ANH2! 8! +5! 1664.53! 8! 4.8!
Lys/ArgArich! novicidin! KNLRRIIRKGIHIIKKYFANH2!!! 18! +9! 3322.09! 4A16! 3.01!
LysArich& 4! KWKLFKKVLKVLTTGANH2!! 15! +6! 2472.41! 4! 1.6!
LysArich& 5! KFLKKAKKFGKAFVKILANH2! 17! +8# 2905.80! 4! 1.3!
LysArich& 6! KWKSFIKKLTKKFLHSAKKFANH2! 20! +9! 3519.35! 2A4! 0.85!
LysArich;!lipidated& 8! PamAKKKKANH2!Lipidated!LysArich! 4! +4! 1224.22! 4A8! 4.9!
Lys/PheArich;!DApeptide& 11! AcAFKKLKKLFSKLFSFKANH2! 15! +6! 2614.58! 8! 3.05!
AlaArich& 7! ALWKTLLKKVLKAAAKANH2! 15! +6! 2465.45! 2A4! 1.21!
Polypeptide!with!fatty!acid!
chains! PMB! C55H96N160132H2SO4!
A! A! 1385.61! 0.25A0.5!
0.27!
Unknown!
!
Achiral!peptoid!/!LysAhArg& HFA1002A2! HA(LysAβNpheAhArgAβNphe)3ANH2! 12! +7! ! 4A8! !
Lys/ArgArich+!Trp/ArgArich+!
Achiral!peptoid!/!LysAhArg!
c*!!!! A! A! A!
!
8! !
!
Table&2:!MIC!values!for!E.coli!clones!selected!after!adaptive!laboratory!evolution,!at!the!end!of!the!
adaptation,!and!after!five,!ten!and!fifteen!re8inoculation!steps!in!absence!of!compound,!
respectively.!The!assay!was!repeated!in!two!independent!experiments.!Clones!are!named!after!the!
compound!they!were!adapted!to!(n!=!novicidin,!HF!=!HF8100282,!c!=!combination),!the!lineage!(i!to!
iv)!and!the!clone!number!(1!to!5).!In!bold,!clones!that!were!selected!for!whole8genome!sequencing!
analysis!(Table!4)!and!assessment!of!cross8resistance!(Table!3).!
!
Clone& MIC&(µg/ml)&
after&ALE&
MIC&(µg/ml)&&
after&culturing&steps&without&compound&
Fold&increase&
from&wt&MIC&
! ! &&&&&&&&&&&&&&&&5th&&&&&&&&&&&&&&&&&&&&&&&&&&&10th&&&&&&&&&&&&&&&&&&&&&&&&15th&& !
nFiv4& 64! 16! 32864! 32864! 488!
HF8i1!
HF8i2!
HF8i3!
HF8i4!
256!
256!
256!
256!
256!
256!
512!
256!
128!
1288256!
128!
128!
64!
648128!
648128!
648128!
8816!
16!
16!
16!
HFFi5& 1288256! 256! 128! 648128! 16!
HFFiii5&
HFFiv5&
16864!
2568512!
32!
512!
32!
256!
16832!
1288256!
4!
32!
P948iii1! 32864! 16! 16832! 16! 182!
P948iii3! 32864! 32! 16832! 32! 284!
P94Fiii4& 32! 16! 16! 8816! 1!
P94Fiii5& 32864! 32864! 16! 64! 488!
c8i1! 16832! 16! 8! 8816! 182!
cFi2& 32! 16! 16832! 16832! 284!
c8ii4!
c8iv2!!
16832!
168128!
8816!
8832!
8832!
8816!
8816!
8816!
182!
182!
cFiv4& 648128! 8! 488! 4816! 1.25!
!
&
&
&
&
Table&3:&Fold!increase!of!E.'coli!MIC!to!peptides!as!compared!to!wt!MIC!values!of!compounds!1811!
and!polymyxin!B!(PMB)!for!selected!clones!that!were!re8cultivated!for!fifteen!steps!in!absence!of!
compound!used!in!the!adaptation.!The!assay!was!repeated!in!two!independent!experiments.!n!=!
novicidin,!HF!=!HF8100282,!c!=!combination,!lineage!number!from!i!to!iv,!clone!number!from!1!to!5.!
*!MIC!of!the!compound!(or!the!combination)!to!which!resistant!and!susceptible!clones!were!
previously!adapted!to.!
Clones!considered!susceptible!
Compound&
&
MIC&
(µg/ml)&&
& Fold&increase&from&wt&MIC&in&selected&clones&
wt## & nFiv4& cFi2& cFiv4& P94F
iii4&
P94Fiii5& HFFi5& HFFiii5& HFFiv5&
*& 8! ! 488! 284! 1.25! 8! 488! 16! 4! 32!
1& 8! ! 16! >16! 16! 0.581! 32! 64! 32! 64!
3& 4! ! 8816! 32! 16! 0.584! 16832! 32! 8832! 32!
6& 284! ! 16832! 32864! 8! 182! 8816! 284! 488! 2!
5& 4! ! 8816! 32! 284! 284! 8! 2! 284! 2!
PMB& 0.2580.5! ! 284! 16! 4! 2! 8! 16! 284! 16!
7& 284! ! 8! 8816! 2! 2! 488! 284! 284! 182!
4& 4! ! 8! 8! 2! 182! 8! 488! 4! 4!
10& 16! ! 182! 8! 2! 1! 2! 4! 284! 8!
2& 284! ! 0.581! 284! 288! 1! 284! 284! 4! 284!
8& 488! ! 2! 284! 182! 182! 2! 182! 1! 182!
11& 8! ! 284! 2! 284! 182! 284! 2! 182! 0.5!
9& 8! ! 1! 2! 1! 182! 182! 1! 1! 1!
! !
& &
Table&4:&Single!nucleotide!variants!(SNVs)!in!clones!that!were!whole8genome!sequenced!after!
adaptation!and!after!fifteen!re8inoculation!steps.!The!total!number!of!amino!acid!changing!SNVs!
and!a!selection!of!the!related!mutational!changes!are!shown.!CDP!=!CDP8glycerol:!N8acetyl8β8D8
mannosaminyl81,48N8acetyl8D8glucosaminyldiphosphoundecaprenyl!glycerophosphotransferase;!n!
=!novicidin,!HF!=!HF8100282,!c!=!combination,!lineage!number!from!i!to!iv,!clone!number!from!1!to!
5.!!
Clones& Number&of&
SNVs&after&ALE!
Mutational&changes! Number&of&
SNVs&after&
15&reF
inoculation&
steps!
Mutational&changes!
n8iv4! 3! 8!CDP!
8!Transcriptional!
activator!of!maltose!
regulon!2C!MalT!
8!S8
formylglutathione!
hydrolase!
10! 8!CDP!
8!Transcriptional!
activator!of!maltose!
regulon!2C!MalT!
8!S8formylglutathione!
hydrolase!
!
c8i2! 1! 8!CDP! 9! 8!CDP!
8!GTP!
pyrophosphokinase!
8!Respiratory!nitrate!
reductase!
8!Propionate!CoA!
ligase!
c8iv4! 7! 8!CDP! 10! 8!CDP!
8!poT!spermidine!ABC!
transporter!
8!Glutamate!synthase!
P948iii4! 1! 8!CDP! 8! 8!T1SS!secreted!
agglutinin!RTX!
P948iii5! 7! ! 3! 8!Glucose818
phosphate!
thymidylyltransferase!
HF8i5! 2! 8!CDP!
8!Outer!membrane!
protein!assembly!
factor!YaeT!
precursor!
12! 8!CDP!
8!1!2!C48α8glucan!
glycogen!branching!
enzyme!2C!
8!Outer!membrane!
protein!assembly!
factor!YaeT!precursor!
HF8iii5! 1! ! 4! 8!CDP!
HF8iv5! 64! 8!CDP! 57! 8!CDP!
!
